



## **PROF. SILVIO DANESE, M.D. Ph.D.**

**Born on** January 10th, 1975 in Guardiagrele (CH), Italy

**Languages:** *Italian, English, Spanish*

**Professional Address:**

IRCCS San Raffaele Scientific Institute  
Via Olgettina, 60  
20132, Milano  
E-Mail: [sdanese@hotmail.com](mailto:sdanese@hotmail.com)

**ORCID ID:**

<https://orcid.org/0000-0001-7341-1351>

### **EDUCATION AND TRAINING**

**1999** *Degree in Medicine*, Catholic University School of Medicine, “A. Gemelli” Hospital, Rome, Italy, 110/110 Cum Laude

**1993** *High School Diploma in Scientific Studies*, Liceo Scientifico Galileo Galilei, Potenza, 60/60

### **RESIDENCY PROGRAM**

**2003** *Residency in Gastroenterology*, Residency Program in Gastroenterology, Catholic University School of Medicine, Rome, Italy, 70/70 Cum Laude

## ACADEMIC CAREER

- 2013** *Full Professor of Gastroenterology (Professore Ordinario)*, National Scientific Habilitation, Italy
- 2013** *Full Professor of Internal Medicine (Professore Ordinario)*, National Scientific Habilitation, Italy
- 2004** *PhD in Metabolism*, Catholic University School of Medicine, Rome, Italy
- 2001 – 2002** *Post-doctoral fellowship*, Case Western Reserve University, Cleveland, Ohio, USA
- 2002 – 2004** *Research Associate*, Case Western Reserve University, Cleveland, Ohio, USA

## ACADEMIC APPOINTMENTS

- 2021 – present** *Full Professor of Gastroenterology*, Vita-Salute San Raffaele University, Milano, Italy
- 2021 – present** *Director*, Residency Program of Gastroenterology Vita-Salute San Raffaele University, Milano, Italy
- 2015 – 2021** *Full Professor of Gastroenterology*, Humanitas University, Rozzano, Milano, Italy
- 2015 – 2020** *Director*, Residency Program of Gastroenterology, Humanitas University, Rozzano, Milano, Italy
- 2019 – present** *Faculty Member*, PhD Program in MOLECULAR AND EXPERIMENTAL MEDICINE, Humanitas University, Rozzano, Milano, Italy
- 2007 – 2014** *Teacher*, School of Medicine of Università degli Studi di Milano, Milano, Italy

## CLINICAL PROFESSIONAL EXPERIENCES

- 2021 – present** *Director*, Gastroenterology and Gastrointestinal Endoscopy Unit Istituto Clinico San Raffaele, Milano

<b>2016 – 2021</b>	<b>Director</b> , Immunocenter, (IBD, Rheumatology, Dermatology) Istituto Clinico Humanitas, Rozzano, Milano
<b>2008 – 2021</b>	<b>Head</b> , IBD Center, Department of Gastroenterology, Istituto Clinico Humanitas, Rozzano, Milano
<b>2006 – 2008</b>	<b>Staff member</b> , Gastroenterology Unit, Department of Gastroenterology, Istituto Clinico Humanitas, Rozzano, Milano

### **PERSONAL STATEMENT**

Prof. Silvio Danese is Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San Raffaele Hospital.

Previously, he was Director of the Immunocenter (Rheumatology, Dermatology, IBD and Pneumology), Head of IBD Center and Laboratory at Humanitas Research Hospital.

His team is one of the leading groups internationally recognized in the field of IBD (Crohn's disease and Ulcerative Colitis) with more than 6000 patients followed up per year, of which half with Crohn's disease and half with ulcerative colitis of any grade of severity.

The team is composed by 11 scientists in the Research Lab (3 junior PI, 3 post-doc, 2 PhD students and 3 technicians) working on mechanisms of chronic inflammation and related complications, tissue remodelling and healing, mediators of inflammation and cancer, and from the Clinical Research Staff, composed by 6 clinicians, 8 data manager, 3 nurses, who are involved in all the aspects of patients' care from diagnosis to therapy, with an excellent experience on new molecules still in clinical development. Moreover, the team is well known for the skills regarding early diagnosis, prevention of complications and bowel damage, including new non-invasive techniques to diagnose IBD. In particular, his team is a worldwide-recognized leader in the use of magnetic resonance imaging and small bowel ultrasound for Crohn's disease, and for early treatment strategies with conventional and experimental drugs.

Prof. Danese and his team collaborate in a multidisciplinary setting with IBD dedicated surgeons, psychologists, nutritionists, and radiologists. It is also involved in several international research projects with the top level IBD Centres in Europe and United States.

Prof. Danese is actively involved in the development of innovative pharmaceuticals for Crohn's Disease and Ulcerative Colitis at international level, and in the identification of new Italian and European guidelines for the treatment of IBD.

### **CLINICAL TRIALS**

Principal Investigator in many phase I, II and III international clinical trials in IBD.

In 2020 the iBD Centre of Istituto Clinico Humanitas, led by Professor Danese, is involved in 107 ongoing phase I, II and III international clinical trials.

## GRANTS

- Memorial fund C. Lentini for the project “Efficacy and tolerability of antibiotics in patients undergoing H. pylori eradication”. (12.000 Euro) (1999)
- Grant from the Italian Society of Gastroenterology (SIGE) for the project “Study of the activation state of platelets in inflammatory bowel disease” (10.000 Euro) (2000)
- 3 years Research Fellowship Award from the Crohn’s & Colitis Foundation of America, Inc., for the project: “The role of activated platelets in IBD pathogenesis mediated by the CD40/CD40ligand system”. (120.000 US \$) (2002)
- Grant from The Italian Society of Internal Medicine (SIMI) for the project: “Angiogenesis as a therapeutic strategy in animal models of inflammatory bowel disease” (8.000 Euro) (2004)
- Grant from the AMICI foundation of Piemonte (Italian Crohn’s and Colitis Foundation) for the Project: “Angiogenesis in human inflammatory bowel disease” (10.000 Euro) (2004)
- 2 years Grant from the Broad Medical Research Program for the project:” Angiogenesis in Inflammatory bowel disease: the contribution of platelet-endothelial interactions and implications for novel therapeutic approaches” (220.000 US \$) (2005)
- 3 years Grant from the European Community (FRP6) for the project: “Usefulness of a new DNA array (“IBDChip”) to predict clinical course, development of complications, and response to therapy in patients with inflammatory bowel disease (IBD)” (155.000 Euro) (2006)
- IRCCS Grant Coordinator for the project: “The protein C pathway in IBD” (170.000 Euro) (2007)
- Research Grant from the Associazione Italiana Ricerca cancro (AIRC) for the project: “Evaluation of the role of activated platelets in colon cancer growth and angiogenesis” (150.000 Euro) (2007)
- Grant award from the Italian Society of Gastroenterology for the project: The role of VEGF-A in IBD (20.000 Euro) (2007)

- 2 years Grant from the Broad Medical Research Program for the project:” Lymphangiogenesis in Inflammatory bowel disease pathogenesis. (286.000 US \$) (2008)
- Grant form the European Crohn’s and Colitis Organization for the project: The role of Lymphatic system in IBD pathogenesis (15.000 Euro) (2008)
- Grant from Fondazione Cariplo for the project: Stem-cell-endothelial interactions in IBD (225.000 Euro) (2008)
- Grant from the Italian Ministry of Health. Manipulation of the lymphatic system as a novel approach for IBD treatment. (600.000 Euro) (2008)
- 3 years Grant from the the Associazione Italiana Ricerca cancro (AIRC) for the project: The lymphatic system in colitis associated cancer (490.000 Euro) (2009)
- 3 years grant from Fondazione Cariplo for the project: The protein C system in IBD pathogenesis. (450.000 Euro) (2009)
- 5 years grant from European Community on Immune mediate diseases. Work package coordinator. (400.000 Euro) (2011)
- 4 years grant from NIH for the project: The lymphatic system in Inflammatory bowel disease (1.000.000 US \$) (2011)
- 2 years Grant from The Broad Foundation for the project: The role of Triggered Receptor Expressed on Myeloid cell-2 (TREM-2) and intestinal flora in colon cancer development (220.000 Euro) (2012)
- 3 years Grant from AIRC for the project: The role of Triggered Receptor Expressed on Myeloid cell-2 (TREM-2) and intestinal flora in colon cancer development (360.000 Euro) (2013)
- 3 years Grant from the Italian Ministry of Health for the project: New cellular and molecular mechanisms in Colitis-Associated Colorectal Cancer: implications for innovative therapeutic approaches (450.000 Euro) (2013)

- 4 years Grant from Italian Ministry of Health (FIRB-Futuro in Ricerca) for the project: New cellular and molecular mechanisms in Colitis-Associated Colorectal Cancer: implications for innovative therapeutic approaches (448.000 Euro) (2013)
- 2 years Grant from Humanitas Research Hospital for the project: The role of TREM-2 in IBD pathogenesis: implications for novel therapeutic approaches (100.000 Euro) (2014)
- 3 years Grant from AIRC for the project: Role of TRPV-4 in the pathogenesis of Colorectal Cancer (450.000 Euro) (2017)
- 2 years Grant from the Broad Medical Research Program for the project: Resolution of IBD by promoting endogenous lipid-mediated pro-resolving pathways: a novel approach to pathogenesis and therapy (140.800 Euro) (2017)
- Coordinator of a 5 year Grant from the Horizon 2020, H2020-JTI-IMI2-2018-15 IMI, Innovative Medicines Initiative 2 for the ImmUniverse project: Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies (15,5 millions Euro) (2020)
- Coordinator of a 3 years grant from EURONANOMED III for the project: Gut-targeted RNA-based nanoparticles for fibrostenotic Crohn's Disease: a novel therapeutic approach (1 million Euro) (2020)

Furthermore, members of Prof. Danese's laboratory, including post-doc and junior PI, have been awarded with several national and international grants, for a total of about 4.000.000 €.

### **PATENT ON NEW DRUGS**

ATN-161 for the treatment of Crohn's disease.

### **ROLES IN SCIENTIFIC SOCIETIES:**

Societa' Italiana di Gastroenterologia (SIGE) - **Member**

United European Gastroenterology (UEG) – **UEG Research Committee Chair Elect 2022 – UEG Research Committee Chair 2023-2026**

European Crohn's Colitis Organisation (ECCO) – **Secretary 2011-2015 – President Elect 2016 -2017 - President 2018-2020**

International Organization for the study of Inflammatory Bowel Disease (IOIBD) – **Current Secretary and Chair of the clinical trial task force**

American Gastroenterology Association (AGA) - **Member**

### **EDITORIAL ROLES**

Prof Danese has covered the following Journal tasks:

**Associate Editor** of *World Journal of Gastroenterology*

**Associate Editor** of *Gut*

**Associate Editor** of *Journal of Crohn's and Colitis*

**Editorial Board** Member of *Current drug target*

**Editorial Board** Member of *Alimentary Pharmacol & Therapeutics*

**Reviewer** for Journal of Clinical Investigation, Gastroenterology, J Immunology, Gut, Inflammatory Bowel Disease, J Clin Immunol, Am J Gastroenterology, Am J Physiology, Clin Gastroenterol Hepatol, Eur J Gastroenterol, Dig Liv Dis, Eur J Immunology

### **AWARDS**

- Travel Award for oral communication to the International IBD meeting, Capri 2003 “Platelets contribute to inflammatory bowel disease by releasing RANTES which mediates T- cell adhesion to intestinal microvascular endothelial cells” (2003)
- Travel Award for the poster to the European Congress of Gastroenterology, Prague 2004 “Homocysteine critically contributes to the inflammatory state of intestinal microvasculature in inflammatory bowel disease” (2004)
- Travel Award for oral communication to the American Physiology Association, Immunological and Pathophysiological Mechanisms in Inflammatory Bowel disease, Snowmass, Colorado, USA: “Angiogenesis: a novel component in IBD pathogenesis” (2004)
- Research Recognition Award from the American Physiology Association for the Oral Communication: “Angiogenesis: a novel component in IBD pathogenesis” (2004)

- Designed Member of the Astra Zeneca program:” Emerging Leaders in Gastroenterology” (2004)
- Designed Member for the ASNEMGE Program:” Rising Star in Gastroenterology 2005” (2005)
- Designed Member of the Astra Zeneca program:” Emerging Leaders Alumni in Gastroenterology” (2006)
- UEG Research Prize Award 2019 for the project “The gut virome as a trigger for IBD: from metagenomics to pathogenesis” (100.000 Euro) (2019)

#### PEER REVIEWED PUBLICATIONS

**Publications:** n 729 (please, be aware that in PubMed there are some hits duplicates because of corrections due to mistakes in the affiliation of some authors)

**Metrics:** Total Impact Factor: 6822,836  
 Citations: 36689 (Scopus); 50622 (Google Scholar)  
 H index: 95 (Scopus); 110 (Google Scholar)  
 i-10 index: 516 (Google Scholar)

1. Cremonini F, **Danese S**, Gasbarrini A.  
 Gender, chronic infection and myocardial infarction.  
*J Intern Med.* 2000 Jan;247(1):156. Doi: 10.1046/j.1365-2796.2000.00635.x (IF 2000: 2,273)
2. Cremonini F, **Danese S**, Carloni E, Zocco MA, Gasbarrini A.  
 Helicobacter pylori and ischemic heart disease: current evidences.  
*Eur Rev Med Pharmacol Sci.* 1999 Jan-Feb;3(1):1-3. Review. (IF 2009: 0,773)
3. **Danese S**, Zoli A, Cremonini F, Gasbarrini A.  
 High prevalence of Helicobacter pylori type I virulent strains in patients with systemic sclerosis.  
*J Rheumatol.* 2000 Jun;27(6):1568-9. (IF 2000: 2,91)
4. **Danese S**, Candelli M, Gasbarrini A.



Elevated homocysteine levels in patients with Raynaud's syndrome.

*J Rheumatol.* 2000 Aug;27(8):2051. (IF 2000: 2,91)

5. Papa A, **Danese S**, Gasbarrini A, Gasbarrini G.  
Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease.  
*Aliment Pharmacol Ther.* 2000 Nov;14(11):1403-9. Review. Doi: 10.1046/j.1365-2036.2000.00860.x (IF 2000: 3,489)
  
6. **Danese S**, Candelli M, Papa A, Gasbarrini A.  
Is cytotoxic-associated gene A-positive *Helicobacter pylori* important?  
*J Clin Gastroenterol.* 2001 Jan;32(1):91-2. Doi: 10.1097/00004836-200101000-00022 (IF 2001: 1,116)
  
7. Gasbarrini A, Anti M, Franceschi F, Armuzzi A, Cotichini R, Ojetti V, Candelli M, Lippi ME, Paolucci M, Cicconi V, Cammarota G, **Danese S**, Silveri NG, Catananti C, Pola P, Stroffolini T, Gasbarrini G.  
Prevalence of and risk factors for *Helicobacter pylori* infection among healthcare workers at a teaching hospital in Rome: the Catholic University Epidemiological Study.  
*Eur J Gastroenterol Hepatol.* 2001 Feb;13(2):185-9. Doi: 10.1097/00042737-200102000-00015 (IF 2001: 1,58)
  
8. Papa A, **Danese S**, Gasbarrini G, Gasbarrini A.  
When can unfractionated heparin really be useful in the treatment of ulcerative colitis?  
*Gastroenterology.* 2001 Apr;120(5):1306-7; author reply 1307-8. Doi: 10.1053/gast.2001.23637 (IF 2001: 13,02)
  
9. **Danese S**, Cremonini F, Armuzzi A, Candelli M, Papa A, Ojetti V, Pastorelli A, Di Caro S, Zannoni G, De Sole P, Gasbarrini G, Gasbarrini A.  
*Helicobacter pylori* CagA-positive strains affect oxygen free radicals generation by gastric mucosa.  
*Scand J Gastroenterol.* 2001 Mar;36(3):247-50. Doi: 10.1080/003655201750074474 (IF 2001: 1,826)
  
10. Papa A, De Stefano V, **Danese S**, Gasbarrini A, Gasbarrini G.  
Thrombotic complications in inflammatory bowel disease: a multifactorial etiology.  
*Am J Gastroenterol.* 2001 Apr;96(4):1301-2. Doi: 10.1111/j.1572-0241.2001.03725.x (IF 2001: 3,549)

11. **Danese S**, Armuzzi A, Romano A, Cremonini F, Candelli M, Franceschi F, Ojetti V, Venuti A, Pola P, Gasbarrini G, Gasbarrini A.  
Efficacy and tolerability of antibiotics in patients undergoing *H. pylori* eradication.  
*Hepatogastroenterology*. 2001 Mar-Apr;48(38):465-7. (IF 2001: 0,886)
12. Ojetti V, Armuzzi A, De Luca A, Nucera E, Franceschi F, Candelli M, Zannoni GF, **Danese S**, Di Caro S, Vastola M, Schiavino D, Gasbarrini G, Patriarca G, Pola P, Gasbarrini A.  
*Helicobacter pylori* infection affects eosinophilic cationic protein in the gastric juice of patients with idiopathic chronic urticaria.  
*Int Arch Allergy Immunol*. 2001 May;125(1):66-72. DOI: 10.1159/000053798 (IF 2001: 2,164)
13. Papa A, De Stefano V, **Danese S**, Chiusolo P, Persichilli S, Casorelli I, Zappacosta B, Giardina B, Gasbarrini A, Leone G, Gasbarrini G.  
Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease.  
*Am J Gastroenterol*. 2001 Sep;96(9):2677-82. Doi: 10.1111/j.1572-0241.2001.04127.x (IF2001: 3.549)
14. **Danese S**, De Vitis I, Gasbarrini A.  
Severe liver injury associated with zafirlukast.  
*Ann Intern Med*. 2001 Nov 20;135(10):930. Doi: 10.7326/0003-4819-135-10-200111200-00023 (IF 2001: 11,13)
15. **Danese S**, Papa A, Gasbarrini G, Gasbarrini A.  
Assessment of prothrombotic risk in patients with Behçet's disease should include homocysteine plasma levels.  
*J Rheumatol*. 2001 Dec;28(12):2764-5. (IF 2001: 2,591)
16. Papa A, **Danese S**, Gasbarrini G, Gasbarrini A.  
Genetic and nutritional predictors of hyperhomocysteinemia in inflammatory bowel disease.  
*Am J Gastroenterol*. 2002 Feb;97(2):490-1. Doi: 10.1111/j.1572-0241.2002.05506.x (IF2002: 3,953)
17. Papa A, **Danese S**, Sgambato A, Ardito R, Zannoni G, Rinelli A, Vecchio FM, Gentiloni- Silveri N, Cittadini A, Gasbarrini G, Gasbarrini A.  
Role of *Helicobacter pylori* CagA+ infection in determining oxidative DNA damage in gastric mucosa.

- Scand J Gastroenterol.* 2002 Apr;37(4):409- 13. Doi: 10.1080/003655202317316033 (IF 2002: 1,847)
18. Ojetti V, Pitocco D, Bartolozzi F, **Danese S**, Migneco A, Lupascu A, Pola P, Ghirlanda G, Gasbarrini G, Gasbarrini A.  
High rate of helicobacter pylori re-infection in patients affected by type 1 diabetes.  
*Diabetes Care.* 2002 Aug;25(8):1485. Doi: 10.2337/diacare.25.8.1485 (IF 2002: 5,447)
19. **Danese S**, Fiocchi C.  
Atherosclerosis and inflammatory bowel disease: sharing a common pathogenic pathway?  
*Circulation.* 2003 Feb 25;107(7):e52. Doi: 10.1161/01.cir.0000055542.47474.a1 (IF 2003: 11,164)
20. Papa A, **Danese S**, Piccirillo N, Toriani-Terenzi C, Bartolozzi F, Piscaglia AC, Grillo A, Leone G, Gentiloni-Silveri N, Gasbarrini G, Gasbarrini A.  
Thrombopoietin serum levels in patients with inflammatory bowel disease with and without previous thromboembolic events.  
*Hepatogastroenterology.* 2003 Jan-Feb;50(49):132-5. (IF 2003: 0,837)
21. Bellino R, Arisio R, D'Addato F, Attini R, Durando A, **Danese S**, Bertone E, Griro R, Massobrio M.  
Metaplastic breast carcinoma: pathology and clinical outcome.  
*Anticancer Res.* 2003 Jan-Feb;23(1B):669-73. (IF 2003: 1,347)
22. **Danese S**, de la Motte C, Sturm A, Vogel JD, West GA, Strong SA, Katz JA, Fiocchi C.  
Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients.  
*Gastroenterology.* 2003 May;124(5):1249-64. Doi: 10.1016/s0016-5085(03)00289-0 (IF 2003: 12,718)
23. Papa A, **Danese S**, Grillo A, Gasbarrini G, Gasbarrini A.  
Review article: inherited thrombophilia in inflammatory bowel disease.  
*Am J Gastroenterol.* 2003 Jun;98(6):1247-51. Review. Doi: 10.1111/j.1572-0241.2003.07491.x (IF 2003: 4,172)
24. Candelli M, Papa A, Nista EC, **Danese S**, Armuzzi A, Bartolozzi F, Tondi P, Ojetti V, Gasbarrini G, Gasbarrini A.  
Antibodies to *Saccharomyces cerevisiae*: are they useful in clinical practice?

*Hepatogastroenterology*. 2003 May-Jun;50(51):718-20. (IF 2003: 0,837)

25. Papa A, **Danese S**, Armuzzi A, Gaetani E, Flex A, Pola P, Gasbarrini A.  
Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in different populations.  
*Gut*. 2003 Aug;52(8):1227-8; author reply 1228. Doi: 10.1136/gut.52.8.1227-b (IF 2003: 5,883)
26. **Danese S**, Katz JA, Saibeni S, Papa A, Gasbarrini A, Vecchi M, Fiocchi C.  
Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients.  
*Gut*. 2003 Oct;52(10):1435-41. Doi: 10.1136/gut.52.10.1435 (IF 2003: 5.883)
27. Vogel JD, West GA, **Danese S**, De La Motte C, Phillips MH, Strong SA, Willis J, Fiocchi C.  
CD40-mediated immune-nonimmune cell interactions induce mucosal fibroblast chemokines leading to T-cell transmigration.  
*Gastroenterology*. 2004 Jan;126(1):63-80. Doi: 10.1053/j.gastro.2003.10.046 (IF 2004: 13,092)
28. **Danese S**, Papa A, Gasbarrini A, Ricci R, Maggiano N.  
Helicobacter pylori eradication down-regulates matrix metalloproteinase-9 expression in chronic gastritis and gastric ulcer.  
*Gastroenterology*. 2004 Jan;126(1):369-71. Doi: 10.1053/j.gastro.2003.06.007 (IF 2004: 13,092)
29. **Danese S**, de la Motte C, Reyes BM, Sans M, Levine AD, Fiocchi C.  
Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification.  
*J Immunol*. 2004 Feb 15;172(4):2011-5. Doi: 10.4049/jimmunol.172.4.2011 (IF 2004: 6,486)
30. **Danese S**, Motte Cd Cde L, Fiocchi C.  
Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications.  
*Am J Gastroenterol*. 2004 May;99(5):938-45. Review. Doi: 10.1111/j.1572-0241.2004.04129.x (IF 2004: 4,716)
31. **Danese S**, Sans M, Fiocchi C.  
The CD40/CD40L costimulatory pathway in inflammatory bowel disease.  
*Gut*. 2004 Jul;53(7):1035-43. Review. Doi: 10.1136/gut.2003.026278 (IF 2004: 6,601)
32. **Danese S**, Sans M, Fiocchi C.  
Inflammatory bowel disease: the role of environmental factors.

- Autoimmun Rev.* 2004 Jul;3(5):394-400. Review. Doi: 10.1016/j.autrev.2004.03.002 (IF 2005: 3,091)
33. Papa A, Pola R, Flex A, **Danese S**, Armuzzi A, Gaetani E, Guidi L, De Vitis I, Urgesi R, Grillo A, Serricchio M, Proia AS, Fedeli G, Gasbarrini G, Pola P, Gasbarrini A.  
Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease.  
*Dig Liver Dis.* 2004 Aug;36(8):528-32. Doi: 10.1016/j.dld.2004.03.015 (IF 2004: 1,429)
34. **Danese S**, Scaldaferri F, Papa A, Pola R, Gasbarrini A, Sgambato A, Cittadini A.  
CD40L- positive platelets induce CD40L expression de novo in endothelial cells: adding a loop to microvascular inflammation.  
*Arterioscler Thromb Vasc Biol.* 2004 Sep;24(9):e162. Doi: 10.1161/01.ATV.0000138073.91195.70 (IF 2004: 7,432)
35. Saibeni S, Bottasso B, Spina L, Bajetta M, **Danese S**, Gasbarrini A, de Franchis R, Vecchi M.  
Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases.  
*Am J Gastroenterol.* 2004 Oct;99(10):1966-70. Doi: 10.1111/j.1572-0241.2004.30203.x (IF 2004: 4,716)
36. Sturm A, Leite AZ, **Danese S**, Krivacic KA, West GA, Mohr S, Jacobberger JW, Fiocchi C.  
Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis.  
*Gut.* 2004 Nov;53(11):1624-31. Doi: 10.1136/gut.2003.033613 (IF 2004: 6,601)
37. **Danese S**, Scaldaferri F, Papa A, Pola R, Sans M, Gasbarrini G, Pola P, Gasbarrini A.  
Platelets: new players in the mucosal scenario of inflammatory bowel disease.  
*Eur Rev Med Pharmacol Sci.* 2004 Sep-Oct;8(5):193-8. Review. (IF 2009: 0,773)
38. Papa A, **Danese S**, Urgesi R, Grillo A, Guglielmo S, Roberto I, Semeraro S, Scaldaferri F, Pola R, Flex A, Fedeli G, Gasbarrini G, Pola P, Gasbarrini A.  
Intercellular adhesion molecule 1 gene polymorphisms in inflammatory bowel disease.  
*Eur Rev Med Pharmacol Sci.* 2004 Sep-Oct;8(5):187-91. Review. (IF 2004: 0,773)
39. Papa A, Urgesi R, Grillo A, **Danese S**, Guglielmo S, Roberto I, Fedeli G, Gasbarrini A, Gasbarrini G.  
Pathophysiology, diagnosis and treatment of non-erosive reflux disease (NERD).

- Minerva Gastroenterol Dietol.* 2004 Sep;50(3):215-26. Review. English, Italian.
40. Ojetti V, Nucera G, Migneco A, Gabrielli M, Lauritano C, **Danese S**, Zocco MA, Nista EC, Cammarota G, De Lorenzo A, Gasbarrini G, Gasbarrini A.  
High prevalence of celiac disease in patients with lactose intolerance.  
*Digestion.* 2005;71(2):106-10. Epub 2005 Mar 16. Doi: 10.1159/000084526 (IF 2005: 1,826)
41. **Danese S**, Sgambato A, Papa A, Scaldaferrì F, Pola R, Sans M, Lovecchio M, Gasbarrini G, Cittadini A, Gasbarrini A.  
Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease.  
*Am J Gastroenterol.* 2005 Apr;100(4):886-95. Doi: 10.1111/j.1572-0241.2005.41469.x (IF 2005: 5,116)
42. **Danese S**, Sans M, Gasbarrini A.  
CD40 antisense based strategy for inflammatory bowel disease: shutting down multiple cellular communication systems.  
*Gut.* 2005 Jun;54(6):891-2. (IF 2005: 7,692)
43. **Danese S**, Fiocchi C.  
Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease.  
*Crit Rev Immunol.* 2005;25(2):103-21. Review. Doi: 10.1615/critrevimmunol.v25.i2.20 (IF 2005: 3,214)
44. Reyes BM, **Danese S**, Sans M, Fiocchi C, Levine AD.  
Redox equilibrium in mucosal T cells tunes the intestinal TCR signaling threshold.  
*J Immunol.* 2005 Aug 15;175(4):2158-66. Doi: 10.4049/jimmunol.175.4.2158 (IF 2005: 6,387)
45. **Danese S**, De la Rue SA, Gasbarrini A.  
Antibody to alpha4beta7 integrin for ulcerative colitis.  
*N Engl J Med.* 2005 Sep 15;353(11):1180-1; author reply 1180-1. Doi: 10.1056/NEJMc051937 (IF 2005: 44,016)
46. **Danese S**, Semeraro S, Marini M, Roberto I, Armuzzi A, Papa A, Gasbarrini A.  
Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation.  
*Dig Liver Dis.* 2005 Nov;37(11):811-8. Epub 2005 Sep 13. Review. Doi: 10.1016/j.dld.2005.03.013 (IF 2005: 1,818)

47. **Danese S**, Gasbarrini A.  
Chemokines in inflammatory bowel disease.  
*J Clin Pathol.* 2005 Oct;58(10):1025-7. Review. Doi: 10.1136/jcp.2005.030916 (IF 2005: 2,17)
48. Papa A, Santoliquido A, **Danese S**, Covino M, Di Campli C, Urgesi R, Grillo A, Guglielmo S, Tondi P, Guidi L, De Vitis I, Fedeli G, Gasbarrini G, Gasbarrini A.  
Increased carotid intima-media thickness in patients with inflammatory bowel disease.  
*Aliment Pharmacol Ther.* 2005 Nov 1;22(9):839-46. Doi: 10.1111/j.1365-2036.2005.02657.x (IF 2008: 3,17)
49. Rutella S, Zavala F, **Danese S**, Kared H, Leone G.  
Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance.  
*J Immunol.* 2005 Dec 1;175(11):7085-91. Review. Doi: 10.4049/jimmunol.175.11.7085 (IF: 6,387)
50. **Danese S**, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, Gasbarrini G, Gasbarrini A.  
Extraintestinal manifestations in inflammatory bowel disease.  
*World J Gastroenterol.* 2005 Dec 14;11(46):7227-36. Review. Doi: 10.3748/wjg.v11.i46.7227 (IF 2003: 3,318)
51. **Danese S**, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cittadini A, Piqué JM, Panes J, Katz JA, Gasbarrini A, Fiocchi C.  
TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease.  
*J Immunol.* 2006 Feb 15;176(4):2617-24. Doi: 10.4049/jimmunol.176.4.2617 (IF 2006: 6,293)
52. **Danese S**, Papa A, Scaldaferri F, Graziani C, Bonizzi M, Armuzzi A, Fedeli G, Gasbarrini G, Gasbarrini A.  
A novel pathogenic role for microvasculature in inflammatory bowel disease.  
*Eur Rev Med Pharmacol Sci.* 2006 Jan-Feb;10(1):3-5. (IF 2009: 0,773)
53. Papa A, **Danese S**, Urgesi R, Grillo A, Guglielmo S, Roberto I, Bonizzi M, Guidi L, De Vitis I, Santoliquido A, Fedeli G, Gasbarrini G, Gasbarrini A.  
Early atherosclerosis in patients with inflammatory bowel disease.  
*Eur Rev Med Pharmacol Sci.* 2006 Jan-Feb;10(1):7-11. (IF 2009: 0,773)

54. Rutella S, Bonanno G, Procoli A, Mariotti A, de Ritis DG, Curti A, **Danese S**, Pessina G, Pandolfi S, Natoni F, Di Febo A, Scambia G, Manfredini R, Salati S, Ferrari S, Pierelli L, Leone G, Lemoli RM.  
Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10<sup>+</sup>IL-12<sup>low/neg</sup> accessory cells with dendritic-cell features.  
*Blood*. 2006 Jul 1;108(1):218-27. Epub 2006 Mar 9. Doi: 10.1182/blood-2005-08-3141 (IF 2006: 10,37)
55. Montemurro F, Donadio M, Clavarezza M, Redana S, Jacomuzzi ME, Valabrega G, **Danese S**, Vietti-Ramus G, Durando A, Venturini M, Aglietta M.  
Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy.  
*Oncologist*. 2006 Apr;11(4):318-24. Doi: 10.1634/theoncologist.11-4-318 (IF 2006: 5,206)
56. Fiocchi C, Ina K, **Danese S**, Leite AZ, Vogel JD.  
Alterations of mesenchymal and endothelial cells in inflammatory bowel diseases.  
*Adv Exp Med Biol*. 2006;579:168-76. Review. Doi: 10.1007/0-387-33778-4\_11 (IF 2006: 0.646)
57. Rutella S, **Danese S**, Leone G.  
Tolerogenic dendritic cells: cytokine modulation comes of age.  
*Blood*. 2006 Sep 1;108(5):1435-40. Epub 2006 May 9. Review. Doi: 10.1182/blood-2006-03-006403 (IF 2006: 10,37)
58. **Danese S**, Sans M, de la Motte C, Graziani C, West G, Phillips MH, Pola R, Rutella S, Willis J, Gasbarrini A, Fiocchi C.  
Angiogenesis as a novel component of inflammatory bowel disease pathogenesis.  
*Gastroenterology*. 2006 Jun;130(7):2060-73. Doi: 10.1053/j.gastro.2006.03.054 (IF 2006: 12,457)
59. **Danese S**, Semeraro S, Armuzzi A, Papa A, Gasbarrini A.  
Biological therapies for inflammatory bowel disease: research drives clinics.  
*Mini Rev Med Chem*. 2006 Jul;6(7):771-84. Review. Doi: 10.2174/138955706777698624 (IF 2006: 3,163)
60. **Danese S**, Fiocchi C.  
Etiopathogenesis of inflammatory bowel diseases.  
*World J Gastroenterol*. 2006 Aug 14;12(30):4807-12. Review. Doi: 10.3748/wjg.v12.i30.4807 (IF 2008: 2,081)



61. **Danese S**, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M.  
Inflammation and coagulation in inflammatory bowel disease: The clot thickens.  
*Am J Gastroenterol.* 2007 Jan;102(1):174-86. Epub 2006 Nov 13. Review. Doi: 10.1111/j.1572-0241.2006.00943.x (IF 2007: 6,101)
62. **Danese S**, Sans M, Spencer DM, Beck I, Doñate F, Plunkett ML, de la Motte C, Redline R, Shaw DE, Levine AD, Mazar AP, Fiocchi C.  
Angiogenesis blockade as a new therapeutic approach to experimental colitis.  
*Gut.* 2007 Jun;56(6):855-62. Epub 2006 Dec 14. Doi: 10.1136/gut.2006.114314 (IF 2007: 10,015)
63. Repici A, Pagano N, Hervoso CM, **Danese S**, Nicita R, Preatoni P, Malesci A.  
Metal stents for malignant colorectal obstruction.  
*Minim Invasive Ther Allied Technol.* 2006;15(6):331-8. Doi: 10.1080/13645700601037954 (IF 2007: 0,978)
64. Sans M, **Danese S**, de la Motte C, de Souza HS, Rivera-Reyes BM, West GA, Phillips M, Katz JA, Fiocchi C.  
Enhanced recruitment of CX3CR1+ T cells by mucosal endothelial cell-derived fractalkine in inflammatory bowel disease.  
*Gastroenterology.* 2007 Jan;132(1):139-53. Epub 2006 Oct 12. Doi: 10.1053/j.gastro.2006.10.010 (IF 2007: 11,673)
65. **Danese S**, Scaldaferrri F, Vetrano S, Stefanelli T, Graziani C, Repici A, Ricci R, Straface G, Sgambato A, Malesci A, Fiocchi C, Rutella S.  
Critical role of the CD40 CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease.  
*Gut.* 2007 Sep;56(9):1248-56. Epub 2007 Feb 22. Doi: 10.1136/gut.2006.111989 (IF 2007: 10,015)
66. **Danese S**, Rutella S.  
The Janus face of CD4+CD25+ regulatory T cells in cancer and autoimmunity.  
*Curr Med Chem.* 2007;14(6):649-66. Review. Doi: 10.2174/092986707780059599 (IF: 4,944)
67. Nenci A, Becker C, Wullaert A, Gareus R, van Loo G, **Danese S**, Huth M, Nikolaev A, Neufert C, Madison B, Gumucio D, Neurath MF, Pasparakis M.  
Epithelial NEMO links innate immunity to chronic intestinal inflammation.

*Nature*. 2007 Mar 29;446(7135):557-61. Epub 2007 Mar 14. Doi: 10.1038/nature05698 (IF 2007: 28,751)

68. **Danese S**, Angelucci E, Malesci A, Caprilli R.

Biological agents for ulcerative colitis: hypes and hopes.

*Med Res Rev*. 2008 Mar;28(2):201-18. Review. Doi: 10.1002/med.20103 (IF 2008: 8,907)

69. **Danese S**, Dejana E, Fiocchi C.

Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation.

*J Immunol*. 2007 May 15;178(10):6017-22. Review. Doi: 10.4049/jimmunol.178.10.6017 (IF 2007: 6,068)

70. **Danese S**.

Inflammation and the mucosal microcirculation in inflammatory bowel disease: the ebb and flow.

*Curr Opin Gastroenterol*. 2007 Jul;23(4):384-9. Review. Doi: 10.1097/MOG.0b013e32810c8de3 (IF 2007: 3,271)

71. Scaldaferri F, Sans M, Vetrano S, Graziani C, De Cristofaro R, Gerlitz B, Repici A, Arena V, Malesci A, Panes J, Grinnell BW, **Danese S**.

Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease.

*J Clin Invest*. 2007 Jul;117(7):1951-60. Doi: 10.1172/JCI31027 (IF 2007: 16,915)

72. Berndt U, Bartsch S, Philipsen L, **Danese S**, Wiedenmann B, Dignass AU, Hämmerle M, Sturm A.

Proteomic analysis of the inflamed intestinal mucosa reveals distinctive immune response profiles in Crohn's disease and ulcerative colitis.

*J Immunol*. 2007 Jul 1;179(1):295-304. Doi: 10.4049/jimmunol.179.1.295 (IF: 6,068)

73. **Danese S**, Pagano N, Angelucci E, Stefanelli T, Repici A, Omodei P, Daperno M, Malesci A.

Tumor necrosis factor-alpha monoclonal antibodies for Crohn's disease: tipping the balance.

*Curr Med Chem*. 2007;14(14):1489-97. Review. Doi: 10.2174/092986707780831104 (IF 2007: 4,944)

74. **Danese S**, Stefanelli T, Omodei P, Zatelli S, Bonifacio C, Balzarini L, Repici A, Malesci A.

Successful treatment of fistulizing Crohn's disease with certolizumab pegol.

*Inflamm Bowel Dis*. 2008 Feb;14(2):292-3. Doi: 10.1002/ibd.20284 (IF 2008: 4,975)

75. Repici A, Barbon V, De Angelis C, Luigiano C, De Caro G, Hervoso C, **Danese S**, Preatoni P, Pagano N, Comunale S, Pennazio M, Rizzetto M.  
Acute small-bowel perforation secondary to capsule endoscopy.  
*Gastrointest Endosc.* 2008 Jan;67(1):180-3. Epub 2007 Nov 5. Doi: 10.1016/j.gie.2007.05.044 (IF 2008: 7,367)
76. Paclik D, Berndt U, Guzy C, Dankof A, **Danese S**, Holzloehner P, Rosewicz S, Wiedenmann B, Wittig BM, Dignass AU, Sturm A.  
Galectin-2 induces apoptosis of lamina propria T lymphocytes and ameliorates acute and chronic experimental colitis in mice.  
*J Mol Med (Berl).* 2008 Dec;86(12):1395-406. Epub 2007 Dec 7. Doi: 10.1007/s00109-007-0290-2 (IF 2010: 5,192)
77. **Danese S**  
Editorial: Inflammatory bowel disease and inflammation-associated colon cancer: partners in crime  
*Curr Drug Targets.* 2008 2008 May;9(5):360. doi: 10.2174/138945008784221134 (IF 2008: 4.187)
78. Repici A, De Caro G, Luigiano C, Fabbri C, Pagano N, Preatoni P, **Danese S**, Fuccio L, Consolo P, Malesci A, D'Imperio N, Cennamo V.  
WallFlex colonic stent placement for management of malignant colonic obstruction: a prospective study at two centers.  
*Gastrointest Endosc.* 2008 Jan;67(1):77-84. Erratum in: *Gastrointest Endosc.* 2008 Feb;67(2):390. Fucci, Lorenzo [corrected to Fuccio, Lorenzo]. Doi: 10.1016/j.gie.2007.08.019 (IF 2008: 7,367)
79. **Danese S**, de la Rue SA, Rutella S.  
Dendritic cells, TGF-beta, and Integrin alphavbeta8 in inflammatory bowel disease: a tolerogenic "ménage à trois".  
*Gastroenterology.* 2008 Jan;134(1):354-5. doi: 10.1053/j.gastro.2007.11.050. doi: 10.1053/j.gastro.2007.11.050 (IF 2008: 12,591)
80. **Danese S**.  
Negative regulators of angiogenesis in inflammatory bowel disease: thrombospondin in the spotlight.  
*Pathobiology.* 2008;75(1):22-4. doi: 10.1159/000113791. Epub 2008 Mar 11. (IF 2008: 1,818)

81. Tursi A, Brandimarte G, Elisei W, Giorgetti GM, Inchingolo CD, **Danese S**, Aiello F.  
Assessment and grading of mucosal inflammation in colonic diverticular disease.  
*J Clin Gastroenterol*. 2008 Jul;42(6):699-703.  
doi: 10.1097/MCG.0b013e3180653ca2. (IF 2008: 2,775)
82. **Danese S**, Mocciaro F, Guidi L, Scribano ML, Comberlato M, Annese V, Colombo E, Stefanelli T, Marzo M, Vangeli M, Pulitano' R, Manca A, Armuzzi A, Malesci A, Prantera C, Cottone M.  
Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use.  
*Inflamm Bowel Dis*. 2008 Aug;14(8):1168-70. doi: 10.1002/ibd.20426. (IF 2008: 4,975)
83. **Danese S**, Angelucci E, Stefanelli T, Omodei P, Luigiano C, Finazzi S, Pagano N, Repici A, Vecchi M, Malesci A.  
Cytapheresis in inflammatory bowel diseases: current evidence and perspectives.  
*Digestion*. 2008;77(2):96-107. doi: 10.1159/000122473. Epub 2008 Apr 1. Review. (IF 2008: 1,836)
84. **Danese S**.  
VEGF in inflammatory bowel disease: a master regulator of mucosal immune- driven angiogenesis.  
*Dig Liver Dis*. 2008 Aug;40(8):680-3. doi: 10.1016/j.dld.2008.02.036. Epub 2008 Apr 10. (IF 2008: 2,577)
85. Papa A, Scaldaferrri F, **Danese S**, Guglielmo S, Roberto I, Bonizzi M, Mocci G, Felice C, Ricci C, Andrisani G, Fedeli G, Gasbarrini G, Gasbarrini A.  
Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects.  
*Dig Dis*. 2008;26(2):149-55. doi: 10.1159/000116773. Epub 2008 Apr 21. Review. (IF 2008: 1,092)
86. Deban L, Correale C, Vetrano S, Malesci A, **Danese S**  
Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a Jack of all trades.  
*Am J Pathol*. 2008 Jun;172(6):1457-66. doi: 10.2353/ajpath.2008.070593. Epub 2008 May 5. Review. (IF 2008: 5,697)
87. Lust M, Vulcano M, **Danese S**.

The protein C pathway in inflammatory bowel disease: the missing link between inflammation and coagulation.

*Trends Mol Med.* 2008 Jun;14(6):237-44. doi: 10.1016/j.molmed.2008.03.005. Epub 2008 May 3. (IF 2008: 9,621)

88. Stefanelli T, Malesci A, Repici A, Vetrano S, **Danese S.**

New insights into inflammatory bowel disease pathophysiology: paving the way for novel therapeutic targets.

*Curr Drug Targets.* 2008 May;9(5):413-8. Review. Doi: 10.2174/138945008784221170 (IF 2008: 4,187)

89. Vulcano M, **Danese S**, Sica A.

Tolerance in intestinal inflammation and cancer.

*Curr Drug Targets.* 2008 May;9(5):404-12. Review. Doi: 10.2174/138945008784221143 (IF 2008: 4,187)

90. Stefanelli T, Malesci A, De La Rue SA, **Danese S.**

Anti-adhesion molecule therapies in inflammatory bowel disease: touch and go.

*Autoimmun Rev.* 2008 May;7(5):364-9. doi: 10.1016/j.autrev.2008.01.002. Epub 2008 Feb 12. Review. (IF 2008: 5,371)

91. Vetrano S, Rescigno M, Cera MR, Correale C, Rumio C, Doni A, Fantini M, Sturm A, Borroni E, Repici A, Locati M, Malesci A, Dejana E, **Danese S.**

Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease.

*Gastroenterology.* 2008 Jul;135(1):173-84. doi: 10.1053/j.gastro.2008.04.002. Epub 2008 Apr 11. (IF 2008: 12,591)

92. Vetrano S, Correale C, Borroni EM, Pagano N, Savino B, Locati M, Malesci A, Repici A, **Danese S.**

Colifagina, a novel preparation of 8 lysed bacteria ameliorates experimental colitis.

*Int J Immunopathol Pharmacol.* 2008 Apr-Jun;21(2):401-7. Doi: 10.1177/039463200802100219 (IF 2008: 2,793)

93. **Danese S**, Peyrin-Biroulet L.

Early combined immunosuppression in Crohn's disease.

*Lancet.* 2008 Jun 14;371(9629):1996; author reply 1996-7. doi: 10.1016/S0140-6736(08)60862-4. (IF 2008: 28,409)

94. **Danese S.**

Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker.

*Dig Liver Dis.* 2008 Jul;40 Suppl 2:S225-8. doi: 10.1016/S1590-8658(08)60530-7. (IF 2008: 2,577)

95. Paclik D, **Danese S**, Berndt U, Wiedenmann B, Dignass A, Sturm A.

Galectin-4 controls intestinal inflammation by selective regulation of peripheral and mucosal T cell apoptosis and cell cycle.

*PLoS One.* 2008 Jul 9;3(7):e2629. doi: 10.1371/journal.pone.0002629. (IF 2009: 4,351)

96. **Danese S**, Angelucci E, Marconi S, Repici A, Malesci A.

Oral beclomethasone: a review of its use in inflammatory bowel disease.

*Mini Rev Med Chem.* 2008 Dec;8(14):1459-63. Review. Doi: 10.2174/138955708786786444 (IF 2008: 3,132)

97. Peyrin-Biroulet L, Bigard MA, Malesci A, **Danese S**.

Step-up and top-down approaches to the treatment of Crohn's disease: early may already be too late.

*Gastroenterology.* 2008 Oct;135(4):1420-2. doi: 10.1053/j.gastro.2008.08.017. Epub 2008 Sep 4. (IF 2008: 12,591)

98. **Danese S**, Papa A.

PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system.

*Eur J Gastroenterol Hepatol.* 2008 Sep;20(9):826-8. doi: 10.1097/MEG.0b013e3282faa769. Review. (IF 2008: 2,08)

99. **Danese S**, Deban L.

Does the mucosal microcirculation play a role in IBD?

*Inflamm Bowel Dis.* 2008 Oct;14 Suppl 2:S125-6. doi: 10.1002/ibd.20716. Erratum in: *Inflamm Bowel Dis.* 2009 Sep;15(9):1438-47. (IF 2008: 4,975)

100. Dessein R, Chamaillard M, **Danese S**.

Innate immunity in Crohn's disease: the reverse side of the medal.

*J Clin Gastroenterol.* 2008 Sep;42 Suppl 3 Pt 1:S144-7. doi: 10.1097/MCG.0b013e3181662c90. Review. (IF 2008: 2,775)

101. **Danese S.**  
Nonimmune cells in inflammatory bowel disease: from victim to villain.  
*Trends Immunol.* 2008 Nov;29(11):555-64. doi: 10.1016/j.it.2008.07.009. Review. (IF: 9,91)
102. Angelucci E, Malesci A, **Danese S.**  
Budesonide: teaching an old dog new tricks for inflammatory bowel disease treatment.  
*Curr Med Chem.* 2008;15(24):2527-35. Review. Doi: 10.2174/092986708785909049 (IF 2008: 4,823)
103. Malesci A, Angelucci E, Bonifacio C, Sociale O, Omodei P, Repici A, Balzarini L, **Danese S.**  
Closure of perianal fistula using adalimumab in a Crohn's disease patient naive to antitumor necrosis factor alpha antibodies.  
*Inflamm Bowel Dis.* 2009 Jun;15(6):814-5. doi: 10.1002/ibd.20739. (IF 2009: 4,643)
104. Repici A, Arezzo A, De Caro G, Morino M, Pagano N, Rando G, Romeo F, Del Conte G, **Danese S**, Malesci A.  
Clinical experience with a new endoscopic over-the-scope clip system for use in the GI tract.  
*Dig Liver Dis.* 2009 Jun;41(6):406-10. doi: 10.1016/j.dld.2008.09.002. Epub 2008 Oct 18. (IF 2009: 2,972)
105. Scaldaferrri F, Vetrano S, Sans M, Arena V, Straface G, Stigliano E, Repici A, Sturm A, Malesci A, Panes J, Yla-Herttuala S, Fiocchi C, **Danese S.**  
VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis.  
*Gastroenterology.* 2009 Feb;136(2):585- 95.e5.  
doi: 10.1053/j.gastro.2008.09.064. Epub 2008 Oct 7. (IF 2009: 12,899)
106. Scaldaferrri F, Sans M, Vetrano S, Correale C, Arena V, Pagano N, Rando G, Romeo F, Potenza AE, Repici A, Malesci A, **Danese S.**  
The role of MAPK in governing lymphocyte adhesion to and migration across the microvasculature in inflammatory bowel disease.  
*Eur J Immunol.* 2009 Jan;39(1):290-300. doi: 10.1002/eji.200838316. (IF 2009: 5,179)
107. De Caro G, Pagano N, Malesci A, Hervoso C, **Danese S**, Romeo F, Delconte G, Repici A.  
Endoclipping for gastric perforation secondary to second session of EMRC in locally residual early gastric cancer: a case report.

- Dig Liver Dis.* 2009 Jul;41(7):e32-4. doi: 10.1016/j.dld.2008.04.004. Epub 2008 Jul 11. (IF 2009: 2,972)
108. Fiorino G, Allez M, Malesci A, **Danese S**.  
Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.  
*Aliment Pharmacol Ther.* 2009 May 1;29(9):921-7. doi: 10.1111/j.1365-2036.2009.03955.x.  
Epub 2009 Feb 10. Review. (IF 2009: 4,357)
109. de la Motte C, Nigro J, VasANJI A, Rho H, Kessler S, Bandyopadhyay S, **Danese S**,  
Fiocchi C, Stern R.  
Platelet-derived hyaluronidase 2 cleaves hyaluronan into fragments that trigger monocyte-mediated production of proinflammatory cytokines.  
*Am J Pathol.* 2009 Jun;174(6):2254- 64. doi: 10.2353/ajpath.2009.080831. Epub 2009 May 14.  
(IF 2009: 5,673)
110. Angelucci E, Orlando A, Ardizzone S, Guidi L, Sorrentino D, Fries W, Astegiano M, Sociale O, Cesarini M, Renna S, Cassinotti A, Marzo M, Quaglia A, Sergi MD, Simondi D, Vernia P, Malesci A, **Danese S**.  
Internet use among inflammatory bowel disease patients: an Italian multicenter survey.  
*Eur J Gastroenterol Hepatol.* 2009 Sep;21(9):1036-41. doi: 10.1097/MEG.0b013e328321b112.  
(IF 2009: 1,662)
111. Vetrano S, **Danese S**.  
The role of JAM-A in inflammatory bowel disease: unrevealing the ties that bind.  
*Ann N Y Acad Sci.* 2009 May;1165:308-13. doi: 10.1111/j.1749-6632.2009.04045.x. Review. (IF 2009: 2,67)
112. Scaldaferrri F, Correale C, Gasbarrini A, **Danese S**.  
Molecular signaling blockade as a new approach to inhibit leukocyte-endothelial interactions for inflammatory bowel disease treatment.  
*Cell Adh Migr.* 2009 Jul-Sep;3(3):296-9. Epub 2009 Jul 2. Doi: 10.4161/cam.3.3.9152 (IF 2011: 1,816)
113. Repici A, Pellicano R, Strangio G, **Danese S**, Fagoonee S, Malesci A.  
Endoscopic mucosal resection for early colorectal neoplasia: pathologic basis, procedures, and outcomes.  
*Dis Colon Rectum.* 2009 Aug;52(8):1502-15.  
doi: 10.1007/DCR.0b013e3181a74d9b. Review. (IF 2009: 2,536)



114. **Danese S**, Angelucci E.  
New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis?  
*Gastroenterol Clin Biol.* 2009 Jun;33 Suppl 3:S217-27. doi: 10.1016/S0399-8320(09)73157-4.  
Review. (IF 2009: 0,928)
115. Szabò H, Fiorino G, Spinelli A, Rovida S, Repici A, Malesci AC, **Danese S**.  
Review article: anti-fibrotic agents for the treatment of Crohn's disease - lessons learnt from other diseases.  
*Aliment Pharmacol Ther.* 2010 Jan 15;31(2):189-201. doi: 10.1111/j.1365-2036.2009.04171.x.  
Epub 2009 Oct 13. Review. (IF 2010: 3,861)
116. Vetrano S, Borroni EM, Sarukhan A, Savino B, Bonecchi R, Correale C, Arena V, Fantini M, Roncalli M, Malesci A, Mantovani A, Locati M, **Danese S**.  
The lymphatic system controls intestinal inflammation and inflammation-associated Colon Cancer through the chemokine decoy receptor D6.  
*Gut.* 2010 Feb;59(2):197-206. doi: 10.1136/gut.2009.183772. Epub 2009 Oct 20. (IF 2010: 10,614)
117. **Danese S**, Vetrano S, Zhang L, Poplis VA, Castellino FJ.  
The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications.  
*Blood.* 2010 Feb 11;115(6):1121-30. doi: 10.1182/blood-2009-09-201616. Epub 2009 Dec 17.  
Review. (IF 2010: 10,558)
118. Di Pucchio T, **Danese S**, De Cristofaro R, Rutella S.  
Inhibitors of indoleamine 2,3- dioxygenase: a review of novel patented lead compounds.  
*Expert Opin Ther Pat.* 2010 Feb;20(2):229-50.  
doi: 10.1517/13543770903512974. Review. (IF 2010: 2,412)
119. **Danese S**, Gao B.  
Interleukin-6: a therapeutic Jekyll and Hyde in gastrointestinal and hepatic diseases.  
*Gut.* 2010 Feb;59(2):149-51. doi: 10.1136/gut.2008.173534. (IF 2010: 10,614)
120. Fava F, **Danese S**.  
Crohn's disease: bacterial clearance in Crohn's disease pathogenesis.  
*Nat Rev Gastroenterol Hepatol.* 2010 Mar;7(3):126-8. doi: 10.1038/nrgastro.2010.1. (IF 2010: 4,558)

121. Deban L, Russo RC, Sironi M, Moalli F, Scanziani M, Zambelli V, Cuccovillo I, Bastone A, Gobbi M, Valentino S, Doni A, Garlanda C, **Danese S**, Salvatori G, Sassano M, Evangelista V, Rossi B, Zenaro E, Constantin G, Laudanna C, Bottazzi B, Mantovani A.  
Regulation of leukocyte recruitment by the long pentraxin PTX3.  
*Nat Immunol.* 2010 Apr;11(4):328-34. doi: 10.1038/ni.1854. Epub 2010 Mar 7. (IF 2010: 25,668)
122. Fiorino G, Rovida S, Correale C, Malesci A, **Danese S**.  
Emerging biologics in the treatment of inflammatory bowel disease: what is around the corner?  
*Curr Drug Targets.* 2010 Feb;11(2):249-60. Review. Doi: 10.2174/138945010790309975 (IF 2010: 3,061)
123. Oussalah A, **Danese S**, Peyrin-Biroulet L.  
Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review.  
*Curr Drug Targets.* 2010 Feb;11(2):156-75. Review. Doi: 10.2174/138945010790309939 (IF 2010: 3,061)
124. **Danese S**.  
Anti TNF-alpha treatment for Crohn' disease: "ménage a trois".  
*Curr Drug Targets.* 2010 Feb;11(2):136-7. Doi: 10.2174/138945010790309911 (IF 2010: 3,061)
125. **Danese S**, Laghi L, Repici A, Malesci A.  
Colorectal cancer screening: dying en route?  
*Dig Liver Dis.* 2010 May;42(5):350-1. doi: 10.1016/j.dld.2010.03.001. Epub 2010 Mar 19. (IF 2010: 2,805)
126. Laverny G, Penna G, Vetrano S, Correale C, Nebuloni M, **Danese S**, Adorini L.  
Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease.  
*Immunol Lett.* 2010 Jun 15;131(1):49-58. doi: 10.1016/j.imlet.2010.03.006. Epub 2010 Mar 27. (IF 2010: 2,511)
127. Fiorino G, Fries W, De La Rue SA, Malesci AC, Repici A, **Danese S**.  
New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut.  
*Curr Med Chem.* 2010;17(17):1851-7. Review. Doi: 10.2174/092986710791111170 (IF 2010: 4,63)

128. **Danese S**, Mantovani A.  
Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer.  
*Oncogene*. 2010 Jun 10;29(23):3313-23. doi: 10.1038/onc.2010.109. Epub 2010 Apr 19. Review. (IF 2010: 7,414)
129. **Danese S**, Fiorino G, Angelucci E, Vetrano S, Pagano N, Rando G, Spinelli A, Malesci A, Repici A.  
Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: a pilot study.  
*World J Gastroenterol*. 2010 May 21;16(19):2396-400. Doi: 10.3748/wjg.v16.i19.2396 (IF 2010: 2,24)
130. Scaldaferri F, Correale C, Gasbarrini A, **Danese S**.  
Mucosal biomarkers in inflammatory bowel disease: key pathogenic players or disease predictors?  
*World J Gastroenterol*. 2010 Jun 7;16(21):2616-25. Review. Doi: 10.3748/wjg.v16.i21.2616 (IF 2010: 2,24)
131. Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, Forti G, Morini S, Hassan C, Pistoia MA, Modeo ME, Rodino' S, D'Amico T, Sebkova L, Sacca' N, Di Giulio E, Luzzza F, Imeneo M, Larussa T, Di Rosa S, Annese V, **Danese S**, et al.  
Treatment of relapsing mild- to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.  
*Am J Gastroenterol*. 2010 Oct;105(10):2218-27. doi: 10.1038/ajg.2010.218. Epub 2010 Jun 1. (IF 2010: 6,882)
132. Repici A, Pagano N, Romeo F, **Danese S**, Arosio M, Rando G, Strangio G, Carlino A, Malesci A.  
Endoscopic flexible treatment of Zenker's diverticulum: a modification of the needle- knife technique.  
*Endoscopy*. 2010 Jul;42(7):532-5. doi: 10.1055/s-0029-1244163. Epub 2010 Jun 30. (IF 2010: 6,096)
133. Fiorino G, Correale C, Fries W, Repici A, Malesci A, **Danese S**.  
Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease.

134. Peyrin-Biroulet L, **Danese S**.  
Infliximab and azathioprine for Crohn's disease: a super-sonic combination?  
*Gastroenterology.* 2010 Sep;139(3):1059-61. doi: 10.1053/j.gastro.2010.07.035. Epub 2010 Jul 24. (IF 2010: 12,032)
135. Jackson CS, Fryer J, **Danese S**, Vanagunas A, Polensky S, Buchman AL.  
Mesenteric vascular thromboembolism in inflammatory bowel disease: a single center experience.  
*J Gastrointest Surg.* 2011 Jan;15(1):97-100. doi: 10.1007/s11605-010-1336-2. Epub 2010 Sep 8. (IF 2011: 2,826)
136. Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D'Inca R, Bossa F, Angelucci E, Biancone L, Gionchetti P, Ardizzone S, Papi C, Fries W, **Danese S**, Riegler G, Cappello M, Castiglione F, Annese V, Orlando A.  
Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.  
*Clin Gastroenterol Hepatol.* 2011 Jan;9(1):30-5. doi: 10.1016/j.cgh.2010.09.026. Epub 2010 Oct 15. (IF 2011: 5,627)
137. Bonanno G, Procoli A, Mariotti A, Corallo M, Perillo A, **Danese S**, De Cristofaro R, Scambia G, Rutella S.  
Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies.  
*J Transl Med.* 2010 Nov 9;8:114. doi: 10.1186/1479-5876-8-114. (IF 2011: 3,474)
138. Allez M, Karmiris K, Louis E, Van Assche G, Ben-Horin S, Klein A, Van der Woude J, Baert F, Eliakim R, Katsanos K, Brynskov J, Steinwurz F, **Danese S**, Vermeire S, Teillaud JL, Lémann M, Chowers Y.  
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects.  
*J Crohns Colitis.* 2010 Oct;4(4):355-66. doi: 10.1016/j.crohns.2010.04.004. Epub 2010 Jun 29. (IF: 2,628)
139. Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, **Danese S**, D'Hoore A, Gassull M, Gomollón F, Hommes DW, Michetti P, O'Morain C, Oresland T, Windsor A, Stange EF, Travis SP; European Crohn's and Colitis Organisation (ECCO).

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management.

*J Crohns Colitis*. 2010 Feb;4(1):28-62. doi: 10.1016/j.crohns.2009.12.002. Epub 2010 Jan 15.

Erratum in: *J Crohns Colitis*. 2010 Sep;4(3):353. Dosage error in article text. (IF 2010: 2,628)

140. Fiorino G, Peyrin-Biroulet L, Repici A, Malesci A, **Danese S**.

Adalimumab in ulcerative colitis: hypes and hopes.

*Expert Opin Biol Ther*. 2011 Jan;11(1):109-16.

doi: 10.1517/14712598.2011.541435. Review. (IF 2011: 3,505)

141. Di Sabatino A, Rovedatti L, Vetrano S, Vidali F, Biancheri P, Rescigno M, **Danese S**, Macdonald TT, Corazza GR.

Involvement of CD40-CD40 ligand in uncomplicated and refractory celiac disease.

*Am J Gastroenterol*. 2011 Mar;106(3):519-27. doi: 10.1038/ajg.2010.450. Epub 2010 Dec 7. (IF 2011: 7,282)

142. **Danese S**.

Role of the vascular and lymphatic endothelium in the pathogenesis of inflammatory bowel disease: 'brothers in arms'.

*Gut*. 2011 Jul;60(7):998-1008. doi: 10.1136/gut.2010.207480. Epub 2011 Jan 6. Review. (IF 2011: 10,111)

143. Rutella S, Vetrano S, Correale C, Graziani C, Sturm A, Spinelli A, De Cristofaro R, Repici A, Malesci A, **Danese S**.

Enhanced platelet adhesion induces angiogenesis in intestinal inflammation and inflammatory bowel disease microvasculature.

*J Cell Mol Med*. 2011 Mar;15(3):625-34. doi: 10.1111/j.1582-4934.2010.01033.x. (IF 2011: 4,125)

144. **Danese S**.

Immune and nonimmune components orchestrate the pathogenesis of inflammatory bowel disease.

*Am J Physiol Gastrointest Liver Physiol*. 2011 May;300(5):G716-22. doi: 10.1152/ajpgi.00472.2010. Epub 2011 Jan 13. Review. (IF 2011: 3,431)

145. Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, Klomp LW, Siersema PD, Schipper ME, **Danese S**, Penna G, Laverny G, Adorini L, Moschetta A, van Mil SW.

- Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease.  
*Gut*. 2011 Apr;60(4):463-72. doi: 10.1136/gut.2010.212159. Epub 2011 Jan 17. (IF 2011: 10,111)
146. Fiorino G, Szabò H, Fries W, Malesci A, Peyrin-Biroulet L, **Danese S**.  
Adalimumab in Crohn's disease: tips and tricks after 5 years of clinical experience.  
*Curr Med Chem*. 2011;18(8):1230-8. Review. Doi: 10.2174/092986711795029726 (IF 2011: 4,859)
147. **Danese S**.  
IBD: of mice and men--shedding new light on IL-13 activity in IBD.  
*Nat Rev Gastroenterol Hepatol*. 2011 Mar;8(3):128-9.  
doi: 10.1038/nrgastro.2011.17. Epub 2011 Feb 8. (IF 2011: 8,102)
148. **Danese S**, Colombel JF, Reinisch W, Rutgeerts PJ.  
Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience.  
*Aliment Pharmacol Ther*. 2011 Apr;33(8):857-69. doi: 10.1111/j.1365-2036.2011.04598.x. Epub 2011 Feb 15. Review. (IF 2011: 3,769)
149. **Danese S**.  
What's hot in inflammatory bowel disease in 2011?  
*World J Gastroenterol*. 2011 Feb 7;17(5):545-6. doi: 10.3748/wjg.v17.i5.545. (IF 2011: 2,471)
150. Fava F, **Danese S**.  
Intestinal microbiota in inflammatory bowel disease: friend of foe?  
*World J Gastroenterol*. 2011 Feb 7;17(5):557-66. doi: 10.3748/wjg.v17.i5.557. (IF 2011: 2,471)
151. Rutella S, Fiorino G, Vetrano S, Correale C, Spinelli A, Pagano N, Arena V, Maggiano N, Repici A, Malesci A, **Danese S**.  
Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease.  
*Am J Gastroenterol*. 2011 Apr;106(4):762-70. doi: 10.1038/ajg.2011.48. Epub 2011 Mar 1. (IF 2011: 7,282)
152. Angulo S, Morales A, **Danese S**, Llacuna L, Masamunt MC, Pultz N, Cifone MG, De Simone C, Delgado S, Vila J, Panes J, Donskey C, Fernández-Checa JC, Fiocchi C, Sans M.

- Probiotic sonicates selectively induce mucosal immune cells apoptosis through ceramide generation via neutral sphingomyelinase.  
*PLoS One*. 2011 Mar 9;6(3):e16953. doi: 10.1371/journal.pone.0016953. (IF 2011: 4,092)
153. **Danese S.**  
Ulcerative colitis: a cinderella story.  
*Curr Drug Targets*. 2011 Sep;12(10):1372. Doi: 10.2174/138945011796818207 (IF 2011: 3,553)
154. Fiorino G, Cesarini M, **Danese S.**  
Biological therapy for ulcerative colitis: what is after anti- TNF.  
*Curr Drug Targets*. 2011 Sep;12(10):1433-9. Review. Doi: 10.2174/138945011796818225 (IF 2011: 3,553)
155. Fiorino G, Bonifacio C, Peyrin-Biroulet L, Minuti F, Repici A, Spinelli A, Fries W, Balzarini L, Montorsi M, Malesci A, **Danese S.**  
Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease.  
*Inflamm Bowel Dis*. 2011 May;17(5):1073-80. doi: 10.1002/ibd.21533. Epub 2010 Nov 8. (IF 2011: 4,855)
156. **Danese S**, Fiorino G, Reinisch W.  
Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF- $\alpha$  therapy.  
*Aliment Pharmacol Ther*. 2011 Jul;34(1):1-10. doi: 10.1111/j.1365-2036.2011.04679.x. Epub 2011 May 3. Review. (IF 2011: 3,769)
157. Pariente B, Cosnes J, **Danese S**, Sandborn WJ, Lewin M, Fletcher JG, Chowers Y, D'Haens G, Feagan BG, Hibi T, Hommes DW, Irvine EJ, Kamm MA, Loftus EV Jr, Louis E, Michetti P, Munkholm P, Oresland T, Panes J, Peyrin-Biroulet L, Reinisch W, Sands BE, et al.  
Development of the Crohn's disease digestive damage score, the Lémann score.  
*Inflamm Bowel Dis*. 2011 Jun;17(6):1415-22. doi: 10.1002/ibd.21506. Epub 2010 Nov 28. (IF 2011: 4,855)
158. Peyrin-Biroulet L, Cieza A, Sandborn WJ, Coenen M, Chowers Y, Hibi T, Kostanjsek N, Stucki G, Colombel JF; International Programme to Develop New Indexes for Crohn's Disease (IPNIC) group.  
Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health.

- Gut*. 2012 Feb;61(2):241-7. doi: 10.1136/gutjnl-2011-300049. Epub 2011 Jun 5. (IF 2012: 10,732)
159. Iborra M, Bernuzzi F, Invernizzi P, **Danese S**.  
MicroRNAs in autoimmunity and inflammatory bowel disease: crucial regulators in immune response.  
*Autoimmun Rev*. 2012 Mar;11(5):305-14. doi: 10.1016/j.autrev.2010.07.002. Epub 2010 Jul 11. Review. (IF 2012: 7,975)
160. Fiorino G, Peyrin-Biroulet L, Naccarato P, Szabò H, Sociale OR, Vetrano S, Fries W, Montanelli A, Repici A, Malesci A, **Danese S**.  
Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study.  
*Inflamm Bowel Dis*. 2012 Jun;18(6):1042-7. doi: 10.1002/ibd.21800. Epub 2011 Jun 14. (IF 2012: 5,119)
161. Nunes T, Fiorino G, **Danese S**, Sans M.  
Familial aggregation in inflammatory bowel disease: is it genes or environment?  
*World J Gastroenterol*. 2011 Jun 14;17(22):2715-22. doi: 10.3748/wjg.v17.i22.2715. Review. (IF 2011: 2,471)
162. Spinelli A, Sacchi M, Fiorino G, **Danese S**, Montorsi M.  
Risk of postoperative recurrence and postoperative management of Crohn's disease.  
*World J Gastroenterol*. 2011 Jul 21;17(27):3213-9. doi: 10.3748/wjg.v17.i27.3213. Review. (IF 2011: 2,471)
163. Peyrin-Biroulet L, Ferrante M, Magro F, Campbell S, Franchimont D, Fidder H, Strid H, Ardizzone S, Veereman-Wauters G, Chevaux JB, Allez M, **Danese S**, Sturm A; Scientific Committee of the European Crohn's and Colitis Organization.  
Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease.  
*J Crohns Colitis*. 2011 Oct;5(5):477-83. doi: 10.1016/j.crohns.2011.06.009. Epub 2011 Aug 3. (IF: 2,566)
164. Repici A, Pagano N, Hassan C, Carlino A, Rando G, Strangio G, Romeo F, Zullo A, Ferrara E, Vitetta E, Ferreira Dde P, **Danese S**, Arosio M, Malesci A  
Balanced propofol sedation administered by nonanesthesiologists: The first Italian experience.



- World J Gastroenterol.* 2011 Sep 7;17(33):3818-23. doi: 10.3748/wjg.v17.i33.3818. (IF 2011: 2,471)
165. **Danese S.**  
Adalimumab for ulcerative colitis: a little is better than none?  
*Inflamm Bowel Dis.* 2012 Apr;18(4):793-4. doi: 10.1002/ibd.21773. Epub 2011 May 3. (IF 2012: 5,119)
166. **Danese S, Malesci A, Vetrano S.**  
Colitis-associated cancer: the dark side of inflammatory bowel disease.  
*Gut.* 2011 Dec;60(12):1609-10. doi: 10.1136/gutjnl-2011-300953. Epub 2011 Oct 13. (IF 2011: 10,111)
167. **Danese S, Fiocchi C.**  
Ulcerative colitis.  
*N Engl J Med.* 2011 Nov 3;365(18):1713-25. doi: 10.1056/NEJMra1102942. Review. (IF 2011: 53,298)
168. **Werner L, Berndt U, Paclik D, Danese S, Schirbel A, Sturm A.**  
TNF $\alpha$  inhibitors restrict T cell activation and cycling via Notch-1 signalling in inflammatory bowel disease.  
*Gut.* 2012 Jul;61(7):1016-27. doi: 10.1136/gutjnl-2011-301267. Epub 2011 Nov 7. (IF 2011: 10,732)
169. **Repici A, Di Stefano AF, Radicioni MM, Jas V, Moro L, Danese S.**  
Methylene blue MMX tablets for chromoendoscopy. Safety tolerability and bioavailability in healthy volunteers.  
*Contemp Clin Trials.* 2012 Mar;33(2):260-7. doi: 10.1016/j.cct.2011.11.006. Epub 2011 Nov 11. (IF 2012: 1,597)
170. **Fiorino G, Bonifacio C, Malesci A, Balzarini L, Danese S.**  
MRI in Crohn's disease--current and future clinical applications.  
*Nat Rev Gastroenterol Hepatol.* 2011 Nov 22;9(1):23-31. doi: 10.1038/nrgastro.2011.214. Review. (IF 2010: 10,426)
171. **Vetrano S, Ploplis VA, Sala E, Sandoval-Cooper M, Donahue DL, Correale C, Arena V, Spinelli A, Repici A, Malesci A, Castellino FJ, Danese S.**

Unexpected role of anticoagulant protein C in controlling epithelial barrier integrity and intestinal inflammation.

*Proc Natl Acad Sci U S A*. 2011 Dec 6;108(49):19830-5. doi: 10.1073/pnas.1107140108. Epub 2011 Nov 22. (IF 2012: 9,737)

172. **Danese S.**

New therapies for inflammatory bowel disease: from the bench to the bedside.

*Gut*. 2012 Jun;61(6):918-32. doi: 10.1136/gutjnl-2011-300904. Epub 2011 Nov 23. Review. (IF 2012: 10,732)

173. Spinelli A, Bazzi P, Spaggiari P, **Danese S**, Montorsi M.

Surgical conduct in case of intraoperative detection of a Meckel's diverticulum in Crohn's disease.

*J Crohns Colitis*. 2011 Dec;5(6):647-8. doi: 10.1016/j.crohns.2011.08.005. Epub 2011 Sep 9. (IF 2011: 2,566)

174. Prantera C, Lochs H, Grimaldi M, **Danese S**, Scribano ML, Gionchetti P; Retic Study Group (Rifaximin-Eir Treatment in Crohn's Disease).

Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease.

*Gastroenterology*. 2012 Mar;142(3):473-481.e4. doi: 10.1053/j.gastro.2011.11.032. Epub 2011 Dec 6. (IF 2012: 12,821)

175. Mikocka-Walus AA, Andrews JM, Bernstein CN, Graff LA, Walker JR, Spinelli A, **Danese S**, van der Woude CJ, Goodhand J, Rampton D, Moser G.

Integrated models of care in managing inflammatory bowel disease: a discussion.

*Inflamm Bowel Dis*. 2012 Aug;18(8):1582-7. doi: 10.1002/ibd.22877. Epub 2012 Jan 12. Review. (IF 2012: 5,119)

176. Sorrentino D, Terrosu G, Paviotti A, Geraci M, Avellini C, Zoli G, Fries W, **Danese S**, Occhipinti P, Croatto T, Zarifi D.

Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: partial benefit by infliximab--a pilot study.

*Dig Dis Sci*. 2012 May;57(5):1341-8. doi: 10.1007/s10620-011-2025-z. Epub 2012 Jan 18. (IF 2012: 2,26)

177. Spinelli A, Sacchi M, Bazzi P, Leone N, **Danese S**, Montorsi M.

Laparoscopic surgery for recurrent Crohn's disease.

- Gastroenterol Res Pract.* 2012;2012:381017. doi: 10.1155/2012/381017. Epub 2012 Jan 2. (IF 2012: 1,615)
178. **Danese S**, Peyrin-Biroulet L.  
Editorial: Imaging Inflammatory Bowel Disease: Looking Beyond the Mucosa,  
*Curr Drug Targets.* 2012 Sep 1;13(10):1223. doi: 10.2174/138945012802429606 (IF 2012: 3,848)
179. **Danese S**, Peyrin-Biroulet L.  
IBD: Mucosal healing--EXTENDING our knowledge in Crohn's disease.  
*Nat Rev Gastroenterol Hepatol.* 2012 Apr 24;9(6):309-11. doi: 10.1038/nrgastro.2012.77. (IF 2012: 10,426)
180. Ponziani FR, Cazzato IA, **Danese S**, Fagioli S, Gionchetti P, Annicchiarico BE, D'Aversa F, Gasbarrini A.  
Folate in gastrointestinal health and disease.  
*Eur Rev Med Pharmacol Sci.* 2012 Mar;16(3):376-85. Review. (IF 2012: 1,093)
181. Fiorino G, Cesarini M, Malesci A, **Danese S**, Sorrentino D.  
The role of magnetic resonance imaging in detecting intestinal fibrosis in Crohn's disease.  
*Curr Drug Targets.* 2012 Sep 1;13(10):1273-9. Doi: 10.2174/138945012802429651 (IF 2012: 3,848)
182. Spinelli A, De Cassan C, Sacchi M, Bazzi P, **Danese S**, Malesci A, Balzarini L, Montorsi M.  
Imaging modalities for perianal Crohn's disease.  
*Curr Drug Targets.* 2012 Sep 1;13(10):1287-93. Review. Doi: 10.2174/138945012802429723 (IF 2012: 3,848)
183. Fiorino G, Peyrin-Biroulet L, **Danese S**.  
Bowel damage assessment in Crohn's disease by magnetic resonance imaging.  
*Curr Drug Targets.* 2012 Sep 1;13(10):1300-7. Review. Doi: 10.2174/138945012802429705 (IF 2012: 3,848)
184. **Danese S**.  
Adalimumab in ulcerative colitis: ready for prime time.  
*Dig Liver Dis.* 2013 Jan;45(1):8-13. doi: 10.1016/j.dld.2012.05.021. Epub 2012 Jul 4. Review. (IF 2013: 2,889)

185. De Cassan C, Fiorino G, **Danese S**.  
Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects?  
*Dig Dis*. 2012;30(4):368-75. doi: 10.1159/000338128. Epub 2012 Jul 12. Review. (IF 2012: 2,725)
186. Reggiani Bonetti L, Migaldi M, Caredda E, Boninsegna A, Ponz De Leon M, Di Gregorio C, Barresi V, Scannone D, **Danese S**, Cittadini A, Sgambato A.  
Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.  
*Scand J Gastroenterol*. 2012 Oct;47(10):1211-7. Epub 2012 Aug 3. Doi: 10.3109/00365521.2012.694904 (IF 2012: 2,1569)
187. Peyrin-Biroulet L, **Danese S**.  
Leukoapheresis in Crohn's disease: the final curtain?  
*Gut*. 2013 Apr;62(4):487-8. doi: 10.1136/gutjnl-2012-302774. Epub 2012 Aug 14. Review. (IF 2013: 13,319)
188. Spinelli A, Bazzi P, Sacchi M, **Danese S**, Fiorino G, Malesci A, Gentilini L, Poggioli G, Montorsi M.  
Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn's disease: a case-matched analysis.  
*J Gastrointest Surg*. 2013 Jan;17(1):126-32; discussion p.132. doi: 10.1007/s11605-012-2012-5. Epub 2012 Sep 5. (IF 2013: 2,391)
189. D'Haens G, Feagan B, Colombel JF, Sandborn WJ, Reinisch W, Rutgeerts P, Carbonnel F, Mary JY, **Danese S**, Fedorak RN, Hanauer S, Lémann M; International Organization for Inflammatory Bowel Diseases (IOIBD) and the Clinical Trial Committee Clincom of the European Crohn's and Colitis Organisation (ECCO).  
Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease.  
*Gastroenterology*. 2012 Dec;143(6):1461-9. doi: 10.1053/j.gastro.2012.09.031. Epub 2012 Sep 20. Review. (IF 2012: 12,821)
190. **Danese S**, Fiorino G, Rutella S.  
Regulatory T-cell therapy for Crohn's disease: in vivo veritas.

- Gastroenterology*. 2012 Nov;143(5):1135-8. doi: 10.1053/j.gastro.2012.09.019. Epub 2012 Sep 20. (IF 2012: 12,821)
191. Van Assche G, Dignass A, Bokemeyer B, **Danese S**, Gionchetti P, Moser G, Beaugerie L, Gomollón F, Hàuser W, Herrlinger K, Oldenburg B, Panes J, Portela F, Rogler G, Stein J, Tilg H, Travis S, Lindsay JO; European Crohn's and Colitis Organisation.  
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations.  
*J Crohns Colitis*. 2013 Feb;7(1):1-33. doi: 10.1016/j.crohns.2012.09.005. Epub 2012 Oct 3. (IF 2013: 3,562)
192. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG; CERTIFI Study Group.  
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.  
*N Engl J Med*. 2012 Oct 18;367(16):1519-28. doi: 10.1056/NEJMoa1203572. (IF 2012: 51,658)
193. Correale C, Genua M, Vetrano S, Mazzini E, Martinoli C, Spinelli A, Arena V, Peyrin-Biroulet L, Caprioli F, Passini N, Panina-Bordignon P, Repici A, Malesci A, Rutella S, Rescigno M, **Danese S**.  
Bacterial sensor triggering receptor expressed on myeloid cells-2 regulates the mucosal inflammatory response.  
*Gastroenterology*. 2013 Feb;144(2):346-356.e3. doi: 10.1053/j.gastro.2012.10.040. Epub 2012 Oct 26. (IF 2013: 13,926)
194. **Danese S**.  
New and emerging therapies for inflammatory bowel disease.  
*Gastroenterol Hepatol (N Y)*. 2012 Dec;8(12):844-6.
195. Peyrin-Biroulet L, Billioud V, D'Haens G, Panaccione R, Feagan B, Panes J, **Danese S**, Schreiber S, Ogata H, Hibi T, Higgins PD, Beaugerie L, Chowers Y, Louis E, Steinwurz F, Reinisch W, Rutgeerts P, Colombel JF, Travis S, Sandborn WJ.  
Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process.  
*Am J Gastroenterol*. 2012 Dec;107(12):1770-6. doi: 10.1038/ajg.2012.117. (IF 2012: 7,553)
196. Peyrin-Biroulet L, **Danese S**.  
Stopping infliximab in Crohn's disease: still an ongoing STORI.

*Inflamm Bowel Dis.* 2012 Nov;18(11):2201-2. Doi: 10.1002/ibd.23016 (IF 2012: 5,119)

197. Jovani M, Fiorino G, **Danese S**.

Commentary: associations between immune activation, intestinal permeability and irritable bowel syndrome.

*Aliment Pharmacol Ther.* 2013 Jan;37(2):277- 8. doi: 10.1111/apt.12136. (IF 2013: 5,478)

198. Cleynen I, González JR, Figuerola C, Franke A, McGovern D, Bortlák M, Crusius BJ, Vecchi M, Artieda M, Szczypiorska M, Bethge J, Arteta D, Ayala E, **Danese S**, van Hogezaand RA, Panes J, Peà SA, Lukas M, Jewell DP, Schreiber S, Vermeire S, Sans M.

Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project.

*Gut.* 2013 Nov;62(11):1556-65. doi: 10.1136/gutjnl- 2011-300777. Epub 2012 Dec 21. (IF 2013: 13,319)

199. **Danese S**, Rutella S, Vetrano S.

Mesenchymal stromal cells in inflammatory bowel disease: conspirators within the 'colitogenic niche'?

*Gut.* 2013 Aug;62(8):1098-9. doi: 10.1136/gutjnl-2012- 303903. Epub 2012 Dec 22. (IF 2013: 13,319)

200. Vetrano S, **Danese S**.

Colitis, microbiota, and colon cancer: an infernal triangle.

*Gastroenterology.* 2013 Feb;144(2):461-3. doi: 10.1053/j.gastro.2012.12.016. Epub 2012 Dec 20. (IF 2013: 13,926)

201. Biancheri P, Di Sabatino A, Rovedatti L, Giuffrida P, Calarota SA, Vetrano S, Vidali F, Pasini A, **Danese S**, Corazza GR, MacDonald TT.

Effect of tumor necrosis factor- $\alpha$  blockade on mucosal addressin cell-adhesion molecule-1 in Crohn's disease.

*Inflamm Bowel Dis.* 2013 Feb;19(2):259-64. doi: 10.1097/MIB.0b013e31828100a4. (IF 2013: 5,475)

202. Travis SP, **Danese S**, Kupcinkas L, Alexeeva O, D'Haens G, Gibson PR, Moro L, Jones R, Ballard ED, Masure J, Rossini M, Sandborn WJ.

Once-daily budesonide MMX in active, mild-to- moderate ulcerative colitis: results from the randomised CORE II study.

- Gut*. 2014 Mar;63(3):433- 41. doi: 10.1136/gutjnl-2012-304258. Epub 2013 Feb 22. (IF 2014: 14,660)
203. Armuzzi A, Pugliese D, **Danese S**, Rizzo G, Felice C, Marzo M, Andrisani G, Fiorino G, Sociale O, Papa A, De Vitis I, Rapaccini GL, Guidi L.  
Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission.  
*Inflamm Bowel Dis*. 2013 Apr;19(5):1065-72. doi: 10.1097/MIB.0b013e3182802909. (IF 2013: 5,475)
204. Peyrin-Biroulet L, Fiorino G, Buisson A, **Danese S**.  
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?  
*Nat Rev Gastroenterol Hepatol*. 2013 Jun;10(6):345-51. doi: 10.1038/nrgastro.2013.31. Epub 2013 Mar 5. Review. Erratum in: *Nat Rev Gastroenterol Hepatol*. 2013 Jun;10(6):ii. (IF 2013: 10,807)
205. Cammarota T, Ribaldone DG, Resegotti A, Repici A, **Danese S**, Fiorino G, Sarno A, Robotti D, Deboni P, Bonenti G, Pellicano R, Andrealli A, Sapone N, Simondi D, Bresso F, Astegiano M.  
Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease.  
*Scand J Gastroenterol*. 2013 May;48(5):552-5. doi: 10.3109/00365521.2013.777774. Epub 2013 Mar 11. (IF 2013: 2,329)
206. **Danese S**, Colombel JF, Peyrin-Biroulet L, Rutgeerts P, Reinisch W.  
Review article: the role of anti-TNF in the management of ulcerative colitis -- past, present and future.  
*Aliment Pharmacol Ther*. 2013 May;37(9):855-66. doi: 10.1111/apt.12284. Epub 2013 Mar 13. Review. (IF 2013: 5,478)
207. Indriolo A, Fagioli S, Pasulo L, Fiorino G, **Danese S**, Ravelli P.  
Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation.  
*Aliment Pharmacol Ther*. 2013 Apr;37(8):840-2. doi: 10.1111/apt.12256. (IF 2013: 5,478)
208. Peyrin-Biroulet L, **Danese S**.  
Tofacitinib: janus bifrons in ulcerative colitis treatment.  
*Gastroenterology*. 2013 May;144(5):1136-8. doi: 10.1053/j.gastro.2013.03.036. Epub 2013 Mar 23. (IF 2013: 13,926)

209. Niess JH, **Danese S**.  
Anti-TNF and skin inflammation in IBD: a new paradox in gastroenterology?  
*Gut*. 2014 Apr;63(4):533-5. doi: 10.1136/gutjnl-2013-304683. Epub 2013 Apr 9. (IF 2013: 13,319)
210. Panes J, Bouhnik Y, Reinisch W, Stoker J, Taylor SA, Baumgart DC, **Danese S**, Halligan S, Marincek B, Matos C, Peyrin-Biroulet L, Rimola J, Rogler G, van Assche G, Ardizzone S, Bassalamah A, Bali MA, Bellini D, Biancone L, Castiglione F, Ehehalt R, Grassi R, et al.  
Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines.  
*J Crohns Colitis*. 2013 Aug;7(7):556-85. doi: 10.1016/j.crohns.2013.02.020. Epub 2013 Apr 11. (IF 2013: 3,562)
211. Saibeni S, Etchevers MJ, Tassies D, Panes J, Reverter JC, **Danese S**, Piqué JM, Bruno S, Vecchi M, Gasbarrini A, Sans M.  
Assessment of anti-prothrombin antibodies in thrombosis complicating inflammatory bowel diseases.  
*Int J Colorectal Dis*. 2013 Sep;28(9):1281-6. doi: 10.1007/s00384-013-1696-7. Epub 2013 Apr 16. (IF 2013: 2,415)
212. Iborra M, Bernuzzi F, Correale C, Vetrano S, Fiorino G, Beltrà;n B, Marabita F, Locati M, Spinelli A, Nos P, Invernizzi P, **Danese S**.  
Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease.  
*Clin Exp Immunol*. 2013 Aug;173(2):250-8. doi: 10.1111/cei.12104. (IF 2013: 3,278)
213. **Danese S**, Gomollón F; Governing Board and Operational Board of ECCO.  
ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).  
*J Crohns Colitis*. 2013 Aug;7(7):586-9. doi: 10.1016/j.crohns.2013.03.011. Epub 2013 Apr 25. (IF 2013: 3,562)
214. Sebastian S, Hernández V, Myrelid P, Kariv R, Tsianos E, Toruner M, Marti-Gallostra M, Spinelli A, van der Meulen-de Jong AE, Yuksel ES, Gasche C, Ardizzone S, **Danese S**.  
Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I).  
*J Crohns Colitis*. 2014 Jan;8(1):5-18. doi: 10.1016/j.crohns.2013.04.008. Epub 2013 May 9. Review. (IF 2014: 6,234)



215. Italian Group for the Study of Inflammatory Bowel Disease, Armuzzi A, Biancone L, Daperno M, Coli A, Pugliese D, Annese V, Aratari A, Ardizzone S, Balestrieri P, Bossa F, Cappello M, Castiglione F, Cicala M, **Danese S**, D'Incà R, Dulbecco P, Feliciangeli G, Fries W, Genise S, Gionchetti P, Gozzi S, et al.  
Adalimumab in active ulcerative colitis: a real-life" observational study."  
*Dig Liver Dis.* 2013 Sep;45(9):738-43. doi: 10.1016/j.dld.2013.03.018. Epub 2013 May 15. (IF 2013: 2,889)
216. Jovani M, Fiorino G, **Danese S**.  
Anti-IL-13 in inflammatory bowel disease: from the bench to the bedside.  
*Curr Drug Targets.* 2013 Nov;14(12):1444-52. Review. Doi: 10.2174/13894501113149990170 (IF 2013: 3,597)
217. Fiorino G, **Danese S**, Pariente B, Allez M.  
Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF- $\alpha$  agents.  
*Autoimmun Rev.* 2014 Jan;13(1):15-9. doi: 10.1016/j.autrev.2013.06.005. Epub 2013 Jun 15. Review. (IF 2014: 7,933)
218. **Danese S**.  
IBD: Golimumab in ulcerative colitis: a 'ménage à trois' of drugs.  
*Nat Rev Gastroenterol Hepatol.* 2013 Sep;10(9):511-2. doi: 10.1038/nrgastro.2013.142. Epub 2013 Jul 30. (IF 2013: 10,807)
219. Fiorino G, Bonifacio C, Padrenostro M, Sposta FM, Spinelli A, Malesci A, Balzarini L, Peyrin-Biroulet L, **Danese S**.  
Comparison between 1.5 and 3.0 Tesla magnetic resonance enterography for the assessment of disease activity and complications in ileo-colonic Crohn's disease.  
*Dig Dis Sci.* 2013 Nov;58(11):3246-55. doi: 10.1007/s10620-013-2781-z. Epub 2013 Aug 1. (IF 2013: 2,55)
220. Allocca M, Fiorino G, **Danese S**.  
Commentary: antibodies reacting with the infliximab Fab portion--something new?  
*Aliment Pharmacol Ther.* 2013 Sep;38(5):552. doi: 10.1111/apt.12401. (IF 2013: 5,478)
221. Ferrante M, Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens GR, van der Woude CJ, **Danese S**, Diamond RH,

Oortwijn AF, Tang KL, Miller M, Cornillie F, Rutgeerts PJ; International Organization for the Study of Inflammatory Bowel Diseases.

Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.

*Gastroenterology*. 2013 Nov;145(5):978- 986.e5. doi: 10.1053/j.gastro.2013.08.010. Epub 2013 Aug 14. (IF 2013: 13,926)

222. Tursi A, Brandimarte G, Elisei W, Picchio M, Forti G, Pianese G, Rodino S, D'Amico T, Sacca N, Portincasa P, Capezzuto E, Lattanzio R, Spadaccini A, Fiorella S, Polimeni F, Polimeni N, Stoppino V, Stoppino G, Giorgetti GM, Aiello F, **Danese S**.

Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease--a double-blind, randomised, placebo-controlled study.

*Aliment Pharmacol Ther*. 2013 Oct;38(7):741- 51. doi: 10.1111/apt.12463. Epub 2013 Aug 19. (IF 2013: 5,478)

223. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, **Danese S**, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group.

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

*N Engl J Med*. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734. (IF 2013: 54,42)

224. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group.

Vedolizumab as induction and maintenance therapy for Crohn's disease.

*N Engl J Med*. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739. (IF 2013: 54,42)

225. Jovani M, **Danese S**.

Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells.

*Curr Drug Targets*. 2013 Nov;14(12):1433-43. Review. Doi: 10.2174/13894501113146660206 (IF 2013: 3,597)

226. Allocca M, Fiorino G, **Danese S**.

Cross-sectional imaging modalities in Crohn's disease.

*Dig Dis*. 2013;31(2):199-201. doi: 10.1159/000353692. Epub 2013 Sep 6. Review. (IF 2013: 1,832)

227. **Danese S**, Peyrin-Biroulet L.  
New mechanisms and targets for IBD Therapy: translational gastroenterology comes of age.  
*Curr Drug Targets*. 2013 Nov;14(12):1377-8. Doi: 10.2174/13894501113146660220 (IF: 3,597)
228. Guidi L, Felice C, Procoli A, Bonanno G, Martinelli E, Marzo M, Mocci G, Pugliese D, Andrisani G, **Danese S**, De Vitis I, Papa A, Armuzzi A, Rutella S.  
FOXP3<sup>+</sup> T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNF $\alpha$  agents.  
*Biomed Res Int*. 2013;2013:286368. doi: 10.1155/2013/286368. Epub 2013 Aug 26. (IF 2014: 1.579)
229. D'Alessio S, Tacconi C, Fiocchi C, **Danese S**.  
Advances in therapeutic interventions targeting the vascular and lymphatic endothelium in inflammatory bowel disease.  
*Curr Opin Gastroenterol*. 2013 Nov;29(6):608-13. doi: 10.1097/MOG.0b013e328365d37c. Review. (IF 2013: 3,664)
230. Reinisch W, Chowers Y, **Danese S**, Dignass A, Gomollón F, Nielsen OH, Lakatos PL, Lees CW, Lindgren S, Lukas M, Mantzaris GJ, Michetti P, Moum B, Peyrin-Biroulet L, Toruner M, van der Woude J, Weiss G, Stoevelaar H.  
The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness method.  
*Aliment Pharmacol Ther*. 2013 Nov;38(9):1109-18. doi: 10.1111/apt.12493. Epub 2013 Sep 17. (IF 2013: 5,478)
231. Stein J, Bager P, Befrits R, Gasche C, Gudehus M, Lerebours E, Magro F, Mearin F, Mitchell D, Oldenburg B, **Danese S**.  
Anaemia management in patients with inflammatory bowel disease: routine practice across nine European countries.  
*Eur J Gastroenterol Hepatol*. 2013 Dec;25(12):1456-63. doi: 10.1097/MEG.0b013e328365ca7f. (IF 2013: 2,152)
232. Allocca M, Jovani M, Fiorino G, Schreiber S, **Danese S**.  
Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target.  
*Curr Drug Targets*. 2013 Nov;14(12):1508-21. Review. Doi: 10.2174/13894501113146660224 (IF 2013: 3,597)
233. Torres J, **Danese S**, Colombel JF.

New therapeutic avenues in ulcerative colitis: thinking out of the box.

*Gut*. 2013 Nov;62(11):1642-52. doi: 10.1136/gutjnl-2012-303959. Review. (IF 2013: 13,319)

234. Tilg H, **Danese S**.

Roseburia hominis: a novel guilty player in ulcerative colitis pathogenesis?

*Gut*. 2014 Aug;63(8):1204-5. doi: 10.1136/gutjnl-2013-305799. Epub 2013 Oct 14. (IF 2014: 14,66)

235. Barello S, Leone D, **Danese S**, Vegni E.

Inflammatory bowel diseases and psychological issues: A new approach for a systematic analysis of the academic debate.

*Psychol Health Med*. 2014;19(5):559-71. doi: 10.1080/13548506.2013.855317. Epub 2013 Nov 12. (IF 2014: 1,255)

236. Cesarini M, Katsanos K, Papamichael K, Ellul P, Lakatos PL, Caprioli F, Kopylov U, Tsianos E, Mantzaris GJ, Ben-Horin S, **Danese S**, Fiorino G.

Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study.

*Dig Liver Dis*. 2014 Feb;46(2):135-9. doi: 10.1016/j.dld.2013.10.007. Epub 2013 Nov 15. (IF 2014: 2,963)

237. Spinelli A, Fiorino G, Bazzi P, Sacchi M, Bonifacio C, De Bastiani S, Malesci A, Balzarini L, Peyrin-Biroulet L, Montorsi M, **Danese S**.

Preoperative magnetic resonance enterography in predicting findings and optimizing surgical approach in Crohn's disease.

*J Gastrointest Surg*. 2014 Jan;18(1):83-90; discussion 90-1. doi: 10.1007/s11605-013-2404-1. Epub 2013 Nov 20. (IF 2014: 2,798)

238. Roblin X, **Danese S**, Peyrin-Biroulet L.

Does anti-TNF therapy cost so many COINs?

*Gastroenterology*. 2014 Jan;146(1):309-11. doi: 10.1053/j.gastro.2013.11.012. Epub 2013 Nov 21. (IF 2014: 16,716)

239. Fiorino G, Allocca M, **Danese S**.

Commentary: anaemia in inflammatory bowel disease--the most common and ignored extra intestinal manifestation.

*Aliment Pharmacol Ther*. 2014 Jan;39(2):227-8. doi: 10.1111/apt.12578. (IF 2014: 5,727)

240. **Danese S**, Peyrin-Biroulet L.  
IBD in 2013: enriching the therapeutic armamentarium for IBD.  
*Nat Rev Gastroenterol Hepatol*. 2014 Feb;11(2):84-6. doi: 10.1038/nrgastro.2013.246. Epub 2013 Dec 24. Review. (IF 2014: 12,61)
241. van der Woude CJ, Metselaar HJ, **Danese S**.  
Management of gastrointestinal and liver diseases during pregnancy.  
*Gut*. 2014 Jun;63(6):1014-23. doi: 10.1136/gutjnl-2013-305418. Epub 2014 Jan 15. Review. (IF 2014: 14,66)
242. Fiorino G, Gilardi D, Naccarato P, Sociale OR, **Danese S**.  
Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis.  
*Dig Liver Dis*. 2014 Apr;46(4):330-4. doi: 10.1016/j.dld.2013.12.008. Epub 2014 Jan 21. (IF 2014: 2,963)
243. **Danese S**, Gomollón F, Michetti P.  
EMA response to ECCO position statement on biosimilars.  
*J Crohns Colitis*. 2014 Mar;8(3):259. doi: 10.1016/j.crohns.2014.01.017. Epub 2014 Feb 7. (IF 2014: 6,234)
244. Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, van Hoogstraten HJ, Chen AC, Zheng H, **Danese S**, Rutgeerts P.  
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.  
*Gastroenterology*. 2014 Feb;146(2):392-400.e3. doi: 10.1053/j.gastro.2013.10.052 (IF 2014: 16,716)
245. Gomollón F, Chowers Y, **Danese S**, Dignass A, Haagen Nielsen O, Lakatos PL, Lees CW, Lindgren S, Lukas M, Mantzaris GJ, Michetti P, Moum B, Peyrin-Biroulet L, Toruner M, van der Woude J, Weiss G, Stoevelaar H, Reinisch W.  
Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicines.  
*Aliment Pharmacol Ther*. 2014 Apr;39(7):743-4. doi: 10.1111/apt.12648. (IF 2014: 5,727)
246. **Danese S**, Siegel CA, Peyrin-Biroulet L.  
Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.

- Aliment Pharmacol Ther.* 2014 May;39(10):1095-103. doi: 10.1111/apt.12712. Epub 2014 Mar 19. Review. (IF 2014: 5,727)
247. Fiorino G, Girolomoni G, Lapadula G, Orlando A, **Danese S**, Olivieri I; SIR, SIDeMaST, and IG-IBD.  
The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper.  
*Autoimmun Rev.* 2014 Jul;13(7):751-5. doi: 10.1016/j.autrev.2014.02.004. Epub 2014 Mar 19. Review. (IF 2014: 7,933)
248. Bressenot A, Cahn V, **Danese S**, Peyrin-Biroulet L.  
Microscopic features of colorectal neoplasia in inflammatory bowel diseases.  
*World J Gastroenterol.* 2014 Mar 28;20(12):3164-72. doi: 10.3748/wjg.v20.i12.3164. (IF 2014: 2,369)
249. Sozzani S, Abbracchio MP, Annese V, **Danese S**, De Pità O, De Sarro G, Maione S, Olivieri I, Parodi A, Sarzi-Puttini P.  
Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review.  
*Autoimmunity.* 2014 Aug;47(5):287-306. doi: 10.3109/08916934.2014.897333. Epub 2014 Apr 3. (IF 2014: 2,714)
250. Nielsen OH, Riis LB, **Danese S**, Bojesen RD, Soendergaard C.  
Proximal collagenous gastroenteritides: clinical management. A systematic review.  
*Ann Med.* 2014 Aug;46(5):311-7. doi: 10.3109/07853890.2014.899102. Epub 2014 Apr 10. (IF 2014: 3,886)
251. Fiorino G, **Danese S**.  
Commentary: Adjunct antibiotic combination therapy for ulcerative colitis--is it time to investigate *Fusobacterium varium*?  
*Aliment Pharmacol Ther.* 2014 Jun;39(11):1333. doi: 10.1111/apt.12742. (IF 2014: 5,727)
252. Allocca M, Fiorino G, Vermeire S, Reinisch W, Cataldi F, **Danese S**.  
Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target.  
*Expert Rev Clin Immunol.* 2014 Jul;10(7):885-95. doi: 10.1586/1744666X.2014.917962. Epub 2014 May 12. Review. (IF 2014: 2,484)

253. Gilardi D, Fiorino G, Genua M, Allocca M, **Danese S**  
Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine?  
*Expert Rev Gastroenterol Hepatol.* 2014 Sep;8(7):835-46. doi: 10.1586/17474124.2014.917954. Epub 2014 May 12. (IF 2014: 2,417)
254. **Danese S**, Fiorino G, Peyrin-Biroulet L, Lucenteforte E, Virgili G, Moja L, Bonovas S.  
Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.  
*Ann Intern Med.* 2014 May 20;160(10):704-11. doi: 10.7326/M13-2403. Review. (IF 2014: 17,81)
255. Genua M, D'Alessio S, Cibella J, Gandelli A, Sala E, Correale C, Spinelli A, Arena V, Malesci A, Rutella S, Ploplis VA, Vetrano S, **Danese S**.  
The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation.  
*Gut.* 2015 Apr;64(4):589-600. doi: 10.1136/gutjnl-2013-305933. Epub 2014 May 21. (IF 2015: 14,921)
256. Fiorino G, **Danese S**.  
The biosimilar road in inflammatory bowel disease: the right way?  
*Best Pract Res Clin Gastroenterol.* 2014 Jun;28(3):465-71. doi: 10.1016/j.bpg.2014.04.006. Epub 2014 May 4. Review. (IF 2014: 3,478)
257. Armuzzi A, Pugliese D, **Danese S**, Rizzo G, Felice C, Marzo M, Andrisani G, Fiorino G, Nardone OM, De Vitis I, Papa A, Rapaccini GL, Guidi L.  
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis.  
*Inflamm Bowel Dis.* 2014 Aug;20(8):1368-74. doi: 10.1097/MIB.000000000000115. (IF 2014: 4,464)
258. Laurenzana A, Biagioni A, D'Alessio S, Bianchini F, Chillà A, Margheri F, Luciani C, Mazzanti B, Pimpinelli N, Torre E, **Danese S**, Calorini L, Del Rosso M, Fibbi G.  
Melanoma cell therapy: Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme.  
*Oncotarget.* 2014 Jun 15;5(11):3711-27. Doi: 10.18632/oncotarget.1987 (IF 2014: 6,359)

259. **Danese S**, Fiorino G, Michetti P.  
Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization.  
*J Crohns Colitis*. 2014 Nov 1;8(11):1548-50. doi: 10.1016/j.crohns.2014.06.007. Epub 2014 Jul 6. (IF 2014: 6,234)
260. D'Alessio S, Correale C, Tacconi C, Gandelli A, Pietrogrande G, Vetrano S, Genua M, Arena V, Spinelli A, Peyrin-Biroulet L, Fiocchi C, **Danese S**.  
VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease.  
*J Clin Invest*. 2014 Sep;124(9):3863-78. doi: 10.1172/JCI72189. Epub 2014 Aug 8. (IF 2014: 13,262)
261. Bortoli A, Daperno M, Kohn A, Politi P, Marconi S, Monterubbianesi R, Castiglione F, Corbellini A, Merli M, Casella G, D'Incà R, Orlando A, Bossa F, Doldo P, Lecis P, Valpiani D, **Danese S**, Comberlato M; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD).  
Patient and physician views on the quality of care in inflammatory bowel disease: results from SOLUTION-1, a prospective IG-IBD study.  
*J Crohns Colitis*. 2014 Dec 1;8(12):1642-52. doi: 10.1016/j.crohns.2014.07.004. Epub 2014 Aug 10. (IF 2014: 6,234)
262. Annese V, Vecchi M; Italian Group for the Study of IBD (IG-IBD).  
Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease.  
*Dig Liver Dis*. 2014 Nov;46(11):963-8. doi: 10.1016/j.dld.2014.07.019. Epub 2014 Aug 17. (IF 2014: 2,963)
263. Tursi A, **Danese S**.  
Preventing diverticulitis recurrence by selecting the right therapy for a complex disease.  
*Gastroenterology*. 2014 Oct;147(4):733-6. doi: 10.1053/j.gastro.2014.08.022. Epub 2014 Sep 11. (IF 2014: 16,716)
264. **Danese S**, Fiorino G, Fernandes C, Peyrin-Biroulet L.  
Catching the therapeutic window of opportunity in early Crohn's disease.  
*Curr Drug Targets*. 2014;15(11):1056-63. Doi: 10.2174/1389450115666140908125738 (IF 2014: 3,021)
265. Spinelli A, Allocca M, Jovani M, **Danese S**.



Review article: optimal preparation for surgery in Crohn's disease.

*Aliment Pharmacol Ther.* 2014 Nov;40(9):1009-22. doi: 10.1111/apt.12947. Epub 2014 Sep 10. (IF 2014: 5,727)

266. Allocca M, Fiorino G, **Danese S**.

Iron deficiency: the hidden miscreant in inflammatory bowel disease.

*Curr Drug Targets.* 2014;15(11):1011-9. Doi: 10.2174/1389450115666140909150850 (IF 2014: 3,021)

267. **Danese S**, Peyrin-Biroulet L.

Editorial. Medical challenges in inflammatory bowel disease: quo vadis in disease complexity?

*Curr Drug Targets.* 2014;15(11):1001. Doi: 10.2174/1389450115666140909153351 (IF 2014: 3,021)

268. **Danese S**, Panes J.

Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.

*Gastroenterology.* 2014 Nov;147(5):981-9. doi: 10.1053/j.gastro.2014.08.044. Epub 2014 Sep 16. Review. (IF 2014: 16,716)

269. Pariente B, Mary JY, **Danese S**, Chowers Y, De Cruz P, D'Haens G, Loftus EV Jr, Louis E, Panes J, Schölmerich J, Schreiber S, Vecchi M, Branche J, Bruining D, Fiorino G, Herzog M, Kamm MA, Klein A, Lewin M, Meunier P, Ordas I, Strauch U, et al.

Development of the Lehmann index to assess digestive tract damage in patients with Crohn's disease.

*Gastroenterology.* 2015 Jan;148(1):52-63.e3. doi: 10.1053/j.gastro.2014.09.015. Epub 2014 Sep 21. (IF 2015: 18,187)

270. Bressenot A, Salleron J, Bastien C, **Danese S**, Boulagnon-Rombi C, Peyrin-Biroulet L.

Comparing histological activity indexes in UC.

*Gut.* 2014 Sep 22. doi:pii: gutjnl-2014-307477. 10.1136/gutjnl-2014-307477. (IF 2014: 14,66)

271. **Danese S**, Hoffman C, Vel S, Greco M, Szabo H, Wilson B, Avedano L.

Anaemia from a patient perspective in inflammatory bowel disease: results from the European Federation of Crohn's and Ulcerative Colitis Association's online survey.

*Eur J Gastroenterol Hepatol.* 2014 Dec;26(12):1385-91. doi: 10.1097/MEG.000000000000200. (IF 2014: 2,253)

272. Cesarini M, **Danese S**.  
Editorial: long-term safety and efficacy of certolizumab pegol for Crohn's disease.  
*Aliment Pharmacol Ther.* 2014 Nov;40(10):1243. doi: 10.1111/apt.12958. (IF 2014: 5,727)
273. **Danese S**, Rudziaski J, Brandt W, Dupas JL, Peyrin-Biroulet L, Bouhnik Y, Kleczkowski D, Uebel P, Lukas M, Knutsson M, Erlandsson F, Hansen MB, Keshav S.  
Tralokinumab for moderate- to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study.  
*Gut.* 2015 Feb;64(2):243-9. doi: 10.1136/gutjnl-2014-308004. Epub 2014 Oct 10. (IF 2015: 14,921)
274. Roulis M, Nikolaou C, Kotsaki E, Kaffe E, Karagianni N, Koliaraki V, Salpea K, Ragoussis J, Aidinis V, Martini E, Becker C, Herschman HR, Vetrano S, **Danese S**, Kollias G.  
Intestinal myofibroblast-specific Tpl2-Cox-2-PGE2 pathway links innate sensing to epithelial homeostasis.  
*Proc Natl Acad Sci U S A.* 2014 Oct 28;111(43):E4658-67. doi: 10.1073/pnas.1415762111. Epub 2014 Oct 14. (IF 2014: 9,674)
275. Genua M, Rutella S, Correale C, **Danese S**.  
The triggering receptor expressed on myeloid cells (TREM) in inflammatory bowel disease pathogenesis.  
*J Transl Med.* 2014 Oct 28;12(1):293. Doi: 10.1186/s12967-014-0293-z (IF 2014: 3,93)
276. Fiorino G, **Danese S**.  
Etrolizumab in ulcerative colitis: tightening leukocyte traffic control in the inflamed mucosa.  
*Gastroenterology.* 2014 Dec;147(6):1433-5. Doi: 10.1053/j.gastro.2014.10.018 (IF 2014: 16,716)
277. Dignass AU, Gasche C, Bettenworth D, Birgegård G, **Danese S**, Gisbert JP, Gomollon F, Iqbal T, Katsanos K, Koutroubakis I, Magro F, Savoye G, Stein J, Vavricka S; European Crohn's and Colitis Organisation [ECCO].  
European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases.  
*J Crohns Colitis.* 2015 Mar;9(3):211-22. doi: 10.1093/ecco-jcc/jju009. Epub 2014 Dec 3. (IF 2015: 6,585)
278. Bravatà I, Fiorino G, Allocca M, Repici A, **Danese S**.  
New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease.

- Scand J Gastroenterol.* 2015 Jan;50(1):113-20. doi: 10.3109/00365521.2014.993700. (IF 2015: 2,199)
279. Dignass A, Allez M, **Danese S**, Marteau P.  
Digestive Diseases. Introduction.  
*Dig Dis.* 2014;32 Suppl 1:1. doi: 10.1159/000367977. Epub 2014 Dec 17. (IF 2014: 2,181)
280. Papa A, Papa V, Marzo M, Scaldaferrri F, Sofo L, Rapaccini GL, **Danese S**, Gasbarrini A.  
Prevention and Treatment of Venous Thromboembolism in Patients with IBD: A Trail Still Climbing.  
*Inflamm Bowel Dis.* 2015 Jan 9. Doi 10.1097/MIB.0000000000000310 (IF 2015: 4,358)
281. Sandborn WJ, **Danese S**, D'Haens G, Moro L, Jones R, Bagin R, Huang M, David Ballard E, Masure J, Travis S.  
Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.  
*Aliment Pharmacol Ther.* 2015 Mar;41(5):409-18. doi: 10.1111/apt.13076. Epub 2015 Jan 15. (IF 2015: 6,32)
282. **Danese S**, Peyrin-Biroulet L, Fiorino G.  
Predicting future disease course in Crohn's disease by colonoscopy or magnetic resonance: which is *the crystal ball*?  
*Gut.* 2015 Jan 28. doi:pii: gutjnl- 2014-308919. 10.1136/gutjnl-2014-308919. (IF 2015: 14,921)
283. Fernandes C, Allocca M, **Danese S**, Fiorino G.  
Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease.  
*Immunotherapy.* 2015 Feb;7(2):175- 90. doi: 10.2217/imt.14.105. (IF 2015: 2,083)
284. Tacconi C, Correale C, Gandelli A, Spinelli A, Dejana E, D'Alessio S, **Danese S**.  
Vascular Endothelial Growth Factor C Disrupts the Endothelial Lymphatic Barrier to Promote Colorectal Cancer Invasion.  
*Gastroenterology.* 2015 Mar 6. doi:pii: S0016-5085(15)00310-8. 10.1053/j.gastro.2015.03.005. (IF 2015: 18,187)
285. Van Assche G, Dignass A, Bokemeyer B, **Danese S**, Gionchetti P, Moser G, Beaugerie L, Gomollan F, Hauser W, Herrlinger K, Oldenburg B, Panes J, Portela F, Rogler G, Stein J, Tilg H, Travis S, Lindsay JO.

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations (Spanish version).

*Rev Gastroenterol Mex.* 2015 Mar 10. doi: 10.1016/j.rgm.2014.10.008.

286. Sala E, Genua M, Petti L, Anselmo A, Arena V, Cibella J, Zanotti L, D'Alessio S, Scaldaferrì F, Luca G, Arato I, Calafiore R, Sgambato A, Rutella S, Locati M, **Danese S**, Vetrano S.

Mesenchymal Stem Cells Reduce Colitis in Mice via Release of TSG6, Independently of Their Localization to the Intestine.

*Gastroenterology.* 2015 Jul;149(1):163-176.e20. doi: 10.1053/j.gastro.2015.03.013. Epub 2015 Mar 17. (IF 2015: 18,187)

287. Kotze PG, Yamamoto T, **Danese S**, Suzuki Y, Teixeira FV, de Albuquerque IC, Saad-Hossne R, de Barcelos IF, da Silva RN, da Silva Kotze LM, Olandoski M, Sacchi M, Yamada A, Takeuchi K, Spinelli A.

Direct Retrospective Comparison of Adalimumab and Infliximab in Preventing Early Postoperative Endoscopic Recurrence After Ileocaecal Resection for Crohn's Disease: Results from the MULTIPER Database.

*J Crohns Colitis.* 2015 Jul;9(7):541-7. doi: 10.1093/ecco-jcc/jjv055. Epub 2015 Mar 28. (IF 2015: 6,585)

288. Moja L, **Danese S**, Fiorino G, Del Giovane C, Bonovas S.

Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease.

*Aliment Pharmacol Ther.* 2015 Jun;41(11):1055-65. doi: 10.1111/apt.13190. Epub 2015 Apr 13. (IF 2015: 6,32)

289. Gilardi D, Fiorino G, Allocca M, Bravatà I, **Danese S**.

Golimumab: clinical update on its use for ulcerative colitis.

*Drugs Today (Barc).* 2015 Mar;51(3):171-16. doi: 10.1358/dot.2015.51.3.2298240. (IF 2015: 1,73)

290. **Danese S**, Fiorino G, Mary JY, Lakatos PL, D'Haens G, Moja L, D'Hoore A, Panes J, Reinisch W, Sandborn WJ, Travis SP, Vermeire S, Peyrin-Biroulet L, Colombel JF.

Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative.

*J Crohns Colitis.* 2015 Apr 23. Doi: 10.1093/ecco-jcc/jjv067 (IF 2015: 6,585)

291. Bonovas S, Moja L, **Danese S**.  
In the Presence of Conceptual Heterogeneity, Results of Network Meta-analysis Comparing Therapies in Crohn's Disease Need to Be Interpreted With Caution.  
*Gastroenterology*. 2015 Jun;148(7):1483-4. doi: 10.1053/j.gastro.2015.02.058. Epub 2015 Apr 30. (IF 2015: 18,187)
292. Fiorino G, Bonifacio C, Allocca M, Repici A, Balzarini L, Malesci A, Peyrin-Biroulet L, **Danese S**.  
Bowel Damage as Assessed by the Lémann Index is Reversible on Anti-TNF Therapy for Crohn's Disease.  
*J Crohns Colitis*. 2015 May 9. Doi: 10.1093/ecco-jcc/jjv080 (IF 2015: 6,585)
293. Quetglas EG, Armuzzi A, Wigge S, Fiorino G, Barnscheid L, Froelich M, **Danese S**.  
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.  
*Eur J Clin Pharmacol*. 2015 Jul;71(7):773-99. doi: 10.1007/s00228-015-1862-7. Epub 2015 May 27. (IF 2015: 2,71)
294. Genua M, Sgambato A, **Danese S**.  
Editorial: CCR7 is required for leukocyte egression in an experimental model of Crohn's disease-like ileitis.  
*J Leukoc Biol*. 2015 Jun;97(6):1000-2. doi: 10.1189/jlb.5CE0215037RR. (IF 2015: 4,165)
295. Peyrin-Biroulet L, Panés J, Sandborn WJ, Vermeire S, **Danese S**, Feagan BG, Colombel JF, Hanauer S SB, Rycroft B.  
Defining disease severity in inflammatory bowel diseases: current and future directions.  
*Clin Gastroenterol Hepatol*. 2015 Jun 10. doi: 10.1016/j.cgh.2015.06.001. (IF 2015: 7,68)
296. Fiorino G, Allocca M, **Danese S**.  
Anemia in IBD: the opening of Pandora's box?  
*Clin Gastroenterol Hepatol*. 2015 Jun 16. doi: 10.1016/j.cgh.2015.06.004. (IF 2015: 7,68)
297. Lichtenstein GR, Travis S, **Danese S**, D'Haens G, Moro L, Jones R, Huang M, Ballard ED, Bagin R, Hardiman Y, Collazo R, Sandborn WJ.  
Budesonide MMX® for the induction of remission of mild to moderate ulcerative colitis: a pooled safety analysis.  
*J Crohns Colitis*. 2015 Jun 20. Doi: 10.1093/ecco-jcc/jjv101 (IF 2015: 6,585)

298. Nuti F, Fiorino G, **Danese S**.  
Adalimumab for the treatment of pediatric Crohn's disease.  
*Expert Rev Clin Immunol*. 2015;11(9):963-72. doi: 10.1586/1744666X.2015.1072048 (IF 2015: 2,596)
299. **Danese S**, Vuitton L, Peyrin-Biroulet L.  
Biologic agents for IBD: practical insights.  
*Nat Rev Gastroenterol Hepatol*. 2015 Sep;12(9):537-45. doi: 10.1038/nrgastro.2015.135 (IF 2015: 14,435)
300. **Danese S**, Fiorino G, Peyrin-Biroulet L.  
Targeting SMAD7 in Crohn's Disease by Mongersen: Therapeutic Revolution Under Way?  
*Gastroenterology*. 2015 Oct;149(4):1121-3. doi: 10.1053/j.gastro.2015.08.023 (IF 2015: 18,187)
301. Alfano M, Cinque P, Giusti G, Proietti S, Nebuloni M, **Danese S**, D'Alessio S, Genua M, Portale F, Lo Porto M, Singhal PC, Rastaldi MP, Saleem MA, Mavilio D, Mikulak  
Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.  
*Sci Rep*. 2015 Sep 18;5:13647. doi: 10.1038/srep13647 (IF 2015: 5,228)
302. Reinisch W, Louis E, **Danese S**.  
The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.  
*Expert Rev Gastroenterol Hepatol*. 2015;9 Suppl 1:17-26. doi: 10.1586/17474124.2015.1091306 (IF 2015: 2,796)
303. Declerck P, Mellstedt H, **Danese S**.  
Biosimilars - terms of use.  
*Curr Med Res Opin*. 2015 Dec;31(12):2325-30. doi: 10.1185/03007995.2015.1098601 (IF 2015: 2,643)
304. Yadav SK, Gupta RK, Saraswat VA, Rangan M, Thomas MA, Rutella S, **Danese S**, Wang E, Marincola FM, Haris M.  
Reduced cortical thickness in patients with acute-on-chronic liver failure due to non-alcoholic etiology.  
*J Transl Med*. 2015 Oct 6;13:322. doi: 10.1186/s12967-015-0679-6 (IF 2015: 3,694)

305. D'Alessio S, Tacconi C, **Danese S**.  
Targeting lymphatics in inflammatory bowel disease.  
*Oncotarget*. 2015 Oct 27;6(33):34047-8. doi: 10.18632/oncotarget.6026 (IF 2015: 5,008)
306. Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, Bastien C, Cahn V, Cadiot G, Diebold MD, **Danese S**, Reinisch W, Schreiber S, Travis S, Peyrin-Biroulet L.  
Development and validation of the Nancy histological index for UC  
*Gut*. 2017 Jan;66(1):43-49. doi: 10.1136/gutjnl-2015-310187. Epub 2015 Oct 13 (IF 2017: 17,016)
307. Mazziere R, Pietrogrande G, Gerasi L, Gandelli A, Colombo P, Moi D, Brombin C, Ambrosi A, **Danese S**, Mignatti P, Blasi F, D'Alessio S.  
Urokinase Receptor Promotes Skin Tumor Formation by Preventing Epithelial Cell Activation of Notch1.  
*Cancer Res*. 2015 Nov 15;75(22):4895-909. doi: 10.1158/0008-5472.CAN-15-0378. Epub 2015 Nov 2 (IF 2015: 8,556)
308. **Danese S**, Grisham MB, Hodge J, Telliez JB.  
JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.  
*Am J Physiol Gastrointest Liver Physiol*. 2016 Feb 1;310(3):G155-62. doi: 10.1152/ajpgi.00311.2015. Epub 2015 Nov 25 (IF 2016: 3,468)
309. Carbonnel F, Carbonne JF, Filippi J, Katsanos KH, Peyrin-Biroulet L, Allez M, Nachury M, Novacek G, **Danese S**, Abitbol V, Bossa F, Moreau J, Bommelaer G, Bourreille A, Fumery M, Roblin X, Reinisch W, Bouhnik Y, Brixi H, Seksik P, Malamut G, FFrtti M, et al.  
Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.  
*Gastroenterology*. 2016 Feb;150(2):380-8.e4. doi: 10.1053/j.gastro.2015.10.050. Epub 2015 Nov 26 (IF 2016: 18,392)
310. Gower-Rousseau C, Sarter H, Savoye G, Tavernier N, Fumery M, Sandborn WJ, Feagan BG, Duhamel A, Guillon-Dellac N, Colombel JF, Peyrin-Biroulet L; and the International Programme to Develop New Indexes for Crohn's Disease (IPNIC) group; International Programme to Develop New Indexes for Crohn's Disease IPNIC group.  
Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort.  
*Gut*. 2017 Apr;66(4):588-596. doi: 10.1136/gutjnl-2015-310151. Epub 2015 Dec 8 (IF 2017: 17,016)

311. Hawkey CJ, Allez M, Clark MM, Labopin M, Lindsay JO, Ricart E, Rogler G, Rovira M, Satsangi J, **Danese S**, Russell N, Gribben J, Johnson P, Larghero J, Thieblemont C, Ardizzone S, Dierickx D, Ibatizi A, Littlewood T, Onida F, Schanz U, Vermeire S, et al.  
Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial.  
*JAMA*. 2015 Dec 15;314(23):2524-34. doi: 10.1001/jama.2015.16700 (IF 2015: 5,65)
312. Bravatà I, Allocca M, Fiorino G, **Danese S**.  
Integrins and adhesion molecules as targets to treat inflammatory bowel disease.  
*Curr Opin Pharmacol*. 2015 Dec;25:67-71. doi: 10.1016/j.coph.2015.11.007 (IF 2015: 4,769)
313. Fiorino G, Bonifacio C, Peyrin-Biroulet L, **Danese S**.  
Preventing collateral damage in Crohn's disease: The Lémann index.  
*J Crohns Colitis*. 2016 Apr;10(4):495-500. doi: 10.1093/ecco-jcc/jjv240. Epub 2016 Jan 7 (IF 2016: 5,813)
314. **Danese S**, Fiocchi C.  
Endothelial Cell-Immune Cell Interaction in IBD.  
*Dig Dis*. 2016;34(1-2):43-50. doi: 10.1159/000442925. Epub 2016 Mar 16
315. Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, Plevy S, Popp J, Cornillie FJ, Lukas M, **Danese S**, Gionchetti P, Hanauer SB, Reinisch W, Sandborn WJ, Sorrentino D, Rutgeerts P; PREVENT Study Group.  
Infliximab Reduces Endoscopic, but not Clinical, Recurrence of Crohn's Disease Following Ileocolonic Resection.  
*Gastroenterology*. 2016 Jun;150(7):1568-1578. doi: 10.1053/j.gastro.2016.02.072. Epub 2016 Mar 3 (IF 2016: 18,392)
316. Salleron J, **Danese S**, D'Agay L, Peyrin-Biroulet L.  
Effectiveness research in inflammatory bowel disease: a necessity and a methodological challenge.  
*J Crohns Colitis*. 2016 Sep;10(9):1096-102. doi: 10.1093/ecco-jcc/jjw068 (IF 2016: 5,813)
317. Peyrin-Biroulet L, **Danese S**.  
Early Combined Immunosuppression in Crohn's Disease: Acting Rather Than REACTing.  
*Gastroenterology*. 2016 Apr;150(4):1040-1. doi: 10.1053/j.gastro.2016.02.056. Epub 2016 Feb 27 (IF 2016: 18,392)



318. Colombel JF, Sands BE, Rutgeerts P, Sandborn W, **Danese S**, D'Haens G, Panaccione R, Loftus EV Jr, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG.  
The safety of vedolizumab for ulcerative colitis and Crohn's disease.  
*Gut*. 2017 May;66(5):839-851. doi: 10.1136/gutjnl-2015-311079. Epub 2016 Feb 18 (IF 2016: 17,016)
319. D'Haens G, Bressler B, **Danese S**, Gibson P, Hanauer SB, Sandborn W.  
The Crohn's Disease-Ulcerative Colitis Clinical Appraisal.  
*Clin Gastroenterol Hepatol*. 2016 Apr;14(4):638-9. doi: 10.1016/j.cgh.2016.01.017. Epub 2016 Feb 2 (IF 2016: 7,398)
320. Armuzzi A, Gionchetti P, Daperno M, **Danese S**, Orlando A, Lia Scribano M, Vecchi M, Rizzello F; GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group.  
Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease.  
*Dig Liver Dis*. 2016 Apr;48(4):360-70. doi: 10.1016/j.dld.2015.12.016. Epub 2016 Jan 7 (IF 2016: 3,061)
321. Ellul P, Zammita SC, Katsanos KH, Cesarini M, Allocca M, **Danese S**, Karatzas P, Moreno SC, Kopylov U, Fiorino G, Torres J, Lopez-Sanroman A, Caruana M, Zammit L, Mantzaris G.  
Perception of Reproductive Health in Women with Inflammatory Bowel Disease.  
*J Crohns Colitis*. 2016 Aug;10(8):886-91. doi: 10.1093/ecco-jcc/jjw011. Epub 2016 Jan 18 (IF 2016: 5,813)
322. Furfaro F, Fiorino G, Allocca M, Gilardi D, **Danese S**.  
Emerging therapeutic targets and strategies in Crohn's disease.  
*Expert Rev Gastroenterol Hepatol*. 2016 Jun;10(6):735-44. doi: 10.1586/17474124.2016.1142372. Epub 2016 Feb 16 (IF 2016: 2,743)
323. Bonovas S, Fiorino G, Allocca M, Lytras T, Tsantes A, Peyrin-Biroulet L, **Danese S**.  
Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.  
*Medicine (Baltimore)*. 2016 Jan;95(2):e2308. doi: 10.1097/MD.0000000000002308 (IF 2016: 1,804)

324. Lopez-Posadas R, Becker C, Ganther C, Tenzer S, Amann K, Billmeier U, Atreya R, Fiorino G, Vetrano S, **Danese S**, Ekici AB, Wirtz S, Thonn V, Watson AJ, Brakebusch C, Berga M, Neurath MF, Atreya I.  
Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation.  
*J Clin Invest.* 2016 Feb;126(2):611-26. doi: 10.1172/JCI80997. Epub 2016 Jan 11. (IF 2016: 12,784)
325. Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, **Danese S**; ADMIRE CD Study Group Collaborators  
Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial.  
*Lancet.* 2016 Sep 24;388(10051):1281-90. doi: 10.1016/S0140-6736(16)31203-X. Epub 2016 Jul 29. (IF 2016: 47,831)
326. Fiorino G, Fazio M, **Danese S**.  
Biosimilar therapies in inflammatory bowel disease: should we care about patient profile?  
*Expert Rev Clin Immunol.* 2016;12(4):361-3. doi: 10.1586/1744666X.2016.1141050 (IF 2016: 3,27)
327. Fiorino G, Gilardi D, **Danese S**.  
The clinical potential of etrolizumab in ulcerative colitis: Hypes and hopes.  
*Therapeutic Advances in Gastroenterology.* 2016 Jul;9(4):503-12. doi: 10.1177/1756283X16647935. Epub 2016 May 19 (IF 2016: 3,648)
328. **Danese S**, Fiocchi C, Panés J.  
Drug development in IBD: From novel target identification to early clinical trials  
*Gut.* 2016 Aug;65(8):1233-9. doi: 10.1136/gutjnl-2016-311717. Epub 2016 May 10. (IF 2016: 16,658)
329. Genua M, Ingangi V, Fonteyne P, Piontini A, Yousif AM, Merlino F, Grieco P, Malesci A, Carriero MV, **Danese S**.  
Treatment with a Urokinase Receptor-derived Cyclized Peptide Improves Experimental Colitis by Preventing Monocyte Recruitment and Macrophage Polarization  
*Inflammatory Bowel Disease.* 2016 Oct;22(10):2390-401. doi: 10.1097/MIB.0000000000000896 (IF 2016: 4,525)

330. Vuitton L, Marteau P, Sandborn WJ, Levesque BG, Feagan B, Vermeire S, **Danese S**, D'Haens G, Lowenberg M, Khanna R, Fiorino G, Travis S, Mary JY, Peyrin-Biroulet L. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. *Gut*. 2016 Sep;65(9):1447-55. doi: 10.1136/gutjnl-2015-309903. Epub 2015 Sep 9 (IF 2016: 16,658)
331. Fiorino G, **Danese S**.  
Diagnostic Delay in Crohn's Disease: Time for Red Flags  
*Dig Dis and Sci*. 2016 Nov;61(11):3097-3098. doi: 10.1007/s10620-016-4298-8. Epub 2016 Sep 16 (IF 2016: 2,875)
332. Ercoli A, Cosma S, Riboni F, Campagna G, Petruzzelli P, Surico D, **Danese S**, Scambia G, Benedetto C.  
Laparoscopic Nerve-Preserving Sacropexy.  
*J Minim Invasive Gynecol*. 2017 Mar 18. doi: 10.1016/j.jmig.2017.03.008. (IF 2017: 3,061)
333. **Danese S**, Bonovas S, Peyrin-Biroulet L.  
Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to-Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile  
*J Crohns Colitis*. 2017 Feb 21. doi: 10.1093/ecco-jcc/jjx025. (IF 2017: 6,637)
334. Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, **Danese S**, Colombel JF, Smyth M, Sandborn WJ, Feagan BG, Reinisch W, Sands BE, Sans M, Fox I.  
Exposure-Efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.  
*J Crohns Colitis*. 2017 Feb 17. doi: 10.1093/ecco-jcc/jjx021. (IF 2017: 6,637)
335. Olivera P, Thiriet L, Luc A, Baumann C, **Danese S**, Peyrin-Biroulet L.  
Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience.  
*Inflamm Bowel Dis*. 2017 Jun;23(6):976-985. doi: 10.1097/MIB.0000000000001072. (IF 2017: 4,347)
336. Lopez A, Mariette X, Bachelez H, Belot A, Bonnotte B, Hachulla E, Lahfa M, Lortholary O, Loulergue P, Paul S, Roblin X, Sibia J, Blum M, **Danese S**, Bonovas S, Peyrin-Biroulet L.  
Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis.

- J Autoimmun.* 2017 Jun;80:10-27. doi: 10.1016/j.jaut.2017.03.011. Epub 2017 Apr 2. Review. (IF 2017: 7,607)
337. Sands BE, Chen J, Feagan BG, Penney M, Rees WA, **Danese S**, Higgins PDR, Newbold P, Faggioni R, Patra K, Li J, Klekotka P, Morehouse C, Pulkstenis E, Drappa J, van der Merwe R, Gasser RA Jr.  
Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study.  
*Gastroenterology.* 2017 Apr 5. doi: 10.1053/j.gastro.2017.03.049. (IF 2017: 20,773)
338. Gulacsi L, Pentek M, Rencz F, Brodszky V, Baji P, Vegh Z, Gecse KB, **Danese S**, Peyrin-Biroulet L, Lakatos PL.  
Biosimilars for the management of inflammatory bowel diseases: economic considerations.  
*Curr Med Chem.* 2017 Apr 6. doi: 10.2174/0929867324666170406112304. (IF 2017: 3,469)
339. Allocca M, Bonifacio C, Fiorino G, Spinelli A, Furfaro F, Balzarini L, Bonovas S, **Danese S**.  
Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience.  
*Dig Liver Dis.* 2017 Mar 30. pii: S1590-8658(17)30792-2. doi: 10.1016/j.dld.2017.03.012. (IF 2017: 3,287)
340. Bonovas S, Peyrin-Biroulet L, **Danese S**.  
Is Mesalamine Effective for the Induction of Remission in Crohn's Disease?  
*Inflamm Bowel Dis.* 2017 May;23(5):E22-E23. doi: 10.1097/MIB.0000000000001124. (IF 2017: 4,347)
341. Dirrenberger B, Clerc-Urmès I, Germain A, Bresler L, Olivera P, Martelli L, **Danese S**, Baumann C, Laurent V, Peyrin-Biroulet L.  
Value of cross-sectional imaging in assessing active Crohn's disease before stoma reversal.  
*Dig Liver Dis.* 2017 Apr 11. doi: 10.1016/j.dld.2017.03.028. (IF 2017: 3,287)
342. Olivera P, Spinelli A, Gower-Rousseau C, **Danese S**, Peyrin-Biroulet L.  
Surgical rates in the era of biological therapy: up, down or unchanged?  
*Curr Opin Gastroenterol.* 2017 Jul;33(4):246- 253. doi: 10.1097/MOG.0000000000000361. (IF 2017: 3,414)

343. Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, **Danese S**, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J  
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators.  
*N Engl J Med.* 2017 May 4;376(18):1723-1736. doi: 10.1056/NEJMoa1606910. (IF 2017: 79,26)
344. Bonovas S, Peyrin-Biroulet L, **Danese S**.  
Clinical development of biologicals and biosimilars - safety concerns.  
*Expert Rev Clin Pharmacol.* 2017 Jun;10(6):567-569. doi: 10.1080/17512433.2017.1293522.  
Epub 2017 May 5. (IF 2017: 2,758)
345. Reinisch W, Jahnsen J, Schreiber S, **Danese S**, Panés J, Balsa A, Park W, Kim J, Lee JU, Yoo DH.  
Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.  
*BioDrugs.* 2017 Jun;31(3):223-237. doi: 10.1007/s40259-017-0219-4. (IF 2017: 3,825)
346. Bonovas S, Fiorino G, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, **Danese S**.  
Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer- authors' reply.  
*Aliment Pharmacol Ther.* 2017 Jun;45(12):1554-1555. doi: 10.1111/apt.14084. (IF 2017: 7,357)
347. Vermeire S, Sandborn WJ, **Danese S**, Hébuterne X, Salzberg BA, Klopocka M, Tarabar D, Vanasek T, Greguš M, Hellstern PA, Kim JS, Sparrow MP, Gorelick KJ, Hinz M, Ahmad A, Pradhan V, Hassan-Zahraee M, Clare R, Cataldi F, Reinisch W.  
Anti-MAdCAM antibody (PF- 00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo- controlled trial.  
*Lancet.* 2017 May 17. pii: S0140-6736(17)30930-3. doi: 10.1016/S0140- 6736(17)30930-3. (IF 2017: 53,254)
348. Cosma S, Petruzzelli P, **Danese S**, Benedetto C.  
Nerve preserving vs standard laparoscopic sacropexy: Postoperative bowel function.  
*World J Gastrointest Endosc.* 2017 May 16;9(5):211-219. doi: 10.4253/wjge.v9.i5.211. (IF 2017: 3,3)
349. **Danese S**, Bonovas S, Peyrin-Biroulet L.  
Positioning ustekinumab in Crohn's disease: from clinical evidence to clinical practice.

*J Crohns Colitis*. 2017 Jun 2. doi: 10.1093/ecco-jcc/jjx079 (IF 2017: 6,637)

350. Spadaccini M, D'Alessio S, Peyrin-Biroulet L, **Danese S**.  
PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue.  
*Int J Mol Sci*. 2017 Jun 15;18(6). pii: E1276. doi: 10.3390/ijms18061276. Review (IF 2017: 3,687)
351. **Danese S**, Fiorino G, Peyrin-Biroulet L.  
Filgotinib in Crohn's Disease: JAK Is Back.  
*Gastroenterology*. 2017 Aug;153(2):603-605. doi: 10.1053/j.gastro.2017.06.040. Epub 2017 Jun 24. (IF 2017: 20,773)
352. **Danese S**, Peyrin-Biroulet L.  
IBD: To switch or not to switch: that is the biosimilar question.  
*Nat Rev Gastroenterol Hepatol*. 2017 Sep;14(9):508-509. doi: 10.1038/nrgastro.2017.86. Epub 2017 Jul 5. (IF 2017: 17,324)
353. Hindryckx P, Novak G, Bonovas S, Peyrin-Biroulet L, **Danese S**.  
Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease.  
*Clin Pharmacol Ther*. 2017 Oct;102(4):633-641. doi: 10.1002/cpt.791. Epub 2017 Aug 16. Review. (IF 2017: 6,544)
354. Argollo M, Fiorino G, Hindryckx P, Peyrin-Biroulet L, **Danese S**.  
Novel therapeutic targets for inflammatory bowel disease.  
*J Autoimmun*. 2017 Dec;85:103-116. doi: 10.1016/j.jaut.2017.07.004. Epub 2017 Jul 12. Review. (IF 2017: 7,607)
355. Allocca M, Fiorino G, **Danese S**.  
Biosimilar Drugs for Inflammatory Bowel Disease: Is Similar Good Enough?  
*Dig Dis Sci*. 2017 Nov;62(11):2964-2965. doi: 10.1007/s10620-017-4693-9. (IF 2017: 2,819)
356. Ungaro F, Tacconi C, Massimino L, Corsetto PA, Correale C, Fonteyne P, Piontini A, Garzarelli V, Calcaterra F, Della Bella S, Spinelli A, Carvello M, Rizzo AM, Vetrano S, Petti L, Fiorino G, Furfaro F, Mavilio D, Maddipati KR, Malesci A, Peyrin-Biroulet L, D'Alessio S, **Danese S**.  
MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces Colitis in Mice.

*Gastroenterology*. 2017 Nov;153(5):1363-1377.e6. doi: 10.1053/j.gastro.2017.07.048. Epub 2017 Aug 4. (IF 2017: 20,773)

357. Hindryckx P, Laukens D, D'Amico F, **Danese S**.  
Unmet Needs in IBD: the Case of Fatigue.  
*Clin Rev Allergy Immunol*. 2017 Aug 29. doi: 10.1007/s12016-017-8641-4. Review. (IF 2017: 6,442)
358. Martelli L, Lopez A, Strobel S, **Danese S**, Roblin X, Baumann C, Peyrin-Biroulet L.  
Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting.  
*J Dig Dis*. 2017 Oct;18(10):566-573. doi: 10.1111/1751-2980.12539. (IF 2017: 1,442)
359. Kay J, Schoels MM, Dörner T, Emery P, Kvien TK, Smolen JS, Breedveld FC; Task Force on the Use of Biosimilars to Treat Rheumatological Diseases.  
Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases.  
*Ann Rheum Dis*. 2018 Feb;77(2):165-174. doi: 10.1136/annrheumdis-2017-211937. Epub 2017 Sep 2. (IF 2018: 14,299)
360. **Danese S**, Fiorino G, Peyrin-Biroulet L.  
Early intervention in Crohn's disease: towards disease modification trials.  
*Gut*. 2017 Dec;66(12):2179-2187. doi: 10.1136/gutjnl-2017-314519. Epub 2017 Sep 5. Review. (IF 2017: 17,016)
361. Pouillon L, Bossuyt P, Vanderstukken J, Moulin D, Netter P, **Danese S**, Jouzeau JY, Loeuille D, Peyrin-Biroulet L.  
Management of patients with inflammatory bowel disease and spondyloarthritis.  
*Expert Rev Clin Pharmacol*. 2017 Dec;10(12):1363-1374. doi: 10.1080/17512433.2017.1377609. Epub 2017 Sep 20. Review. (IF 2017: 2,758)
362. Bossuyt P, Pouillon L, Bonnaud G, **Danese S**, Peyrin-Biroulet L.  
E-health in inflammatory bowel diseases: More challenges than opportunities?  
*Dig Liver Dis*. 2017 Dec;49(12):1320-1326. doi: 10.1016/j.dld.2017.08.026. Epub 2017 Aug 24. (IF 2017: 3,287)
363. Allocca M, Landi R, Bonovas S, Fiorino G, Papa A, Spinelli A, Furfaro F, Peyrin-Biroulet L, Armuzzi A, **Danese S**.  
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting.

*Digestion*. 2017;96(3):166-172. doi: 10.1159/000480231. Epub 2017 Sep 14. (IF 2017: 2,037)

364. Gilardi D, Fiorino G, Furfaro F, Alfieri MF, Orlandi I, Allocca M, **Danese S**.  
Comparison of two methods for the in-vivo diagnosis of *Helicobacter pylori* infection using a tablet of <sup>13</sup>C-urea.  
*Minerva Gastroenterol Dietol*. 2017 Dec;63(4):319-326. doi: 10.23736/S1121-421X.17.02411-4. (IF 2017: 1,3)
365. **Danese S**, Furfaro F, Vetrano S.  
Targeting S1P in Inflammatory bowel disease: new avenues for modulating intestinal leukocyte migration.  
*J Crohns Colitis*. 2017 Jul 28. doi: 10.1093/ecco-jcc/jjx107. (IF 2017: 6,637)
366. Kökten T, Gibot S, Lepage P, D'Alessio S, Hablot J, Ndiaye NC, Busby-Venner H, Monot C, Garnier B, Moulin D, Jouzeau JY, Hansmannel F, **Danese S**, Guéant JL, Muller S, Peyrin-Biroulet L.  
TREM-1 Inhibition Restores Impaired Autophagy Activity and Reduces Colitis in Mice.  
*J Crohns Colitis*. 2018 Jan 24;12(2):230-244. doi: 10.1093/ecco-jcc/jjx129. (IF 2018: 7,827)
367. Hindryckx P, Vande Casteele N, Novak G, Khanna R, D'Haens G, Sandborn WJ, **Danese S**, Jairath V, Feagan BG.  
The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?  
*J Crohns Colitis*. 2018 Jan 5;12(1):105-119. doi: 10.1093/ecco-jcc/jjx117. (IF 2018: 7,827)
368. Travis S, Feagan BG, Peyrin-Biroulet L, Panaccione R, **Danese S**, Lazar A, Robinson AM, Petersson J, Pappalardo BL, Bereswill M, Chen N, Wang S, Skup M, Thakkar RB, Chao J.  
Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspiraDA.  
*J Crohns Colitis*. 2017 Oct 27;11(11):1317-1325. doi: 10.1093/ecco-jcc/jjx093. (IF 2017: 6,637)
369. Bonovas S, Nikolopoulos GK, Lytras T, Fiorino G, Peyrin-Biroulet L, **Danese S**.  
Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis.  
*Br J Clin Pharmacol*. 2018 Feb;84(2):239-251. doi: 10.1111/bcp.13456. Epub 2017 Dec 1. (IF 2018: 3,867)



370. Westera L, van Viegen T, Jeyarajah J, Azad A, Bilsborough J, van den Brink GR, Cremer J, **Danese S**, D'Haens G, Eckmann L, Faubion W, Filice M, Korf H, McGovern D, Panes J, Salas A, Sandborn WJ, Silverberg MS, Smith MI, Vermeire S, Vetrano S, Shackelton LM, Stitt L, Jairath V, Levesque BG, Spencer DM, Feagan BG, Vande Casteele N.  
Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study.  
*Clin Transl Gastroenterol.* 2017 Nov 2;8(11):e126. doi: 10.1038/ctg.2017.52. (IF 2017: 4,621)
371. Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, Danalioglu A, Novacek G, Armuzzi A, Hébuterne X, Travis S, **Danese S**, Reinisch W, Sandborn WJ, Rutgeerts P, Hommes D, Schreiber S, Neimark E, Huang B, Zhou Q, Mendez P, Petersson J, Wallace K, Robinson AM, Thakkar RB, D'Haens G.  
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.  
*Lancet.* 2018 Dec 23;390(10114):2779-2789. doi: 10.1016/S0140-6736(17)32641-7. Epub 2017 Oct 31. Erratum in: *Lancet.* 2018 Dec 23;390(10114):2768. (IF 2018: 59,102)
372. Ungaro F, Rubbino F, **Danese S**, D'Alessio S.  
Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases.  
*Front Immunol.* 2017 Oct 23;8:1331. doi: 10.3389/fimmu.2017.01331. eCollection 2017. Review. (IF 2017: 5,511)
373. Allen PB, Gower-Rousseau C, **Danese S**, Peyrin-Biroulet L.  
Preventing disability in inflammatory bowel disease.  
*Therap Adv Gastroenterol.* 2017 Nov;10(11):865-876. doi: 10.1177/1756283X17732720. Epub 2017 Oct 16. Review. (IF 2017: 4,168)
374. Avila-Ribeiro P, Fiorino G, **Danese S**.  
The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.  
*Curr Pharm Des.* 2017;23(44):6759-6769. doi: 10.2174/1381612824666171204095342. (IF 2017: 2,757)
375. **Danese S**, Vermeire S, Hellstern P, Panaccione R, Rogler G, Fraser G, Kohn A, Desreumaux P, Leong RW, Comer GM, Cataldi F, Banerjee A, Maguire MK, Li C, Rath N, Beebe J, Schreiber S.  
Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II).

*Gut*. 2017 Dec 15. doi: 10.1136/gutjnl-2017-314562. (IF 2017: 17,016)

376. Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Diez MC, Tagarro I, Leselbaum A, **Danese S**; ADMIRE CD Study Group Collaborators.  
Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease.  
*Gastroenterology*. 2017 Dec 24. doi: 10.1053/j.gastro.2017.12.020. (IF 2017: 20,773)
377. Šimurina M, de Haan N, Vučković F, Kennedy NA, Štambuk J, Falck D, Trbojević-Akmačić I, Clerc F, Razdorov G, Khon A, Latiano A, D'Inca R, **Danese S**, Targan S, Landers C, Dubinsky M; Inflammatory Bowel Disease Biomarkers Consortium, McGovern DPB, Annesse V, Wuhrer M, Lauc G.  
Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases.  
*Gastroenterology*. 2018 Jan 6. doi: 10.1053/j.gastro.2018.01.002. (IF 2018: 19,809)
378. Allocca M, Gilardi D, Fiorino G, Furfaro F, Peyrin-Biroulet L, **Danese S**.  
Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men.  
*Eur J Gastroenterol Hepatol*. 2018 Mar;30(3):316-322. doi: 10.1097/MEG.0000000000001074. (IF 2018: 2,198)
379. Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, **Danese S**, Colombel JF, Smyth M, Sandborn WJ, Feagan BG, Reinisch W, Sands BE, Sans M, Fox I.  
Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.  
*J Crohns Colitis*. 2018 Jan 29. doi: 10.1093/ecco-jcc/jjx168.
380. Jaboli F, Pouillon L, Bossuyt P, **Danese S**, Peyrin-Biroulet L.  
Telehealth in Inflammatory Bowel Disease: Every Patient May Need a Coach!  
*Gastroenterology*. 2018 Mar;154(4):1196-1198. doi: 10.1053/j.gastro.2018.01.036. Epub 2018 Jan 31. (IF 2018: 19,809)
381. Argollo M, Fiorino G, Peyrin-Biroulet L, **Danese S**.  
Vedolizumab for the treatment of Crohn's disease.

- Expert Rev Clin Immunol*. 2018 Mar;14(3):179-189. doi: 10.1080/1744666X.2018.1438189. Epub 2018 Feb 23. (IF 2018: 3,907)
382. Fiorino G, Ruiz-Argüello MB, Maguregui A, Nagore D, Correale C, Radice S, Gilardi D, Allocca M, Furfaro F, Martínez A, **Danese S**.  
Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.  
*Inflamm Bowel Dis*. 2018 Feb 15;24(3):601-606. doi: 10.1093/ibd/izx086. (IF 2018: 4,005)
383. Feagan BG, Schwartz D, **Danese S**, Rubin DT, Lissos TW, Xu J, Lasch K.  
Efficacy of vedolizumab in fistulising Crohn's disease: Exploratory analyses of data from GEMINI 2.  
*J Crohns Colitis*. 2018 Feb 17. doi: 10.1093/ecco-jcc/jjy019. (IF 2018: 7,827)
384. Cohen HP, Blauvelt A, Rifkin RM, **Danese S**, Gokhale SB, Woollett G.  
Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes.  
*Drugs*. 2018 Mar 3. doi: 10.1007/s40265-018-0881-y. Review. (IF 2018: 4,993)
385. Baji P, Gulácsi L, Brodsky V, Végh Z, **Danese S**, Irving PM, Peyrin-Biroulet L, Schreiber S, Rencz F, Lakatos PL, Péntek M.  
Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe.  
*United European Gastroenterol J*. 2018 Mar;6(2):310-321. doi: 10.1177/2050640617708952. Epub 2017 May 8. (IF 2018: 3,453)
386. **Danese S**, Bonovas S, Lopez A, Fiorino G, Sandborn WJ, Rubin DT, Kamm MA, Colombel JF, Sands BE, Vermeire S, Panes J, Rogler G, D'Haens G, Peyrin-Biroulet L.  
Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease.  
*Gastroenterology*. 2018 Jul;155(1):76-87. doi: 10.1053/j.gastro.2018.03.032. Epub 2018 Mar 28. (IF 2018: 19,809)
387. Bonovas S, Peyrin-Biroulet L, **Danese S**.  
Infliximab biosimilar CT-P13 for inflammatory bowel disease.  
*Lancet Gastroenterol Hepatol*. 2018 Jun;3(6):373-375. doi: 10.1016/S2468-1253(18)30116-X. Epub 2018 Mar 30. (IF 2018: 12,856)

388. Armuzzi A, Ardizzone S, Biancone L, Castiglione F, **Danese S**, Gionchetti P, Orlando A, Rizzello F, Scribano ML, Vecchi M, Daperno M.  
Ustekinumab in the management of Crohn's disease: Expert opinion.  
*Dig Liver Dis.* 2018 Jul;50(7):653-660. doi: 10.1016/j.dld.2018.02.017. Epub 2018 Mar 11. (IF 2018: 3,037)
389. **Danese S**, D'Amico F, Bonovas S, Peyrin-Biroulet L.  
Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis.  
*Inflamm Bowel Dis.* 2018 Sep 15;24(10):2106-2112. doi: 10.1093/ibd/izy076. (IF 2018: 4,005)
390. Pouillon L, Laurent V, Pouillon M, Bossuyt P, Bonifacio C, **Danese S**, Deepak P, Loftus EV Jr, Bruining DH, Peyrin-Biroulet L.  
Diffusion-weighted MRI in inflammatory bowel disease.  
*Lancet Gastroenterol Hepatol.* 2018 Jun;3(6):433-443. doi: 10.1016/S2468-1253(18)30054-2. (IF 2018: 12,856)
391. Sandborn WJ, Bhandari BR, Randall C, Younes ZH, Romanczyk T, Xin Y, Wendt E, Chai H, McKevitt M, Zhao S, Sundy JS, Keshav S, **Danese S**.  
Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.  
*J Crohns Colitis.* 2018 May 14. doi: 10.1093/ecco-jcc/jjy049. (IF 2018: 7,827)
392. **Danese S**, Fiorino G.  
Anti-TNF biosimilars in inflammatory bowel disease: searching the proper patient's profile?  
*Curr Med Chem.* 2018 May 13. doi: 10.2174/0929867325666180514100204. (IF 2018: 3,894)
393. Cohen HP, Blauvelt A, Rifkin RM, **Danese S**, Gokhale SB, Woollett G. Authors' Reply to Pires et al.  
Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes.  
*Drugs.* 2018 Jun;78(8):853-855. doi: 10.1007/s40265-018-0919-1. (IF 2018: 4,993)
394. Clerc F, Novokmet M, Dotz V, Reiding KR, de Haan N, Kammeijer GSM, Dalebout H, Bladergroen MR, Vukovic F, Rapp E; IBD-BIOM Consortium, Targan SR, Barron G, Manetti N, Latiano A, McGovern DPB, Annese V, Lauc G, Wuhrer M.  
Plasma N-Glycan Signatures Are Associated With Features of Inflammatory Bowel Diseases.

*Gastroenterology*. 2018 Sep;155(3):829-843. doi: 10.1053/j.gastro.2018.05.030. Epub 2018 May 21. (IF 2018: 19,809)

395. Goncalves J, Santos M, Acurcio R, Iria I, Gouveia L, Matos Brito P, Catarina Cunha-Santos A, Barbas A, Galvão J, Barbosa I, Aires da Silva F, Alcobia A, Cavaco M, Cardoso M, Delgado Alves J, Carey JJ, Dörner T, Eurico Fonseca J, Palmela C, Torres J, Lima Vieira C, Trabuco D, Fiorino G, Strik A, Yavzori M, Rosa I, Correia L, Magro F, D'Haens G, Ben-Horin S, Lakatos PL, **Danese S**.

Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition.

*Aliment Pharmacol Ther*. 2018 Sep;48(5):507-522. doi: 10.1111/apt.14808. Epub 2018 Jun 5. (IF 2018: 7,731)

396. Momozawa Y, Dmitrieva J, Théâtre E, Deffontaine V, Rahmouni S, Charlotiaux B, Crins F, Docampo E, Elansary M, Gori AS, Lecut C, Mariman R, Mni M, Oury C, Altukhov I, Alexeev D, Aulchenko Y, Amininejad L, Bouma G, Hoentjen F, Löwenberg M, Oldenburg B, Pierik MJ, Vander Meulen-de Jong AE, Janneke van der Woude C, Visschedijk MC; International IBD Genetics Consortium, Lathrop M, Hugot JP, Weersma RK, De Vos M, Franchimont D, Vermeire S, Kubo M, Louis E, Georges M.

IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes.

*Nat Commun*. 2018 Jun 21;9(1):2427. doi: 10.1038/s41467-018-04365-8. (IF 2018: 11,878)

397. Peyrin-Biroulet L, **Danese S**, Argollo M, Pouillon L, Peppas S, Gonzalez-Lorenzo M, Lytras T, Bonovas S.

Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis.

*Clin Gastroenterol Hepatol*. 2018 Jun 20. doi: 10.1016/j.cgh.2018.06.026. (IF 2018: 7,958)

398. D'Amico F, Fiorino G, Furfaro F, Allocca M, **Danese S**.

Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials.

*Expert Opin Investig Drugs*. 2018 Jul;27(7):595-599. doi: 10.1080/13543784.2018.1492547. Epub 2018 Jul 6. (IF 2018: 4,031)

399. Bonovas S, Peyrin-Biroulet L, **Danese S**.

Meta-analysis of the Association between anti-TNF use and Lymphoma Risk in Patients with Inflammatory bowel Disease: Methodological Considerations.

*J Crohns Colitis*. 2018 Jun 27. doi: 10.1093/ecco-jcc/jjy094. (IF 2018: 7,827)

400. Peyrin-Biroulet L, Baumgart DC, Armuzzi A, Gionchetti P, Sebastian S, **Danese S**, Magro F, Higgins S, Yaworksy A, Banderas B, Kachroo S.  
Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach.  
*Dig Dis*. 2018;36(5):346-353. doi: 10.1159/000489845. Epub 2018 Jul 3. (IF 2018: 2,908)
401. Allocca M, Fiorino G, Bonifacio C, Furfaro F, Gilardi D, Argollo M, Peyrin-Biroulet L, **Danese S**.  
Comparative accuracy of bowel ultrasound versus magnetic resonance enterography in combination with colonoscopy in assessing Crohn's disease and guiding clinical decision-making.  
*J Crohns Colitis*. 2018 Jul 5. doi: 10.1093/ecco-jcc/jjy093. (IF 2018: 7,827)
402. Allocca M, Gilardi D, Fiorino G, Furfaro F, Argollo M, Peyrin-Biroulet L, Danese S.  
PF-00547659 for the treatment of Crohn's disease and ulcerative colitis.  
*Expert Opin Investig Drugs*. 2018 Jul;27(7):623-629. doi: 10.1080/13543784.2018.1494722.  
Epub 2018 Jul 16. (IF 2018: 4,031)
403. Thierry ML, Rousseau H, Pouillon L, Girard-Gavanier M, Baumann C, Lopez A, **Danese S**, Laurent V, Peyrin-Biroulet L.  
Accuracy of diffusion-weighted magnetic resonance imaging in detecting mucosal healing and treatment response, and in predicting surgery, in Crohn's disease.  
*J Crohns Colitis*. 2018 Jul 9. doi: 10.1093/ecco-jcc/jjy098. (IF 2018: 7,827)
404. Klasić M, Markulin D, Vojta A, Samaržija I, Biruš I, Dobrinić P, Ventham NT, Trbojević-Akmačić I, Šimurina M, Štambuk J, Razdorov G, Kennedy NA, Satsangi J, Dias AM, Pinho S, Annese V, Latiano A, D'Inca R; IBD consortium, Lauc G, Zoldoš V, Kolarich D, Wuhrer M, McGovern DPB, Pemberton IK, Spencer DIR, Fernandes DL, Kalla R, O'Leary K, Adams AT, Drummond H, Nimmo E, Boyapati R, Wilson DC, Doran R, Rudan I, Lionetti P, Manetti N, Bossa F, Cantoro P, Kohn A, Sturniolo G, **Danese S**, Pierik M, Wilson DC.  
Promoter methylation of the MGAT3 and BACH2 genes correlates with the composition of the immunoglobulin G glycome in inflammatory bowel disease.  
*Clin Epigenetics*. 2018 Jun 4;10:75. doi: 10.1186/s13148-018-0507-y. eCollection 2018. (IF 2018: 5,496)
405. Pariente B, Hu S, Bettenworth D, Specia S, Desreumaux P, Meuwis MA, **Danese S**, Rieder F, Louis E.  
Treatments for Crohn's Disease-Associated Bowel Damage: A Systematic Review.

*Clin Gastroenterol Hepatol.* 2018 Aug 23. doi: 10.1016/j.cgh.2018.06.043. (IF 2018: 7,958)

406. Hanauer S, Panaccione R, **Danese S**, Cheifetz A, Reinisch W, Higgins PDR, Woodworth DA, Zhang H, Friedman GS, Lawendy N, Quirk D, Nduaka CI, Su C.  
Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis.  
*Clin Gastroenterol Hepatol.* 2018 Sep 10. doi: 10.1016/j.cgh.2018.07.009. (IF 2018: 7,958)
407. Allocca M, Peyrin-Biroulet L, **Danese S**.  
Evolving strategies and goals of treatment in ulcerative colitis.  
*Best Pract Res Clin Gastroenterol.* 2018 Feb - Apr;32-33:1-2. doi: 10.1016/j.bpg.2018.07.001.  
(IF 2018: 3,583)
408. Lopez A, Pouillon L, Beaugerie L, **Danese S**, Peyrin-Biroulet L.  
Colorectal cancer prevention in patients with ulcerative colitis.  
*Best Pract Res Clin Gastroenterol.* 2018 Feb - Apr;32-33:103-109. doi:  
10.1016/j.bpg.2018.05.010. Epub 2018 May 16. (IF 2018: 3,583)
409. Pouillon L, Van Stappen J, Bossuyt P, **Danese S**, Peyrin-Biroulet L.  
Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?  
*Best Pract Res Clin Gastroenterol.* 2018 Feb - Apr;32-33:17-25. doi: 10.1016/j.bpg.2018.05.006.  
Epub 2018 May 12. (IF 2018: 3,583)
410. Bonovas S, Pantavou K, Evripidou D, Bastiampillai AJ, Nikolopoulos GK, Peyrin-Biroulet L, **Danese S**.  
Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses.  
*Best Pract Res Clin Gastroenterol.* 2018 Feb - Apr;32-33:43-47. doi: 10.1016/j.bpg.2018.05.005.  
Epub 2018 Jun 11. (IF 2018: 3,583)
411. Argollo MC, Kotze PG, Spinelli A, Gomes TNF, **Danese S**.  
The impact of biologics in surgical outcomes in ulcerative colitis.  
*Best Pract Res Clin Gastroenterol.* 2018 Feb - Apr;32-33:79-87. doi: 10.1016/j.bpg.2018.05.014.  
Epub 2018 Jun 8. (IF 2018: 3,583)
412. Fiorino G, D'Amico F, Italia A, Gilardi D, Furfaro F, **Danese S**.  
JAK inhibitors: Novel developments in management of ulcerative colitis.

- Best Pract Res Clin Gastroenterol.* 2018 Feb - Apr;32-33:89-93. doi: 10.1016/j.bpg.2018.05.015. Epub 2018 May 23 (IF 2018: 3,583)
413. Allocca M, Furfaro F, Fiorino G, Gilardi D, D'Alessio S, **Danese S**.  
Can IL-23 be a good target for ulcerative colitis?  
*Best Pract Res Clin Gastroenterol.* 2018 Feb - Apr;32-33:95-102. doi: 10.1016/j.bpg.2018.05.016. Epub 2018 May 23. (IF 2018: 3,583)
414. Peyrin-Biroulet L, Lopez A, Cummings JRF, Dignass A, Detlie TE, **Danese S**.  
Review article: treating-to-target for inflammatory bowel disease-associated anaemia.  
*Aliment Pharmacol Ther.* 2018 Sep;48(6):610-617. doi: 10.1111/apt.14922. Epub 2018 Aug 1. (IF 2018: 7,731)
415. Allocca M, Fiorino G, Bonovas S, Furfaro F, Gilardi D, Argollo M, Magnoni P, Peyrin-Biroulet L, **Danese S**.  
Accuracy of Humanitas Ultrasound Criteria in assessing disease activity and severity in ulcerative colitis: a prospective study.  
*J Crohns Colitis.* 2018 Aug 4. doi: 10.1093/ecco-jcc/jjy107. (IF 2018: 7,827)
416. Pouillon L, Socha M, Demore B, Thilly N, Abitbol V, **Danese S**, Peyrin-Biroulet L.  
The nocebo effect: a clinical challenge in the era of biosimilars.  
*Expert Rev Clin Immunol.* 2018 Sep;14(9):739-749. doi: 10.1080/1744666X.2018.1512406. Epub 2018 Aug 30. (IF 2018: 3,907)
417. Armuzzi A, Fiorino G, Variola A, Manetti N, Fries W, Orlando A, Maconi G, Bossa F, Cappello M, Biancone L, Cantoro L, Costa F, D'Incà R, Lionetti P, Principi M, Castiglione F, Annunziata ML, Di Sabatino A, Di Girolamo M, Terpin MM, Cortelezzi CC, Saibeni S, Amato A, Ardizzone S, Guidi L, **Danese S**, Massella A, Ventra A, Rizzuto G, Massari A, Perri F, Annese V; PROSIT Investigators.  
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy.  
*Inflamm Bowel Dis.* 2018 Aug 18. doi: 10.1093/ibd/izy264. (IF 2018: 4,005)
418. Goncalves J, Magro F, **Danese S**, Lakatos PL, Ben-Horin S.  
Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars. Authors' reply.  
*Aliment Pharmacol Ther.* 2018 Sep;48(5):575-576. doi: 10.1111/apt.14860. (IF 2018: 7,731)



419. Conte P, Frassoldati A, Bisagni G, Brandes AA, Donadio M, Garrone O, Piacentini F, Cavanna L, Giotta F, Aieta M, Gebbia V, Molino A, Musolino A, Ferro A, Maltoni R, **Danese S**, Zamagni C, Rimanti A, Cagossi K, Russo A, Pronzato P, Giovanardi F, Moretti G, Lombardo L, Schirone A, Beano A, Amaducci L, Bajardi EA, Vicini R, Balduzzi S, D'Amico R, Guarneri V. 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. *Ann Oncol.* 2018 Sep 13. doi: 10.1093/annonc/mdy414. (IF 2018: 14,196)
420. Sebastian S, Black C, Pugliese D, Armuzzi A, Sahnun K, Elkady SM, Katsanos KH, Christodoulou DK, Selinger C, Maconi G, Fearnhead NS, Kopylov U, Davidov Y, Bosca-Watts MM, Ellul P, Muscat M, Karmiris K, Hart AL, **Danese S**, Ben-Horin S, Fiorino G. The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. *Aliment Pharmacol Ther.* 2018 Sep 18. doi: 10.1111/apt.14969. (IF 2018: 7,731)
421. Ungaro F, Massimino L, Furfaro F, Rimoldi V, Peyrin-Biroulet L, D'Alessio S, **Danese S**. Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease. *Gut Microbes.* 2018 Sep 25:1-10. doi: 10.1080/19490976.2018.1511664. (IF 2018: 7,823)
422. Reinisch W, Bressler B, Curtis R, Parikh A, Yang H, Rosario M, Røseth A, **Danese S**, Feagan B, Sands BE, Ginsburg P, Dassopoulos T, Lewis J, Xu J, Wyant T. Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1. *Inflamm Bowel Dis.* 2018 Oct 5. doi: 10.1093/ibd/izy304. (IF 2018: 4,005)
423. **Danese S**, Banerjee R, Cummings JF, Dotan I, Kotze PG, Leong RWL, Paridaens K, Peyrin-Biroulet L, Scott G, Assche GV, Wehkamp J, Yamamoto-Furusho JK. Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach. *Intest Res.* 2018 Oct;16(4):522-528. doi: 10.5217/ir.2018.00073. Epub 2018 Oct 16.
424. Pouillon L, Baumann C, Rousseau H, Choukour M, Andrianjafy C, **Danese S**, Peyrin-Biroulet L. Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience. *Inflamm Bowel Dis.* 2018 Oct 16. doi: 10.1093/ibd/izy322. (IF 2018: 4,005)

425. Vegni E, Gilardi D, Bonovas S, Corrà BE, Menichetti J, Leone D, Mariangela A, Furfaro F, **Danese S**, Fiorino G.  
Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study.  
*J Crohns Colitis*. 2018 Dec 4. doi: 10.1093/ecco-jcc/jyy183. (IF 2018: 7,827)
426. Lovisa S, Genovese G, **Danese S**.  
Role of epithelial-to-mesenchymal transition in inflammatory bowel disease.  
*J Crohns Colitis*. 2018 Dec 6. doi: 10.1093/ecco-jcc/jyy201. (IF 2018: 7,827)
427. Ellul P, Zammit SC, Katsanos KH, Cesarini M, Allocca M, **Danese S**, Karatzas P, Moreno SC, Kopylov U, Fiorino G, Torres J, Lopez-Sanroman A, Caruana M, Zammit L, Mantzaris G.  
Corrigendum: Perception of Reproductive Health in Women with Inflammatory Bowel Disease.  
*J Crohns Colitis*. 2019 Apr 5. doi: 10.1093/ecco-jcc/jyy221.
428. Yamamoto T, Teixeira FV, Saad-Hossne R, Kotze PG, **Danese S**.  
Anti-TNF and postoperative complications in abdominal Crohn's disease surgery.  
*Curr Drug Targets*. 2019 Apr 4. doi: 10.2174/1389450120666190404144048. (IF 2019: 2,632)
429. Pouillon L, **Danese S**, Hart A, Fiorino G, Argollo M, Selmi C, Carlo-Stella C, Loeuille D, Costanzo A, Lopez A, Vegni E, Radice S, Gilardi D, Socha M, Fazio M, González-Lorenzo M, Bonovas S, Magro F, Peyrin-Biroulet L.  
Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients.  
*Aliment Pharmacol Ther*. 2019 May;49(9):1181-1187. doi: 10.1111/apt.15223. Epub 2019 Apr 1. (IF 2019: 7,515)
430. Kotze PG, **Danese S**.  
Biosimilar and Originator Product in Inflammatory Bowel Diseases: Mind the Gap?  
*Curr Med Chem*. 2019;26(2):246-247. doi: 10.2174/092986732602190314161008. (IF 2019: 4,184)
431. Argollo M, Kotze PG, Lamonaca L, Gilardi D, Furfaro F, Yamamoto T, **Danese S**.  
Prevention of postoperative recurrence in Crohn's disease: tailoring treatment to patient profile.  
*Curr Drug Targets*. 2019 Mar 19. doi: 10.2174/1389450120666190320110809. (IF 2019: 2,632)

432. Ungaro F, Colombo P, Massimino L, Ugolini GS, Correale C, Rasponi M, Garlatti V, Rubbino F, Tacconi C, Spaggiari P, Spinelli A, Carvello M, Sacchi M, Spanò S, Vetrano S, Malesci A, Peyrin-Biroulet L, **Danese S**, D'Alessio S.  
Lymphatic endothelium contributes to colorectal cancer growth via the soluble matrisome component GDF11.  
*Int J Cancer*. 2019 Mar 19. doi: 10.1002/ijc.32286. (IF 2019: 5,145)
433. Fiorino G, Caprioli F, Daperno M, Mocciaro F, Principi M, Viscido A, Fantini MC, Orlando A, Papi C, Annese V, **Danese S**, Vecchi M, Rizzello F, Armuzzi A; National patients' association representatives.  
Use of biosimilars in inflammatory bowel disease: A position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).  
*Dig Liver Dis*. 2019 Feb 19.. doi: 10.1016/j.dld.2019.02.004. (IF 2019: 3,57)
434. Argollo M, Fiorino G, Gilardi D, Furfaro F, Roda G, Loy L, Allocca M, Peyrin-Biroulet L, **Danese S**.  
Biosimilars of adalimumab in IBD: are we ready for that?  
*Curr Pharm Des*. 2019 Mar 11. doi: 10.2174/1381612825666190312113610. (IF 2019: 2,208)
435. D'Amico F, Fiorino G, Peyrin-Biroulet L, **Danese S**.  
Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing.  
*Immunotherapy*. 2019 May;11(7):565-575. doi: 10.2217/imt-2018-0209. Epub 2019 Mar 12. (IF 2019: 2,964)
436. D'Amico F, Roda G, Peyrin-Biroulet L, **Danese S**.  
Anti-adhesion molecules in IBD: does gut specificity really make the difference?  
*Curr Pharm Des*. 2019 Mar 7. doi: 10.2174/1381612825666190307165703. (IF 2019: 2,208)
437. Argollo M, Gilardi D, Roda G, Fiorino G, Peyrin-Biroulet L, **Danese S**.  
Anti-fibrotic drugs for Crohn's disease: Ready for prime time?  
*Curr Pharm Des*. 2019 Mar 7. doi: 10.2174/1381612825666190308100844. (IF 2019: 2,208)
438. Beeg M, Nobili A, Orsini B, Rogai F, Gilardi D, Fiorino G, **Danese S**, Salmona M, Garattini S, Gobbi M.  
A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies.  
*Sci Rep*. 2019 Feb 14;9(1):2064. doi: 10.1038/s41598-018-37950-4. (IF 2019: 3,998)

439. **Danese S**, Allez M, van Bodegraven AA, Dotan I, Gisbert JP, Hart A, Lakatos PL, Magro F, Peyrin-Biroulet L, Schreiber S, Tarabar D, Vavricka S, Halfvarson J, Vermeire S. Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. *Dig Dis*. 2019;37(4):266-283. doi: 10.1159/000496739. Epub 2019 Feb 6. (IF 2019: 2,493)
440. Le Berre C, **Danese S**, Peyrin-Biroulet L. Timely Use of Biologics in Early Crohn's Disease: The Return of "Hit Hard and Early"? *Dig Dis Sci*. 2019 Feb 6. doi: 10.1007/s10620-019-05504-x. (IF 2019: 2,751)
441. Pouillon L, Rousseau H, Busby-Venner H, De Carvalho Bittencourt M, Choukour M, Gauchotte G, Zallot C, **Danese S**, Baumann C, Peyrin-Biroulet L. Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis. *J Crohns Colitis*. 2019 Jan 29. doi: 10.1093/ecco-jcc/jjz029. (IF 2019: 8,658)
442. Leone D, Gilardi D, Corrà BE, Menichetti J, Vegni E, Correale C, Mariangela A, Furfaro F, Bonovas S, Peyrin-Biroulet L, **Danese S**, Fiorino G. Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. *Inflamm Bowel Dis*. 2019 Jan 28. doi: 10.1093/ibd/izy400. (IF 2019: 4,261)
443. Olivera P, **Danese S**, Jay N, Natoli G, Peyrin-Biroulet L. Big data in IBD: a look into the future. *Nat Rev Gastroenterol Hepatol*. 2019 Jan 18. doi: 10.1038/s41575-019-0102-5. Review. (IF 2019: 29,869)
444. Fiorino G, Gilardi D, Correale C, Furfaro F, Roda G, Loy L, Argollo M, Allocca M, Peyrin-Biroulet L, **Danese S**. Biosimilars of adalimumab: the upcoming challenge in IBD. *Expert Opin Biol Ther*. 2019 Jan 2. doi: 10.1080/14712598.2019.1564033 (IF 2019: 3,224)
445. Olivera P, **Danese S**, Pouillon L, Bonovas S, Peyrin-Biroulet L. Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence. *Dig Liver Dis*. 2019 Mar;51(3):327-334. doi: 10.1016/j.dld.2018.11.002. Epub 2018 Nov 16. Review (IF 2019: 3,57)
446. D'Amico F, Fiorini G, Tursi A, Saracino IM, Pavoni M, **Danese S**, Vaira D.

- Efficacy of a New Nutraceutical Formulation in Patients with Symptomatic Uncomplicated Diverticular Disease (SUDD): a Prospective Observational Study.  
*J Gastrointest Liver Dis.* 2020 Jan 8;28 suppl.1:49-52. doi: 10.15403/jgld-560. (IF 2020: 2,008)
447. **Danese S**, Neurath MF, Kopoń A, Zakko SF, Simmons TC, Fogel R, Siegel CA, Panaccione R, Zhan X, Usiskin K, Chitkara D.  
Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis.  
*Clin Gastroenterol Hepatol.* 2020 Jan 8. doi: 10.1016/j.cgh.2019.12.032. (IF 2020: 11,382)
448. Olivera P, Lasa J, Bonovas S, **Danese S**, Peyrin-Biroulet L.  
Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis.  
*Gastroenterology.* 2020 Jan 8. doi: 10.1053/j.gastro.2020.01.001 (IF 2020: 22,682)
449. Wasmann KATGM, de Groof EJ, Stellingwerf ME, D'Haens GR, Ponsioen CY, Geese KB, Dijkgraaf MGW, Gerhards MF, Jansen JM, Pronk A, van Tuyl SAC, Zimmerman DDE, Bruin KF, Spinelli A, **Danese S**, van der Bilt JDW, Mundt MW, Bemelman WA, Buskens CJ.  
Treatment of perianal fistulas in Crohn's disease, seton versus anti-TNF versus surgical closure following anti-TNF (PISA): a randomised controlled trial.  
*J Crohns Colitis.* 2020 Jan 10. doi: 10.1093/ecco-jcc/jjaa004. (IF 2020: 9,071)
450. **Danese S**, Rimola J, Siegelman J.  
REPLY TO GASTRO-D-19-02389.  
*Gastroenterology.* 2020 Jan 3. doi: 10.1053/j.gastro.2019.12.024. (IF 2020: 22,682)
451. Spinelli A, Armuzzi A, Ciccocioppo R, **Danese S**, Gionchetti P, Luglio G, Orlando A, Rispo A, Rizzello F, Sofo L, Solina G, Poggioli G.  
Management of patients with complex perianal fistulas in Crohn's disease: Optimal patient flow in the Italian clinical reality.  
*Dig Liver Dis.* 2020 May;52(5):506-515. doi: 10.1016/j.dld.2019.11.016. Epub 2019 Dec 31. (IF 2020: 4,088)
452. D'Amico F, Baumann C, Rousseau H, **Danese S**, Peyrin-Biroulet L.  
Phase 1, 2 and 3 trials in inflammatory bowel diseases: a practical guide for the non-specialist.  
*J Crohns Colitis.* 2020 Jan 4. doi: 10.1093/ecco-jcc/jjz214. (IF 2020: 9,071)
453. Parigi TL, Roda G, Argollo M, Gilardi D, **Danese S**.

Is there a role for therapeutic sphingolipids in inflammatory bowel disease?

*Expert Rev Gastroenterol Hepatol.* 2019 Dec 30:1-8. doi: 10.1080/17474124.2020.1709446. (IF 2020: 3,869)

454. **Danese S.**

New Drugs In The Ulcerative Colitis Pipeline: Prometheus Unbound.

*Gastroenterology.* 2019 Dec 17. doi: 10.1053/j.gastro.2019.12.011. (IF 2020: 22,682)

455. Fauny M, D'Amico F, Bonovas S, Netter P, **Danese S**, Loeuille D, Peyrin-Biroulet L.

Fecal calprotectin for the diagnosis of bowel inflammation in patients with rheumatological diseases: a systematic review.

*J Crohns Colitis.* 2019 Dec 20. doi: 10.1093/ecco-jcc/jjz205. (IF 2019: 8,658)

456. Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, **Danese S.**

Histological healing: should it be considered as a new outcome for ulcerative colitis?

*Expert Opin Biol Ther.* 2020 Jan 10:1-6. doi: 10.1080/14712598.2020.1701652. (IF 2019: 3,224)

457. Peyrin-Biroulet L, Lönnfors S, Avedano L, **Danese S.**

Changes in inflammatory bowel disease patients' perspectives on biosimilars: A follow-up survey.

*United European Gastroenterol J.* 2019 Dec;7(10):1345-1352. doi: 10.1177/2050640619883704. Epub 2019 Oct 14. (IF 2019: 3,549)

458. Pantavou K, Yiallourou AI, Piovani D, Evripidou D, **Danese S**, Peyrin-Biroulet L, Bonovas S, Nikolopoulos GK.

Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses.

*United European Gastroenterol J.* 2019 Dec;7(10):1285-1303. doi: 10.1177/2050640619883566. Epub 2019 Oct 17. Review. (IF 2019: 3,549)

459. Adedokun OJ, Xu Z, Marano C, O'Brien C, Szapary P, Zhang H, Johanns J, Leong RW, Hisamatsu T, van Assche G, **Danese S**, Abreu MT, Sands BE, Sandborn WJ.

Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis: Ustekinumab PK and exposure-response in UC.

*Clin Gastroenterol Hepatol.* 2019 Dec 6. doi: 10.1016/j.cgh.2019.11.059. (IF 2019: 8,549)

460. Allen PB, Bonovas S, **Danese S**, Peyrin-Biroulet L.

Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective.

*Expert Opin Biol Ther.* 2019 Dec 9. doi: 10.1080/14712598.2020.1702020. (IF 2019: 3,224)

461. Allocca M, **Danese S**, Laurent V, Peyrin-Biroulet L.  
Use of Cross-sectional Imaging for Tight Monitoring of Inflammatory Bowel Diseases.  
*Clin Gastroenterol Hepatol.* 2019 Dec 5. doi: 10.1016/j.cgh.2019.11.052. Review. (IF 2020: 11,382)
462. D'Amico F, Pouillon L, Argollo M, Hart A, Fiorino G, Vegni E, Radice S, Gilardi D, Fazio M, Leone S, Bonovas S, Magro F, **Danese S**, Peyrin-Biroulet L.  
Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group.  
*Dig Liver Dis.* 2019 Dec 4. doi: 10.1016/j.dld.2019.11.004. Review. (IF 2020: 4,088)
463. Chateau T, Feakins R, Marchal-Bressenot A, Magro F, **Danese S**, Peyrin-Biroulet L.  
Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure.  
*Am J Gastroenterol.* 2019 Dec 5. doi: 10.14309/ajg.0000000000000437. (IF 2020: 10,864)
464. Dieci MV, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Giotta F, Aieta M, Gebbia V, Musolino A, Garrone O, Donadio M, Rimanti A, Beano A, Zamagni C, Soto Parra H, Piacentini F, **Danese S**, Ferro A, Cagossi K, Sarti S, Gambaro AR, Romito S, Bazan V, Amaducci L, Moretti G, Foschini MP, Balduzzi S, Vicini R, D'Amico R, Griguolo G, Guarneri V, Conte PF.  
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial.  
*BMC Med.* 2019 Nov 21;17(1):207. doi: 10.1186/s12916-019-1445-z. (IF 2019: 6,782)
465. **Danese S**, Hart A, Dignass A, Fiorino G, Louis E, Bonovas S, D'Haens G, Dotan I, Rogler G, Paridaens K, Peyrin-Biroulet L.  
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX®) for active, mild-to-moderate ulcerative colitis.  
*United European Gastroenterol J.* 2019 Nov;7(9):1171-1182. doi: 10.1177/2050640619864848. Epub 2019 Jul 17 (IF 2019: 3,549)
466. Iacucci M, Cannatelli R, Tontini GE, Panaccione R, **Danese S**, Fiorino G, Matsumoto T, Kochhar GS, Shen B, Kiesslich R, Ghosh S.  
Improving the quality of surveillance colonoscopy in inflammatory bowel disease.

- Lancet Gastroenterol Hepatol.* 2019 Dec;4(12):971-983. doi: 10.1016/S2468-1253(19)30194-3. Review. (IF 2019: 14,789)
467. de Chambrun GP, **Danese S**, Peyrin-Biroulet L.  
Time to include patients with ulcerative proctitis in clinical trials.  
*Lancet Gastroenterol Hepatol.* 2019 Dec;4(12):900-902. doi: 10.1016/S2468-1253(19)30341-3. (IF 2019: 14,789)
468. Mikulak J, Oriolo F, Bruni E, Roberto A, Colombo FS, Villa A, Bosticardo M, Bortolomai I, Lo Presti E, Meraviglia S, Dieli F, Vetrano S, **Danese S**, Della Bella S, Carvello MM, Sacchi M, Cugini G, Colombo G, Klinger M, Spaggiari P, Roncalli M, Prinz I, Ravens S, di Lorenzo B, Marcenaro E, Silva-Santos B, Spinelli A, Mavilio D.  
NKp46-expressing human gut-resident intraepithelial V $\delta$ 1 T cell subpopulation exhibits high antitumor activity against colorectal cancer.  
*JCI Insight.* 2019 Dec 19;4(24). doi: 10.1172/jci.insight.125884. (IF 2019: 6,205)
469. Salem F, Kindt N, Marchesi JR, Netter P, Lopez A, Kokten T, **Danese S**, Jouzeau JY, Peyrin-Biroulet L, Moulin D.  
Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences.  
*United European Gastroenterol J.* 2019 Oct;7(8):1008-1032. doi: 10.1177/2050640619867555. Epub 2019 Aug 1. Review. (IF 2019: 3,549)
470. Ungaro F, Massimino L, D'Alessio S, **Danese S**.  
The gut virome in inflammatory bowel disease pathogenesis: From metagenomics to novel therapeutic approaches.  
*United European Gastroenterol J.* 2019 Oct;7(8):999-1007. doi: 10.1177/2050640619876787. Epub 2019 Sep 27. Review. (IF 2019: 3,549)
471. Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, **Danese S**, Panés J, Bressler B, Colombel JF, Lawendy N, Maller E, Zhang H, Chan G, Salese L, Tsilkos K, Marren A, Su C.  
Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.  
*Aliment Pharmacol Ther.* 2020 Jan;51(2):271-280. doi: 10.1111/apt.15555. Epub 2019 Oct 29. (IF 2020: 8,171)
472. Piovani D, **Danese S**, Peyrin-Biroulet L, Bonovas S.



Inflammatory bowel disease: estimates from the global burden of disease 2017 study.

*Aliment Pharmacol Ther.* 2020 Jan;51(2):261-270. doi: 10.1111/apt.15542. Epub 2019 Oct 29. (IF 2020: 8,171)

473. Lewis JD, Rutgeerts P, Feagan BG, D'haens G, **Danese S**, Colombel JF, Reinisch W, Rubin DT, Selinger C, Bewtra M, Barcomb L, Lacerda AP, Wallace K, Butler JW, Wu M, Zhou Q, Liao X, Sandborn WJ.  
Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease.  
*Inflamm Bowel Dis.* 2020 Jan 6;26(2):304-313. doi: 10.1093/ibd/izz241 (IF 2020: 5,325)
474. Sandborn WJ, Panés J, Sands BE, Reinisch W, Su C, Lawendy N, Koram N, Fan H, Jones TV, Modesto I, Quirk D, **Danese S**.  
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.  
*Aliment Pharmacol Ther.* 2019 Nov;50(10):1068-1076. doi: 10.1111/apt.15514. Epub 2019 Oct 9. (IF 2019: 7,515)
475. Le Berre C, Sandborn WJ, Aridhi S, Devignes MD, Fournier L, Smail-Tabbone M, **Danese S**, Peyrin-Biroulet L.  
Application of Artificial Intelligence to Gastroenterology and Hepatology.  
*Gastroenterology.* 2020 Jan;158(1):76-94.e2. doi: 10.1053/j.gastro.2019.08.058. Epub 2019 Oct 5. Review. (IF 2020: 22,682)
476. Viola A, Monterubbianesi R, Scalisi G, Furfaro F, Rea M, Saibeni S, Aratari A, Bringiotti R, Casella G, Cantoro L, Frankovic I, Calella F, Pugliese D, Orlando S, Samperi L, Cappello M, Mocci G, Manetti N, Annese V, Privitera AC, Inserra G, Caprioli F, D'Inca R, Principi M, Papi C, Castiglione F, **Danese S**, Ardizzone S, Bossa F, Kohn A, Manguso F, Alibrandi A, Fiorino G, Armuzzi A, Fries W; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).  
Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study.  
*Eur J Gastroenterol Hepatol.* 2019 Nov;31(11):1361-1369. doi: 10.1097/MEG.0000000000001546. (IF 2019: 2,251)
477. Daperno M, Armuzzi A, **Danese S**, Fries W, Liguori G, Orlando A, Papi C, Principi M, Rizzello F, Viscido A, Gionchetti P.  
Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus.

*Gastroenterol Res Pract.* 2019 Sep 2;2019:3108025. doi: 10.1155/2019/3108025. eCollection 2019. (IF 2019: 1,806)

478. Kotze PG, Peyrin-Biroulet L, **Danese S**.  
Medico-surgical Management: A Solid Therapeutic Pillar for Improved Patients' Outcomes in Inflammatory Bowel Diseases.  
*Curr Drug Targets.* 2019;20(13):1315-1316. doi: 10.2174/138945012013190902150906. (IF 2019: 2,632)
479. Sands BE, Peyrin-Biroulet L, Loftus EV Jr, **Danese S**, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group.  
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.  
*N Engl J Med.* 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. (IF 2019: 74,699)
480. Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johans J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, **Danese S**, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C; UNIFI Study Group.  
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.  
*N Engl J Med.* 2019 Sep 26;381(13):1201-1214. doi: 10.1056/NEJMoa1900750. (IF 2019: 74,699)
481. **Danese S**, Roda G, Peyrin-Biroulet L.  
Evolving therapeutic goals in ulcerative colitis: towards disease clearance.  
*Nat Rev Gastroenterol Hepatol.* 2020 Jan;17(1):1-2. doi: 10.1038/s41575-019-0211-1. (IF 2020: 46,802)
482. Piovani D, **Danese S**, Peyrin-Biroulet L, Bonovas S.  
Environmental, Nutritional and Socio-Economic Determinants of IBD Incidence: A Global Ecological Study.  
*J Crohns Colitis.* 2019 Aug 29. doi: 10.1093/ecco-jcc/jjz150. (IF 2019: 29,869)
483. Le Berre C, Roda G, Nedeljkovic Protic M, **Danese S**, Peyrin-Biroulet L.  
Modern use of 5-aminosalicylic acid compounds for ulcerative colitis.  
*Expert Opin Biol Ther.* 2019 Sep 18:1-16. doi: 10.1080/14712598.2019.1666101. (IF 2019: 3,224)

484. Sandborn WJ, Baert F, **Danese S**, Krznarić Ž, Kobayashi T, Yao X, Chen J, Rosario M, Bhatia S, Kisfalvi K, D'Haens G, Vermeire S.  
Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.  
*Gastroenterology*. 2019 Aug 28. doi: 10.1053/j.gastro.2019.08.027. (IF 2019: 17,373)
485. Candido FD, Fiorino G, Spadaccini M, **Danese S**, Spinelli A.  
Are Surgical Rates Decreasing in the Biological Era In IBD?  
*Curr Drug Targets*. 2019;20(13):1356-1362. doi: 10.2174/1389450120666190426165325. (IF 2019: 2,632)
486. Spadaccini M, Aghemo A, Caprioli F, Lleo A, Invernizzi F, **Danese S**, Donato MF.  
Safety of vedolizumab in liver transplant recipients: A systematic review.  
*United European Gastroenterol J*. 2019 Aug;7(7):875-880. doi: 10.1177/2050640619858050. Epub 2019 Jun 20. Review (IF 2019: 3,549)
487. Ungaro F, Garlatti V, Massimino L, Spinelli A, Carvello M, Sacchi M, Spanò S, Colasante G, Valassina N, Vetrano S, Malesci A, Peyrin-Biroulet L, **Danese S**, D'Alessio S.  
mTOR-Dependent Stimulation of IL20RA Orchestrates Immune Cell Trafficking through Lymphatic Endothelium in Patients with Crohn's Disease.  
*Cells*. 2019 Aug 18;8(8). doi: 10.3390/cells8080924. (IF 2019: 4,366)
488. Roda G, Porru E, Katsanos K, Skamnelos A, Kyriakidi K, Fiorino G, Christodoulou D, **Danese S**, Roda A.  
Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs.  
*Cells*. 2019 Aug 2;8(8). doi: 10.3390/cells8080817. (IF 2019: 4,366)
489. Reinisch W, Gottlieb K, Colombel JF, **Danese S**, Panaccione R, Panes J, Peyrin-Biroulet L, Rubin D, Sands BE, Schreiber S, Vermeire S, Mulberg A, Sandborn B.  
Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development.  
*Clin Gastroenterol Hepatol*. 2019 Aug;17(9):1673-1679.e1. doi: 10.1016/j.cgh.2018.10.032. Epub 2018 Oct 26. Review. (IF 2019: 8,549)
490. Roda G, Lleo A, **Danese S**, Aghemo A.  
All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis.  
*Clin Gastroenterol Hepatol*. 2020 Jan;18(1):51-53. doi: 10.1016/j.cgh.2019.07.020. Epub 2019 Jul 16. (IF 2020: 11,382)

491. Peyrin-Biroulet L, **Danese S**, Cummings F, Atreya R, Greveson K, Pieper B, Kang T. Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach. *Expert Rev Gastroenterol Hepatol.* 2019 Aug;13(8):731-738. doi: 10.1080/17474124.2019.1645595. Epub 2019 Jul 26. Review. (IF 2019: 3,514)
492. Le Berre C, Ananthkrishnan AN, **Danese S**, Singh S, Peyrin-Biroulet L. Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment. *Clin Gastroenterol Hepatol.* 2020 Jan;18(1):14-23. doi: 10.1016/j.cgh.2019.07.005. Epub 2019 Jul 10. Review. (IF 2020:11,382)
493. **Danese S**, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, Siegelman J, Jones S, Bornstein JD, Feagan BG. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. *Gastroenterology.* 2019 Oct;157(4):1007-1018.e7. doi: 10.1053/j.gastro.2019.06.038. Epub 2019 Jul 4. (IF 2019: 17,373)
494. Bonovas S, Nikolopoulos GK, Piovani D, González-Lorenzo M, Pantavou K, Lytras T, Peyrin-Biroulet L, **Danese S**. Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis. *Br J Clin Pharmacol.* 2019 Oct;85(10):2244-2254. doi: 10.1111/bcp.14051. Epub 2019 Jul 31. Review. (IF 2019: 3,74)
495. D'Haens G, Rieder F, Feagan BG, Higgins PDR, Panes J, Maaser C, Rogler G, Löwenberg M, van der Voort R, Pinzani M, Peyrin-Biroulet L, **Danese S**; IOIBD Fibrosis Working Group. Challenges in the Pathophysiology, Diagnosis and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. *Gastroenterology.* 2019 Jun 26. doi: 10.1053/j.gastro.2019.05.072. (IF 2019: 17,373)
496. Tacconi C, Ungaro F, Correale C, Arena V, Massimino L, Detmar M, Spinelli A, Carvello M, Mazzone M, Oliveira AI, Rubbino F, Garlatti V, Spanò S, Lugli E, Colombo FS, Malesci A, Peyrin-Biroulet L, Vetrano S, **Danese S**, D'Alessio S. Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer.

- Cancer Res.* 2019 Aug 15;79(16):4196-4210. doi: 10.1158/0008-5472.CAN-18-3657. Epub 2019 Jun 25. (IF 2019: 9,727)
497. Dulai PS, Peyrin-Biroulet L, **Danese S**, Sands BE, Dignass A, Turner D, Mantzaris G, Schölmerich J, Mary JY, Reinisch W, Sandborn WJ.  
Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases.  
*Gastroenterology.* 2019 Oct;157(4):1032-1043.e1. doi: 10.1053/j.gastro.2019.06.018. Epub 2019 Jun 19. Review. (IF 2019: 17,373)
498. **Danese S**, Argollo M, Le Berre C, Peyrin-Biroulet L.  
JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?  
*Gut.* 2019 Oct;68(10):1893-1899. doi: 10.1136/gutjnl-2019-318448. Epub 2019 Jun 21. Review. (IF 2019: 19,819)
499. Dotan I, Allez M, **Danese S**, Keir M, Tole S, McBride J.  
The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies.  
*Med Res Rev.* 2020 Jan;40(1):245-262. doi: 10.1002/med.21601. Epub 2019 Jun 19. Review. (IF 2020: 12,944)
500. D'Amico F, Parigi TL, Fiorino G, Peyrin-Biroulet L, **Danese S**.  
Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience.  
*Therap Adv Gastroenterol.* 2019 May 16;12:1756284819848631. doi: 10.1177/1756284819848631. eCollection 2019. Review (IF 2019: 3,52)
501. Argollo M, **Danese S**.  
Novel Targets for Therapeutic Intervention in Inflammatory Bowel Disease: Research Drives Clinic.  
*Curr Pharm Des.* 2019;25(1):5-6. doi: 10.2174/138161282501190514105602. (IF 2019: 2,208)
502. Argollo M, Gilardi D, Peyrin-Biroulet C, Chabot JF, Peyrin-Biroulet L, **Danese S**.  
Comorbidities in inflammatory bowel disease: a call for action.  
*Lancet Gastroenterol Hepatol.* 2019 Aug;4(8):643-654. doi: 10.1016/S2468-1253(19)30173-6. Epub 2019 Jun 3. Review. (IF 2019: 14,789)
503. Fiorino G, Sturniolo GC, Bossa F, Cassinotti A, di Sabatino A, Giuffrida P, **Danese S**.

A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis.

*Cells*. 2019 May 30;8(6). doi: 10.3390/cells8060523. (IF 2019: 4,366)

504. Argollo MC, Allocca M, Furfaro F, Peyrin-Biroulet L, **Danese S**.  
Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?  
*Curr Pharm Des*. 2019;25(1):25-31. doi: 10.2174/1381612825666190313140811. (IF 2019: 2,208)
505. Chateau T, Bonovas S, Le Berre C, Mathieu N, **Danese S**, Peyrin-Biroulet L.  
Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review.  
*J Crohns Colitis*. 2019 Dec 10;13(12):1569-1577. doi: 10.1093/ecco-jcc/jjz095. (IF 2019: 8,658)
506. Leone D, Gilardi D, Corrà BE, Menichetti J, Vegni E, Correale C, Allocca M, Furfaro F, Bonovas S, Peyrin-Biroulet L, **Danese S**, Fiorino G.  
Psychological Functioning of Patients With Inflammatory Bowel Disease.  
*Inflamm Bowel Dis*. 2019 Aug 20;25(9):e112. doi: 10.1093/ibd/izz082. (IF 2019: 4,261)
507. Fiorino G, Peyrin-Biroulet L, **Danese S**.  
Effectiveness of Infliximab Biosimilar in Crohn's Disease: A Dime, A Dozen.  
*Gastroenterology*. 2019 Jun;156(8):2349-2351. doi: 10.1053/j.gastro.2019.04.029. Epub 2019 Apr 26. (IF 2019: 17,373)
508. Piovani D, **Danese S**, Peyrin-Biroulet L, Nikolopoulos GK, Lytras T, Bonovas S.  
Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses.  
*Gastroenterology*. 2019 Sep;157(3):647-659.e4. doi: 10.1053/j.gastro.2019.04.016. Epub 2019 Apr 20. (IF 2019: 17,373)
509. Loy L, Roda G, Fiorino G, Allocca M, Furfaro F, Argollo M, Peyrin-Biroulet L, **Danese S**.  
Detection and management of early stage inflammatory bowel disease: an update for clinicians.  
*Expert Rev Gastroenterol Hepatol*. 2019 Jun;13(6):547-555. doi: 10.1080/17474124.2019.1605291. Epub 2019 Apr 22. Review. (IF 2019: 3,514)
510. Allocca M, Fiorino G, Bonifacio C, Peyrin-Biroulet L, **Danese S**.

Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease.

*Clin Gastroenterol Hepatol.* 2019 Nov;17(12):2397-2415. doi: 10.1016/j.cgh.2019.04.025. Epub 2019 Apr 14. Review. (IF 2019: 8,549)

511. Kotze PG, Spinelli A, Warusavitarne J, Di Candido F, Sahnun K, Adegbola SO, **Danese S.**

Darvadstrocel for the treatment of patients with perianal fistulas in Crohn's disease.

*Drugs Today (Barc).* 2019 Feb;55(2):95-105. doi: 10.1358/dot.2019.55.2.2914336. Review. (IF 2019: 1,373)

512. D'Amico F, Fiorino G, Furfaro F, Allocca M, Roda G, Loy L, Zilli A, Solitano V, Peyrin-Biroulet L, **Danese S.**

Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach.

*Expert Rev Gastroenterol Hepatol.* 2020 May 19. doi: 10.1080/17474124.2020.1772057. Epub ahead of print. PMID: 32427002. (IF 2020: 3,869)

513. Sandborn WJ, Panés J, Sands BE, Reinisch W, Su C, Lawendy N, Koram N, Fan H, Jones TV, Modesto I, Quirk D, **Danese S.**

Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' reply.

*Aliment Pharmacol Ther.* 2020 Jun;51(11):1209-1210. doi: 10.1111/apt.15735. PMID: 32424928. (IF 2020: 8,171)

514. Kotze PG, Peyrin-Biroulet L, **Danese S.**

Balancing risks and benefits in inflammatory bowel disease patients during the COVID-19 pandemic.

*Gastroenterology.* 2020 May 15: S0016-5085(20)30660-0. doi: 10.1053/j.gastro.2020.04.075. (IF 2020: 22,682)

515. D'Amico F, Rahier JF, Leone S, Peyrin-Biroulet L, **Danese S.**

Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey.

*Lancet Gastroenterol Hepatol.* 2020 May 13. doi: 10.1016/S2468-1253(20)30151-5. Epub ahead of print. PMID: 32411920. (IF 2020: 18,486)

516. Carvello M, Di Candido F, Greco M, Foppa C, Maroli A, Fiorino G, Cecconi M, **Danese S,** Spinelli A.

The trend of C-Reactive protein allows a safe early discharge after surgery for Crohn's disease.  
*Updates Surg.* 2020 May 13. doi: 10.1007/s13304-020-00789-4. (IF 2020: 2,797)

517. D'Amico F, Nancey S, **Danese S**, Peyrin-Biroulet L.  
A practical guide for faecal calprotectin measurement: myths and realities.  
*J Crohns Colitis.* 2020 May 11:jjaa093. doi: 10.1093/ecco-jcc/jjaa093. (IF 2020: 9,071)
518. Higgins PDR, Ng S, **Danese S**, Rao K.  
The Risk of SARS-CoV-2 in Immunosuppressed IBD Patients.  
*J Crohns Colitis* 360. 2020 Apr;2(2): otaa026. doi: 10.1093/crocol/otaa026. Epub 2020 Apr 16.  
(IF 2020: 9,071)
519. Parigi TL, Bonifacio C, **Danese S**.  
Is it Crohn's disease?  
*Gastroenterology.* 2020 May 1:S0016-5085(20)30587-4. doi: 10.1053/j.gastro.2020.04.066. (IF 2020: 22,682)
520. Allocca M, Fiorino G, Zallot C, Furfaro F, Gilardi D, Radice S, **Danese S**, Peyrin-Biroulet L.  
Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts.  
*Clin Gastroenterol Hepatol.* 2020 Apr 30: S1542-3565(20)30616-9. doi: 10.1016/j.cgh.2020.04.071. (IF 2020:11,382)
521. D'Amico F, **Danese S**, Peyrin-Biroulet L; ECCO COVID taskforce.  
Inflammatory bowel disease management during the COVID-19 outbreak: a survey from the European Crohn's and Colitis Organization (ECCO).  
*Gastroenterology.* 2020 Apr 30: S0016-5085(20)30578-3. doi: 10.1053/j.gastro.2020.04.059. (IF 2020: 22,682)
522. Bezzio C, Saibeni S, Variola A, Allocca M, Massari A, Gerardi V, Casini V, Ricci C, Zingone F, Amato A, Caprioli F, Lenti MV, Viganò C, Ascolani M, Bossa F, Castiglione F, Cortelezzi C, Grossi L, Milla M, Morganti D, Pastorelli L, Ribaldone DG, Sartini A, Soriano A, Manes G, **Danese S**, Fantini M, Armuzzi A, Daperno M, Fiorino G; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).  
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study.  
*Gut.* 2020 Apr 30: gutjnl-2020-321411. doi: 10.1136/gutjnl-2020-321411. (IF 2020: 23,059)



523. D'Amico F, Pugliese N, Peyrin-Biroulet L, **Danese S**.  
Efficacy of anti-TNF $\alpha$  drugs in patients with stricturing Crohn's disease.  
*Expert Rev Gastroenterol Hepatol*. 2020 May 12;1-7. doi: 10.1080/17474124.2020.1759417. (IF 2020: 3,869)
524. Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, **Danese S**, Panés J, Bressler B, Colombel JF, Lawendy N, Maller E, Zhang H, Chan G, Salese L, Tsilkos K, Marren A, Su C.  
Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply.  
*Aliment Pharmacol Ther*. 2020 May;51(10):997-998. doi: 10.1111/apt.15716. (IF 2020: 8,171)
525. Daude S, Remen T, Chateau T, **Danese S**, Gastin I, Baumann C, Gueant JL, Peyrin-Biroulet L.  
Comparative accuracy of ferritin, transferrin saturation and soluble transferrin receptor for the diagnosis of iron deficiency in inflammatory bowel disease.  
*Aliment Pharmacol Ther*. 2020 Jun;51(11):1087-1095. doi: 10.1111/apt.15739. Epub 2020 Apr 22. (IF 2020: 8,171)
526. Pugliese N, Roda G, Peyrin-Biroulet L, **Danese S**.  
Emerging therapies for the treatment of ulcerative colitis.  
*Expert Opin Emerg Drugs*. 2020 Mar 9:1-9. doi: 10.1080/14728214.2020.1737009. (IF 2020: 4,191)
527. Pellino G, Keller DS, Sampietro GM, Carvello M, Celentano V, Coco C, Colombo F, Geccherle A, Luglio G, Rottoli M, Scarpa M, Sciaudone G, Sica G, Sofo L, Zinicola R, Leone S, **Danese S**, Spinelli A, Delaini G, Selvaggi F; Italian Society of Colorectal Surgery SICCR.  
Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis.  
*Tech Coloproctol*. 2020 May;24(5):397-419. doi: 10.1007/s10151-020-02175-z. Epub 2020 Mar 2.  
Erratum in: *Tech Coloproctol*. 2020 Aug;24(8):905. doi: 10.1007/s10151-020-02258-x (IF 2020: 3,781)
528. Reinisch W, Panaccione R, Bossuyt P, Baert F, Armuzzi A, Hébuterne X, Travis S, **Danese S**, Sandborn WJ, Schreiber S, Berg S, Zhou Q, Kligys K, Neimark E, Suleiman AA, D'Haens G, Colombel JF.  
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study.

*Inflamm Bowel Dis.* 2020 Feb 27; iza025. doi: 10.1093/ibd/iza025. (IF 2020: 5,325)

529. Argollo M, Furfaro F, Gilardi D, Roda G, Allocca M, Peyrin-Biroulet L, **Danese S**.  
Modulation of sphingosine-1-phosphate in ulcerative colitis.  
*Expert Opin Biol Ther.* 2020 Apr;20(4):413-420. doi: 10.1080/14712598.2020.1732919. Epub  
2020 Feb 25. (IF 2020: 3,869)
530. Vermeire S, Lukáš M, Magro F, Adsul S, Lindner D, Rosario M, Roth J, **Danese S**.  
Vedolizumab Efficacy, Safety, and Pharmacokinetics with Reduced Frequency of Dosing From  
Every 4 Weeks to Every 8 Weeks in Patients with Crohn's Disease or Ulcerative Colitis.  
*J Crohns Colitis.* 2020 Feb 15; jjaa027. doi: 10.1093/ecco-jcc/jjaa027. (IF 2020: 9,071)
531. D'Amico F, Bonovas S, **Danese S**, Peyrin-Biroulet L.  
Review article: faecal calprotectin and histologic remission in ulcerative colitis.  
*Aliment Pharmacol Ther.* 2020 Apr;51(7):689-698. doi: 10.1111/apt.15662. Epub 2020 Feb 12.  
(IF 2020: 8,171)
532. Fiorino G, Allocca M, Correale C, Roda G, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L,  
**Danese S**.  
Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block.  
*Expert Opin Biol Ther.* 2020 Apr;20(4):421-427. doi: 10.1080/14712598.2020.1727437. Epub  
2020 Feb 13. (IF 2020: 3,869)
533. Kim H, Alten R, Avedano L, Dignass A, Gomollón F, Greveson K, Halfvarson J, Irving  
PM, Jahnsen J, Lakatos PL, Lee J, Makri S, Parker B, Peyrin-Biroulet L, Schreiber S, Simoens S,  
Westhovens R, **Danese S**, Jeong JH.  
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory  
Diseases.  
*Drugs.* 2020 Feb;80(2):99-113. doi: 10.1007/s40265-020-01256-5. (IF 2020: 9,546)
534. Tavares De Sousa H, Estevinho MM, Peyrin-Biroulet L, **Danese S**, Dias CC, Carneiro F,  
Magro F.  
Transmural Histological Scoring Systems in Crohn's Disease: A Systematic Review With  
Assessment of Methodological Quality and Operating Properties.  
*J Crohns Colitis.* 2020 Jan 27; jjz178. doi: 10.1093/ecco-jcc/jjz178. (IF 2020: 9,071)
535. Parigi TL, D'Amico F, **Danese S**.  
Upadacitinib for Crohn's disease and ulcerative colitis treatment: hitting the selective JAKpot.

- Gastroenterology*. 2020 Apr 17; S0016-5085(20)30517-5. doi: 10.1053/j.gastro.2020.04.034. (IF 2020: 22,682)
536. D'Amico F, Peyrin-Biroulet L, **Danese S**.  
*Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy*.  
*Gastroenterology*. 2020 Apr 16; S0016-5085(20)30515-1. doi: 10.1053/j.gastro.2020.04.032. (IF 2020: 22,682)
537. Iacucci M, Cannatelli R, Labarile N, Mao R, Panaccione R, **Danese S**, Kochhar GS, Ghosh S, Shen B.  
Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period.  
*Lancet Gastroenterol Hepatol*. 2020 Jun;5(6):598-606. doi: 10.1016/S2468-1253(20)30119-9. (IF 2020: 18,486)
538. Allocca M, Fiorino G, Furfaro F, Gilardi D, Radice S, D'Amico F, Zilli A, **Danese S**.  
Maintaining the Quality Standards of Care for Inflammatory Bowel Disease Patients During the COVID-19 Pandemic.  
*Clin Gastroenterol Hepatol*. 2020 Apr 15; S1542-3565(20)30524-3. doi: 10.1016/j.cgh.2020.04.028. (IF 2020: 11,382)
539. Pouillon L, Travis S, Bossuyt P, **Danese S**, Peyrin-Biroulet L.  
Head-to-head trials in inflammatory bowel disease: past, present and future.  
*Nat Rev Gastroenterol Hepatol*. 2020 Apr 17. doi: 10.1038/s41575-020-0293-9. (IF 2020: 46,802)
540. **Danese S**, Ran ZH, Repici A, Tong J, Omodei P, Aghemo A, Malesci A.  
Gastroenterology department operational reorganisation at the time of covid-19 outbreak: an Italian and Chinese experience.  
*Gut*. 2020 Jun;69(6):981-983. doi: 10.1136/gutjnl-2020-321143. Epub 2020 Apr 16. (IF 2020: 23,059)
541. Fiorino G, Colombo M, Natale C, Azzolini E, Lagioia M, **Danese S**.  
Clinician Education and Adoption of Preventive Measures for COVID-19: A Survey of a Convenience Sample of General Practitioners in Lombardy, Italy.  
*Ann Intern Med*. 2020 Apr 15;M20-1447. doi: 10.7326/M20-1447. (IF 2020: 25,391)

542. Zanolì L, Mikhailidis DP, Bruno RM, Abreu MT, **Danese S**, Eliakim R, Gionchetti P, Katsanos KH, Kirchgerner J, Koutroubakis IE, Kucharzik T, Lakatos PL, Nguyen GC, Papa A, Vavrìcka SR, Wilkinson IB, Boutouyrie P.  
Aortic Stiffening Is an Extraintestinal Manifestation of Inflammatory Bowel Disease: Review of the Literature and Expert Panel Statement.  
*Angiology*. 2020 Apr 15;3319720918509. doi: 10.1177/0003319720918509. (IF 2020: 3,619)
543. D'Amico F, Baumgart DC, **Danese S**, Peyrin-Biroulet L.  
Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management.  
*Clin Gastroenterol Hepatol*. 2020 Apr 8: S1542-3565(20)30481-X. doi: 10.1016/j.cgh.2020.04.001. (IF 2020: 11,382)
544. Gadaleta RM, Garcia-Irigoyen O, Cariello M, Scialpi N, Peres C, Vetrano S, Fiorino G, **Danese S**, Ko B, Luo J, Porru E, Roda A, Sabbà C, Moschetta A.  
Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor.  
*EBioMedicine*. 2020 Apr; 54:102719. doi: 10.1016/j.ebiom.2020.102719. Epub 2020 Apr 5. (IF 2020: 8,143)
545. Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, **Danese S**.  
Crohn's disease.  
*Nat Rev Dis Primers*. 2020 Apr 2;6(1):22. doi: 10.1038/s41572-020-0156-2. (IF 2020: 52,329)
546. Ungaro RC, Yzet C, Bossuyt P, Baert FJ, Vanasek T, D'Haens GR, Joustra VW, Panaccione R, Novacek G, Reinisch W, Armuzzi A, Golovchenko O, Prymak O, Goldis A, Travis SP, Hébuterne X, Ferrante M, Rogler G, Fumery M, **Danese S**, Rydzewska G, Pariente B, Hertervig E, Stanciu C, Serrero M, Diculescu M, Peyrin-Biroulet L, Laharie D, Wright JP, Gomollón F, Gubonina I, Schreiber S, Motoya S, Hellström PM, Halfvarson J, Butler JW, Petersson J, Petralia F, Colombel JF.  
Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease.  
*Gastroenterology*. 2020 Mar 25: S0016-5085(20)30390-5. Doi: 10.1053/j.gastro.2020.03.039. (IF 2020: 22,682)
547. Tursi A, Scarpignato C, Strate LL, Lanás A, Kruis W, Lahat A, **Danese S**.  
Colonic diverticular disease.  
*Nat Rev Dis Primers*. 2020 Mar 26;6(1):20. doi: 10.1038/s41572-020-0153-5.

- Erratum in: *Nat Rev Dis Primers*. 2020 Apr 29;6(1):35. doi: 10.1038/s41572-020-0176-y, *Nat Rev Dis Primers*. 2020 Jun 17;6(1):50. doi: 10.1038/s41572-020-0192-y (IF 2020: 52,329)
548. **Danese S**, Cecconi M, Spinelli A.  
Management of IBD during the COVID-19 outbreak: resetting clinical priorities. *Nat Rev Gastroenterol Hepatol*. 2020 May;17(5):253-255. doi: 10.1038/s41575-020-0294-8. (IF 2020: 46,802)
549. Fiorino G, Bonifacio C, Allocca M, **Danese S**.  
Impact of therapies on bowel damage in Crohn's disease.  
*United European Gastroenterol J*. 2020 May;8(4):410-417. doi: 10.1177/2050640620908696. Epub 2020 Feb 20. (IF 2020: 4,623)
550. Fiorino G, Allocca M, Furfaro F, Gilardi D, Zilli A, Radice S, Spinelli A, **Danese S**.  
Inflammatory bowel disease care in the COVID-19 pandemic era: the Humanitas, Milan experience.  
*J Crohns Colitis*. 2020 Mar 24: jjaa058. doi: 10.1093/ecco-jcc/jjaa058. (IF 2020: 9,071)
551. **Danese S**, Schabel E, Ainsworth MA, Peyrin-Biroulet L.  
Challenges and opportunities for IBD drug development: from early stage to regulatory approval.  
*Gut*. 2020 Mar 16;gutjnl-2019-320542. doi: 10.1136/gutjnl-2019-320542. (IF 2020: 23,059)
552. Piovani D, **Danese S**, Peyrin-Biroulet L, Nikolopoulos GK, Bonovas S.  
Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease.  
*Aliment Pharmacol Ther*. 2020 May;51(9):820-830. doi: 10.1111/apt.15692. Epub 2020 Mar 13. (IF 2020: 8,171)
553. Peppas S, Piovani D, Peyrin-Biroulet L, **Danese S**, Bonovas S.  
Statins and inflammatory bowel disease: Where do we stand?  
*Eur J Intern Med*. 2020 May;75:10-14. doi: 10.1016/j.ejim.2020.02.017. Epub 2020 Mar 6. (IF 2020: 4,487)
554. **Danese S**, Fiorino G, Peyrin-Biroulet L.  
Positioning Therapies in Ulcerative Colitis.  
*Clin Gastroenterol Hepatol*. 2020 May;18(6):1280-1290.e1. doi: 10.1016/j.cgh.2020.01.017. Epub 2020 Jan 23. (IF 2020: 11,382)

555. D'Amico F, **Danese S**, Peyrin-Biroulet L.  
Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?  
*Expert Opin Biol Ther.* 2020 Apr;20(4):353-361. doi: 10.1080/14712598.2020.1717465. Epub 2020 Jan 21. (IF 2020: 3,869)
556. Olivera PA, Lasa JS, Bonovas S, **Danese S**, Peyrin-Biroulet L.  
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.  
*Gastroenterology.* 2020 May;158(6):1554-1573.e12. doi: 10.1053/j.gastro.2020.01.001. Epub 2020 Jan 9. (IF 2020: 22,682)
557. Wasmann KATGM, de Groof EJ, Stellingwerf ME, D'Haens GR, Ponsioen CY, Gecse KB, Dijkgraaf MGW, Gerhards MF, Jansen JM, Pronk A, van Tuyl SAC, Zimmerman DDE, Bruin KF, Spinelli A, **Danese S**, van der Bilt JDW, Mundt MW, Bemelman WA, Buskens CJ.  
Treatment of perianal fistulas in Crohn's disease, seton versus anti-TNF versus surgical closure following anti-TNF (PISA): a randomised controlled trial.  
*J Crohns Colitis.* 2020 Jan 10: jjaa004. doi: 10.1093/ecco-jcc/jjaa004. (IF 2020: 9,071)
558. Spinelli A, Armuzzi A, Ciccocioppo R, **Danese S**, Gionchetti P, Luglio G, Orlando A, Rispo A, Rizzello F, Sofo L, Solina G, Poggioli G.  
Management of patients with complex perianal fistulas in Crohn's disease: Optimal patient flow in the Italian clinical reality.  
*Dig Liver Dis.* 2020 May;52(5):506-515. doi: 10.1016/j.dld.2019.11.016. Epub 2019 Dec 31. (IF 2020: 4,088)
559. D'Amico F, Peyrin-Biroulet L, **Danese S**.  
Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic.  
*J Clin Med.* 2020 May 19;9(5):1536. doi: 10.3390/jcm9051536. (IF 2020: 4,241)
560. D'Amico F, Parigi TL, Bonovas S, Peyrin-Biroulet L, **Danese S**.  
Long-term safety of approved biologics for ulcerative colitis.  
*Expert Opin Drug Saf.* 2020 Jun 8:1-9. doi: 10.1080/14740338.2020.1773430. (IF 2020: 4,250)
561. Fiorino G, Peyrin-Biroulet L, **Danese S**.  
Protecting patients with IBD during the COVID-19 pandemic.  
*Lancet Gastroenterol Hepatol.* 2020 Jul;5(7):639. doi: 10.1016/S2468-1253(20)30152-7. Epub 2020 May 20. (IF 2020: 18,486)

562. Cecconi M, Piovani D, Brunetta E, Aghemo A, Greco M, Ciccarelli M, Angelini C, Voza A, Omodei P, Vespa E, Pugliese N, Parigi TL, Folci M, **Danese S**, Bonovas S.  
Early Predictors of Clinical Deterioration in a Cohort of 239 Patients Hospitalized for Covid-19 Infection in Lombardy, Italy.  
*J Clin Med*. 2020 May 20;9(5):1548. doi: 10.3390/jcm9051548. (IF 2020: 4,241)
563. Peck-Radosavljevic M, **Danese S**, Hartmann D, Saftoiu A, Van Hooteigem P; UEG Public Affairs Committee.  
COVID-19 and digestive health.  
*United European Gastroenterol J*. 2020 Jun;8(5):624-626. doi: 10.1177/2050640620927955. (IF 2020: 4,623)
564. Vespa E, Pugliese N, Piovani D, Capogreco A, **Danese S**, Aghemo A; Humanitas Covid-19 Task Force.  
Liver tests abnormalities in COVID-19: trick or treat?  
*J Hepatol*. 2020 May 27: S0168-8278(20)30352-4. doi: 10.1016/j.jhep.2020.05.033. (IF 2020: 25,083)
565. **Danese S**, Sands B, Ng SC, Peyrin-Biroulet L.  
The day after COVID-19 in IBD: how to go back to 'normal'.  
*Nat Rev Gastroenterol Hepatol*. 2020 Jun 1:1–3. doi: 10.1038/s41575-020-0322-8. (IF 2020: 46,802)
566. D'Amico F, Chateau T, Laurent V, **Danese S**, Peyrin-Biroulet L.  
Which MRI Score and Technique Should Be Used for Assessing Crohn's Disease Activity?  
*J Clin Med*. 2020 Jun 2;9(6): E1691. doi: 10.3390/jcm9061691. (IF 2020: 4,241)
567. Magro F, Doherty G, Peyrin-Biroulet L, Svrcek M, Borralho P, Walsh A, Carneiro F, Rosini F, de Hertogh G, Biedermann L, Pouillon L, Scharl M, Tripathi M, **Danese S**, Villanacci V, Feakins R.  
ECCO Position Paper: Harmonisation of the approach to Ulcerative Colitis Histopathology.  
*J Crohns Colitis*. 2020 Jun 6: jjaa110. doi: 10.1093/ecco-jcc/jjaa110. (IF 2020: 9,071)
568. Zacharopoulou E, Craviotto V, Fiorino G, Furfaro F, Zilli A, Gilardi D, Peyrin-Biroulet L, **Danese S**, Allocca M.  
Targeting the gut layers in Crohn's disease: mucosal or transmural healing?  
*Expert Rev Gastroenterol Hepatol*. 2020 Jun 18:1-13. doi: 10.1080/17474124.2020.1780914. (IF 2020: 3,869)

569. Piovani D, Pansieri C, Peyrin-Biroulet L, **Danese S**, Bonovas S.  
A snapshot of the ongoing clinical research on COVID-19.  
*F1000Res*. 2020 May 18; 9:373. doi: 10.12688/f1000research.23843.1. (IF 2020: 2,30)
570. Reinisch W, **Danese S**, Peyrin-Biroulet L, Loftus EV.  
Clinical trials for inflammatory bowel disease: a global guidance during COVID-19 pandemic.  
*J Crohns Colitis*. 2020 Jun 10: jjaa119. doi: 10.1093/ecco-jcc/jjaa119. (IF 2020: 9,071)
571. Roda G, Dal Buono A, Argollo M, **Danese S**.  
JAK selectivity: more precision less troubles.  
*Expert Rev Gastroenterol Hepatol*. 2020 Jun 16:1-8. doi: 10.1080/17474124.2020.1780120. (IF 2020: 3,869)
572. Furfaro F, Vuitton L, Fiorino G, Koch S, Allocca M, Gilardi D, Zilli A, D'Amico F, Radice S, Chevaux JB, Schaefer M, Chaussade S, **Danese S**, Peyrin-Biroulet L.  
SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience.  
*Nat Rev Gastroenterol Hepatol*. 2020 Jun 11:1–10. doi: 10.1038/s41575-020-0319-3. (IF 2020: 46,802)
573. Zilli A, Capogreco A, Furfaro F, Allocca M, Roda G, Loy L, Fiorino G, **Danese S**.  
Improving quality of care in endoscopy of inflammatory bowel disease: can we do better?  
*Expert Rev Gastroenterol Hepatol*. 2020 Jun 22:1-10. doi: 10.1080/17474124.2020.1780913. (IF 2020: 3,869)
574. Feagan BG, Sandborn WJ, **Danese S**, Wolf DC, Liu WJ, Hua SY, Minton N, Olson A, D'Haens G.  
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.  
*Lancet Gastroenterol Hepatol*. 2020 Jun 15: S2468-1253(20)30188-6. doi: 10.1016/S2468-1253(20)30188-6. (IF 2020: 18,486)
575. D'Amico F, Baumgart DC, **Danese S**, Peyrin-Biroulet L.  
Response.  
*Clin Gastroenterol Hepatol*. 2020 Jun 19: S1542-3565(20)30849-1. doi: 10.1016/j.cgh.2020.06.038. (IF 2020: 11,382)



576. Gilardi D, Gabbiadini R, Allocca M, Correale C, Fiorino G, Furfaro F, Zilli A, Peyrin-Biroulet L, **Danese S**.  
PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD.  
*Expert Rev Gastroenterol Hepatol*. 2020 Jul 1:1-10. doi:10.1080/17474124.2020.1785868. (IF 2020: 3,869)
577. D'Amico F, Peyrin-Biroulet L, **Danese S**.  
JAK or GUT Selectivity: Tipping the Balance for Efficacy and Safety in Ulcerative Colitis.  
*J Crohns Colitis*. 2020 Jun 24: jjaa074. doi: 10.1093/ecco-jcc/jjaa074. (IF 2020: 9,071)
578. D'Amico F, Peyrin-Biroulet L, **Danese S**.  
Tofacitinib for Acute Severe Colitis: When the going Gets Tough, the Tough Get Going.  
*J Crohns Colitis*. 2020 Jun 24: jjaa028. doi: 10.1093/ecco-jcc/jjaa028. (IF 2020: 9,071)
579. Allocca M, Guidelli GM, Borroni RG, Selmi C, Narcisi A, **Danese S**, Fiorino G.  
Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: experience from Humanitas Center, Milan.  
*Pharmacol Res*. 2020 Jul 3:105061. doi: 10.1016/j.phrs.2020.105061. (IF 2020: 7,658)
580. Reinisch W, Gecse K, Halfvarson J, Irving PM, Jahnsen J, Peyrin-Biroulet L, Rogler G, Schreiber S, **Danese S**.  
Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease.  
*Inflamm Bowel Dis*. 2020 Jul 7: iza078. doi: 10.1093/ibd/iza078. (IF 2020: 5,325)
581. Papa A, Tursi A, **Danese S**, Rapaccini G, Gasbarrini A, Papa V.  
Venous Thromboembolism in Patients with Inflammatory Bowel Disease: The Role of Pharmacological Therapy and Surgery.  
*J Clin Med*. 2020 Jul 4;9(7): E2115. doi: 10.3390/jcm9072115. (IF 2020: 4,241)
582. Fiorino G, Bonovas S, Gilardi D, Di Sabatino A, Allocca M, Furfaro F, Roda G, Lenti MV, Aronico N, Mengoli C, Angeli E, Gaffuri N, Peyrin-Biroulet L, **Danese S**.  
Validation of the Red Flags Index for Early Diagnosis of Crohn's Disease: A Prospective Observational IG-IBD Study Among General Practitioners.  
*J Crohns Colitis*. 2020 Sep 28:jjaa111. doi: 10.1093/ecco-jcc/jjaa111. (IF 2020: 9,071)

583. Sandborn WJ, Feagan BG, **Danese S**, O'Brien CD, Ott E, Marano C, Baker T, Zhou Y, Volger S, Tikhonov I, Gasink C, Sands BE, Ghosh S.  
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies.  
*Inflamm Bowel Dis.* 2020 Sep 23;23:2366-2368. doi: 10.1093/ibd/izaa236. (IF 2020: 5,325)
584. Aghemo A, Piovani D, Parigi TL, Brunetta E, Pugliese N, Vespa E, Omodei PD, Preatoni P, Lleo A, Repici A, Voza A, Cecconi M, Malesci A, Bonovas S, **Danese S**; Humanitas COVID-19 Task Force.  
COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy.  
*Clin Gastroenterol Hepatol.* 2020 Sep;18(10):2366-2368.e3. doi: 10.1016/j.cgh.2020.05.011. Epub 2020 May 11. (IF 2020: 11,382)
585. Peyrin-Biroulet L, **Danese S**.  
More on Covid-19 in Immune-Mediated Inflammatory Diseases.  
*N Engl J Med.* 2020 Aug 20;383(8):796. doi: 10.1056/NEJMc2018011. Epub 2020 Jul 10. (IF 2020: 31,245)
586. Gracey E, Vereecke L, McGovern D, Fröhling M, Schett G, **Danese S**, De Vos M, Van den Bosch F, Elewaut D.  
Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis.  
*Nat Rev Rheumatol.* 2020 Aug;16(8):415-433. doi: 10.1038/s41584-020-0454-9. Epub 2020 Jul 13. (IF 2020: 20,543)
587. Biancone L, Ardizzone S, Armuzzi A, Castiglione F, D'Incà R, **Danese S**, Daperno M, Gionchetti P, Rizzello F, Scribano ML, Vecchi M, Orlando A.  
Ustekinumab for treating ulcerative colitis: an expert opinion.  
*Expert Opin Biol Ther.* 2020 Jul 24:1-9. doi: 10.1080/14712598.2020.1792882. (IF 2020: 3,869)
588. Sousa P, Estevinho MM, Dias CC, Ministro P, Kopylov U, **Danese S**, Peyrin-Biroulet L, Magro F.  
Thiopurines' Metabolites and Drug Toxicity: A Meta-Analysis.  
*J Clin Med.* 2020 Jul 13;9(7):2216. doi: 10.3390/jcm9072216. (IF 2020: 4,241)
589. Allocca M, Furfaro F, Fiorino G, Peyrin-Biroulet L, **Danese S**.  
Point-of-care ultrasound in Inflammatory Bowel Disease.  
*J Crohns Colitis.* 2020 Jul 17;14:1511-1516. doi: 10.1093/ecco-jcc/jjaa151. (IF 2020: 9,071)

590. Privitera G, Onali S, Pugliese D, Renna S, Savarino E, Viola A, Ribaldone DG, Buda A, Bezzio C, Fiorino G, Fantini MC, Scaldaferrì F, Guidi L, **Danese S**, Gasbarrini A, Orlando A, Armuzzi A.  
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease.  
*J Crohns Colitis*. 2020 Jul 17;jjaa149. doi: 10.1093/ecco-jcc/jjaa149. (IF 2020: 9,071)
591. D'Amico F, Wexner SD, Vaizey CJ, Gouynou C, **Danese S**, Peyrin-Biroulet L.  
Tools for fecal incontinence assessment: lessons for inflammatory bowel disease trials based on a systematic review.  
*United European Gastroenterol J*. 2020 Oct;8(8):886-922. doi: 10.1177/2050640620943699. Epub 2020 Jul 17. (IF 2020: 4,623)
592. D'Amico F, **Danese S**, Peyrin-Biroulet L.  
Adaptive Designs: Lessons for Inflammatory Bowel Disease Trials.  
*J Clin Med*. 2020 Jul 23;9(8):2350. doi: 10.3390/jcm9082350. (IF 2020: 4,241)
593. Dal Buono A, Roda G, Argollo M, Paridaens K, Peyrin-Biroulet L, **Danese S**.  
Treat to target in mild to moderate ulcerative colitis: evidence to support this strategy.  
*Curr Drug Targets*. 2020 Jul 27. doi: 10.2174/1389450121666200727120305. (IF 2020: 3,465)
594. Ungaro F, D'Alessio S, **Danese S**.  
The Role of Pro-Resolving Lipid Mediators in Colorectal Cancer-Associated Inflammation: Implications for Therapeutic Strategies.  
*Cancers (Basel)*. 2020 Jul 26;12(8):2060. doi: 10.3390/cancers12082060. (IF 2020: 6,639)
595. Parigi TL, Vespa E, Pugliese N, **Danese S**.  
COVID-19 and gastrointestinal symptoms: the dust has not settled yet.  
*Expert Rev Gastroenterol Hepatol*. 2020 Oct;14(10):877-878. doi: 10.1080/17474124.2020.1801415. Epub 2020 Aug 1. (IF 2020: 3,869)
596. Vespa E, Furfaro F, Allocca M, Fiorino G, Correale C, Gilardi D, Argollo M, Zilli A, Zacharopoulou E, Loy L, **Danese S**.  
Endoscopy after surgery in inflammatory bowel disease: Crohn's disease recurrence and pouch surveillance.  
*Expert Rev Gastroenterol Hepatol*. 2020 Sep;14(9):829-841. doi: 10.1080/17474124.2020.1807325. Epub 2020 Aug 18. (IF 2020: 3,869)

597. Dal Buono A, Roda G, Argollo M, Zacharopoulou E, Peyrin-Biroulet L, **Danese S**.  
Treat to target or 'treat to clear' in inflammatory bowel diseases: one step further?  
*Expert Rev Gastroenterol Hepatol.* 2020 Sep;14(9):807-817. doi:  
10.1080/17474124.2020.1804361. Epub 2020 Aug 18. (IF 2020: 3,869)
598. D'Amico F, **Danese S**, Peyrin-Biroulet L.  
Systematic Review on IBD Patients With COVID-19: It Is Time to Take Stock.  
*Clin Gastroenterol Hepatol.* 2020 Aug 7:S1542-3565(20)31080-6. doi:  
10.1016/j.cgh.2020.08.003. (IF 2020: 11,382)
599. Guillo L, D'Amico F, Serrero M, Angioi K, Loeuille D, Costanzo A, **Danese S**, Peyrin-Biroulet L.  
Assessment of extraintestinal manifestations in inflammatory bowel diseases: A systematic review and a proposed guide for clinical trials.  
*United European Gastroenterol J.* 2020 Aug 10:2050640620950093. doi:  
10.1177/2050640620950093. (IF 2019: 4,623)
600. Parigi TL, D'Amico F, Peyrin-Biroulet L, **Danese S**.  
Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13.  
*Expert Opin Biol Ther.* 2020 Aug 31:1-10. doi: 10.1080/14712598.2020.1811849. (IF 2020: 3,869)
601. Solitano V, D'Amico F, Zacharopoulou E, Peyrin-Biroulet L, **Danese S**.  
Early Intervention in Ulcerative Colitis: Ready for Prime Time?  
*J Clin Med.* 2020 Aug 14;9(8):2646. doi: 10.3390/jcm9082646. (IF 2020: 4,241)
602. D'Amico F, Netter P, Baumann C, Veltin M, Zallot C, Aimone-Gastin I, **Danese S**, Peyrin-Biroulet L.  
Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience.  
*J Clin Med.* 2020 Aug 20;9(9):E2697. doi: 10.3390/jcm9092697. (IF 2020: 4,241)
603. Fiorino G, Gilardi D, Radice S, Furfaro F, Allocca M, **Danese S**.  
Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures.

- Am J Gastroenterol.* 2020 Oct;115(10):1719-1721. doi: 10.14309/ajg.0000000000000829. (IF 2020: 10,864)
604. D'Amico F, Solitano V, Peyrin-Biroulet L, **Danese S**.  
Nocebo effect and biosimilars in inflammatory bowel diseases: what's new and what's next?  
*Expert Opin Biol Ther.* 2020 Sep 6:1-9. doi: 10.1080/14712598.2020.1817374. (IF 2020: 3,869)
605. Loftus EV Jr, Feagan BG, Panaccione R, Colombel JF, Sandborn WJ, Sands BE, **Danese S**, D'Haens G, Rubin DT, Shafran I, Parfionovas A, Rogers R, Lirio RA, Vermeire S.  
Long-term safety of vedolizumab for inflammatory bowel disease.  
*Aliment Pharmacol Ther.* 2020 Sep 2;52(8):1353–65. doi: 10.1111/apt.16060. (IF 2020: 8,171)
606. Solitano V, Fiorino G, D'Amico F, Peyrin-Biroulet L, **Danese S**.  
Thrombosis in IBD in the era of JAK inhibition.  
*Curr Drug Targets.* 2020 Sep 2. doi: 10.2174/1389450121666200902164240. (IF 2020: 3,465)
607. Magro F, Estevinho MM, Dias CC, Correia L, Lago P, Ministro P, Portela F, Feakins R, **Danese S**, Peyrin-Biroulet L.  
Clinical, endoscopic and histological outcomes in induction of moderate-to-severe ulcerative colitis: a systematic review with meta-analysis.  
*J Crohns Colitis.* 2020 Sep 8;jjaa176. doi: 10.1093/ecco-jcc/jjaa176. (IF 2020: 9,071)
608. Solitano V, D'Amico F, Fiorino G, Paridaens K, Peyrin-Biroulet L, **Danese S**.  
Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis.  
*J Clin Med.* 2020 Sep 8;9(9):E2905. doi: 10.3390/jcm9092905. (IF 2020: 4,241)
609. Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, **Danese S**, Peyrin-Biroulet L, Hibi T.  
Ulcerative colitis.  
*Nat Rev Dis Primers.* 2020 Sep 10;6(1):74. doi: 10.1038/s41572-020-0205-x. (IF 2020: 52,329)
610. Muller M, D'Amico F, Bonovas S, **Danese S**, Peyrin-Biroulet L.  
TNF inhibitors and risk of malignancy in patients with inflammatory bowel diseases: a systematic review.  
*J Crohns Colitis.* 2020 Sep 11;jjaa186. doi: 10.1093/ecco-jcc/jjaa186. (IF 2020: 9,071)
611. Magro F, Alves C, Lopes J, Lopes S, Tavares de Sousa H, Cotter J, Macedo da Silva V, Lago P, Vieira A, Brito M, Duarte MA, Portela F, Silva JP, Ministro P, Arroja B, Carvalho L,

- Torres J, Santiago M, Estevinho M, **Danese S**, Peyrin-Biroulet L, Dias CC, Borralho P, Feakins RM, Carneiro F.  
Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy.  
*Clin Gastroenterol Hepatol.* 2020 Sep 10:S1542-3565(20)31274-X. doi: 10.1016/j.cgh.2020.09.017. (IF 2020: 11,382)
612. Livanos AE, Jha D, Cossarini F, Gonzalez-Reiche AS, Tokuyama M, Aydilto T, Parigi TL, Ramos I, Dunleavy K, Lee B, Dixon R, Chen ST, Martinez-Delgado G, Nagula S, Ko HM, Reidy J, Naymagon S, Grinspan A, Ahmad J, Tankelevich M, Gordon R, Sharma K, Britton GJ, Chen-Liaw A, Spindler MP, Plitt T, Wang P, Cerutti A, Faith JJ, Colombel JF, Kenigsberg E, Argmann C, Merad M, Gnjatic S, Harpaz N, **Danese S**, Rahman A, Kumta NA, Aghemo A, Petralia F, van Bakel H, Garcia-Sastre A, Mehandru S.  
Gastrointestinal involvement attenuates COVID-19 severity and mortality.  
*medRxiv [Preprint]*. 2020 Sep 9:2020.09.07.20187666. doi: 10.1101/2020.09.07.20187666.
613. Vaillant S, Guillo L, Michot N, D'Amico F, Germain A, **Danese S**, Baumann C, Rousseau H, Quilliot D, Peyrin-Biroulet L.  
Predictors for short bowel syndrome in Crohn's disease.  
*Dig Liver Dis.* 2020 Sep 14:S1590-8658(20)30448-5. doi: 10.1016/j.dld.2020.08.029. (IF 2020: 4,088)
614. Muller M, Broséus J, Feugier P, Thieblemont C, Laurent B, **Danese S**, Arnone D, Ndiaye NC, Kokten T, Houlgatte R, Peyrin-Biroulet L.  
Characteristics Of Lymphoma In Patients With Inflammatory Bowel Disease: A Systematic Review.  
*J Crohns Colitis.* 2020 Sep 19:jjaa193. doi: 10.1093/ecco-jcc/jjaa193. (IF 2020: 9,071)
615. Solitano V, D'Amico F, Fiorino G, Peyrin-Biroulet L, **Danese S**.  
Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice.  
*Expert Rev Clin Immunol.* 2020 Sep 29:1-10. doi: 10.1080/1744666X.2021.1826311. (IF 2020: 4,473)
616. Allocca M, Chaparro M, Gonzalez HA, Bosca-Watts MM, Palmela C, D'Amico F, Zacharopoulou E, Kopylov U, Ellul P, Bamias G, Ntelis V, Lahat A, Mantzaris GJ, Papaconstantinou I, Katsanos K, Uspenskaya Y, Christodoulou D, Ben Horin S, Peyrin-Biroulet L, Torres J, Sebastian S, Gisbert JP, **Danese S**, Fiorino G.

Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study.

*J Clin Med.* 2020 Oct 31;9(11):E3533. doi: 10.3390/jcm9113533. (IF 2020: 4,241)

617. Panaccione R, **Danese S**, Sandborn WJ, O'Brien CD, Zhou Y, Zhang H, Adedokun OJ, Tikhonov I, Targan S, Abreu MT, Hisamatsu T, Scherl EJ, Leong RW, Rowbotham DS, Arasaradnam RP, Sands BE, Marano C.

Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.

*Aliment Pharmacol Ther.* 2020 Oct 21. doi: 10.1111/apt.16119. (IF 2020: 8,171)

618. Guillo L, Rabaud C, Choy EH, D'Amico F, **Danese S**, Ng SC, Peyrin-Biroulet L.

Herpes zoster and vaccination strategies in inflammatory bowel diseases: a practical guide.

*Clin Gastroenterol Hepatol.* 2020 Oct 17:S1542-3565(20)31440-3. doi: 10.1016/j.cgh.2020.10.027. (IF 2020: 11,382)

619. Fiorino G, **Danese S**, Giacobazzi G, Spinelli A.

Medical therapy versus surgery in moderate-to-severe ulcerative colitis.

*Dig Liver Dis.* 2020 Oct 10:S1590-8658(20)30502-8. doi: 10.1016/j.dld.2020.09.022. (IF 2020: 4,088)

620. Reinisch W, **Danese S**, Peyrin-Biroulet L, Loftus EV

Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic.

*J Crohns Colitis.* 2020 Oct 21;14(Supplement\_3):S820. doi: 10.1093/ecco-jcc/jjaa138. (IF 2020: 9,071)

621. **Danese S**, Chitkara D, Usiskin K.

Reply.

*Clin Gastroenterol Hepatol.* 2020 Dec;18(13):3057-3058. doi: 10.1016/j.cgh.2020.03.023 (IF 2020: 11,382)

622. Solitano V, D'Amico F, Correale C, Peyrin-Biroulet L, **Danese S**

Thiopurines and non-melanoma skin cancer: partners in crime in inflammatory bowel diseases.

*Br Med Bull.* 2020 Dec 15;136(1):107-117. doi: 10.1093/bmb/ldaa033 (IF 2020: 4,291)

623. **Danese S**, Subramaniam K, Van Zyl J, Adsul S, Lindner D, Roth J, Vermeire S.

Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme.

*Aliment Pharmacol Ther.* 2021 Jan;53(2):265-272. doi: 10.1111/apt.16160. Epub 2020 Nov 18.  
(IF 2020: 8,171)

624. Gabbiadini R, Zacharopoulou E, Furfaro F, Craviotto V, Zilli A, Gilardi D, Roda G, Loy L, Fiorino G, Peyrin-Biroulet L, **Danese S**, Allocca M.

Application of Ultrasound Elastography for Assessing Intestinal Fibrosis in Inflammatory Bowel Disease: Fiction or Reality?

*Curr Drug Targets.* 2020 Nov 19. doi: 10.2174/1389450121666201119142919. Online ahead of print. (IF 2020: 3,465)

625. Petti L, Rizzo G, Rubbino F, Elangovan S, Colombo P, Restelli S, Piontini A, Arena V, Carvello M, Romano B, Cavalleri T, Anselmo A, Ungaro F, D'Alessio S, Spinelli A, Stifter S, Grizzi F, Sgambato A, **Danese S**, Laghi L, Malesci A, Vetrano S

Unveiling role of sphingosine-1-phosphate receptor 2 as a brake of epithelial stem cell proliferation and a tumor suppressor in colorectal cancer.

*J Exp Clin Cancer Res.* 2020 Nov 23;39(1):253. doi: 10.1186/s13046-020-01740-6. (IF 2020: 11,161)

626. Weislinger L, Guillo L, D'Amico F, **Danese S**, Achit H, Ayav C, Guillemin F, Peyrin-Biroulet L, Frimat L

Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel disease.

*Eur J Gastroenterol Hepatol.* 2020 Nov 30. doi: 10.1097/MEG.0000000000002008. Online ahead of print. (IF 2020: 2,566)

627. D'Amico F, Peyrin-Biroulet L, **Danese S**, Fiorino G.

New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?

*Curr Opin Pharmacol.* 2020 Dec;55:141-150. doi: 10.1016/j.coph.2020.10.015. Epub 2020 Nov 27. (IF 2020: 5,547)

628. Piovani D, Pansieri C, Peyrin-Biroulet L, **Danese S**, Bonovas S.

Confounding and bias in observational studies in inflammatory bowel disease: a meta-epidemiological study.

*Aliment Pharmacol Ther.* 2020 Dec 9. doi: 10.1111/apt.16222. Online ahead of print. (IF 2020: 8,171)

629. Borrega R, Araújo C, Aguiam N, Magro F, Fonseca JE, **Danese S**, Lopes J, Goncalves J.



Systematic Review and Principal Components Analysis of the Immunogenicity of Adalimumab.

*BioDrugs*. 2021 Jan;35(1):35-45. doi: 10.1007/s40259-020-00458-3. (IF 2020: 5,807)

630. Loy L, Fiorino G, Roda G, Allocca M, Furfaro F, Zilli A, Gilardi D, Radice S, Peyrin-Biroulet L, **Danese S**.

New Paradigms to Help Decisions in Treatment Choice: Head to Head Trial of Biological Therapies in Inflammatory Bowel Diseases.

*Curr Drug Targets*. 2020 Dec 11. doi: 10.2174/1389450121666201211162527. Online ahead of print. (IF 2020: 3,465)

631. Allocca M, Filippi E, Costantino A, Bonovas S, Fiorino G, Furfaro F, Peyrin-Biroulet L, Fraquelli M, Caprioli F, **Danese S**.

Milan Ultrasound Criteria are accurate in assessing disease activity in ulcerative colitis: External validation.

*United European Gastroenterol J*. 2020 Dec 21:2050640620980203. doi: 10.1177/2050640620980203. (IF 2020: 4,623)

632. Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, **Danese S**, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A; International Organization for the Study of IBD.

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.

*Gastroenterology*. 2020 Dec 21:S0016-5085(20)35572-4. doi: 10.1053/j.gastro.2020.12.031. Online ahead of print. (IF 2020: 22,682)

633. Guillo L, D'Amico F, **Danese S**, Peyrin-Biroulet L.

Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review.

*J Crohns Colitis*. 2020 Dec 24:jjaa260. doi: 10.1093/ecco-jcc/jjaa260. Online ahead of print. (IF 2020: 9,071)

634. Lang-Schwarz C, Agaimy A, Atreya R, Becker C, **Danese S**, Fléjou JF, Gaßler N, Grabsch HI, Hartmann A, Kamarádová K, Kühl AA, Lauwers GY, Lugli A, Nagtegaal I,

Neurath MF, Oberhuber G, Peyrin-Biroulet L, Rath T, Riddell R, Rubio CA, Sheahan K, Tilg H, Villanacci V, Westerhoff M, Vieth M.

Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease.

*Virchows Arch.* 2020 Dec 29. doi: 10.1007/s00428-020-02982-7. Online ahead of print. (IF 2020: 4,064)

635. Furfaro F, Solitano V, **Danese S.**

An unusual case of cardiac involvement in Crohn's Disease.

*Gastroenterology.* 2020 Dec 29:S0016-5085(20)35589-X. doi: 10.1053/j.gastro.2020.12.038. Online ahead of print. (IF 2020: 22,682)

636. Pouillon L, Travis S, Bossuyt P, **Danese S,** Peyrin-Biroulet L.

Author Correction: Head-to-head trials in inflammatory bowel disease: past, present and future.

*Nat Rev Gastroenterol Hepatol.* 2021 Feb;18(2):143. doi: 10.1038/s41575-020-00409-x

637. Le Berre C, Peyrin-Biroulet L; SPIRIT-IOIBD study group.

Selecting Endpoints for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT consensus from the IOIBD.

*Gastroenterology.* 2021 Jan 6:S0016-5085(21)00016-0. doi: 10.1053/j.gastro.2020.10.065. Online ahead of print. (IF 2020: 22,682)

638. **Danese S,** Subramaniam K, Van Zyl J, Adsul S.

Editorial: vedolizumab in inflammatory bowel diseases-less is more? Authors' reply.

*Aliment Pharmacol Ther.* 2021 Feb;53(3):445-446. doi: 10.1111/apt.16227. (IF 2020: 8,171)

639. D'Amico F, Peyrin-Biroulet L, **Danese S.**

Clinical pharmacists and patients with inflammatory bowel diseases: are we ready for the multidisciplinary approach?

*Gastroenterology.* 2021 Jan 5:S0016-5085(21)00012-3. doi: 10.1053/j.gastro.2020.12.072. Online ahead of print. (IF 2020: 22,682)

640. Massimino L, Lovisa S, Antonio Lamparelli L, **Danese S,** Ungaro F.

Gut eukaryotic virome in colorectal carcinogenesis: Is that a trigger?

*Comput Struct Biotechnol J.* 2020 Dec 7;19:16-28. doi: 10.1016/j.csbj.2020.11.055.  
eCollection 2021. (IF 2020: 7,271)

641. Siegel CA, Melmed GY, McGovern DP, Rai V, Krammer F, Rubin DT, Abreu MT, Dubinsky MC; International Organization for the Study of Inflammatory Bowel Disease (IOIBD); International Organization for the Study of Inflammatory Bowel Diseases (IOIBD).  
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.  
*Gut.* 2021 Jan 20:gutjnl-2020-324000. doi: 10.1136/gutjnl-2020-324000. Online ahead of print. (IF 2020: 23,059)
642. D'Amico F, Rabaud C, Peyrin-Biroulet L, **Danese S.**  
SARS-CoV-2 vaccination in IBD: more pros than cons.  
*Nat Rev Gastroenterol Hepatol.* 2021 Jan 20:1-3. doi: 10.1038/s41575-021-00420-w. Online ahead of print. (IF 2020: 46,802)
643. Furfaro F, Alfarone L, Gilardi D, Correale C, Allocca M, Fiorino G, Argollo M, Zilli A, Zacharopoulou E, Loy L, Roda G, **Danese S.**  
TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease.  
*Curr Drug Targets.* 2021 Jan 20. doi: 10.2174/1389450122999210120205607. Online ahead of print. (IF 2020: 3,465)
644. Allocca M, Bonovas S, **Danese S.**  
Letter to the Editor Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound index.  
*J Crohns Colitis.* 2021 Jan 25;jjab018. doi: 10.1093/ecco-jcc/jjab018. Online ahead of print. (IF 2020: 9,071)
645. Laurain PA, Guillo L, D'Amico F, Netter P, **Danese S**, Baumann C, Luc A, Clerc-Urmes I, Spyridon S, Peyrin-Biroulet L.  
Incidence of and risk factors for colorectal strictures in ulcerative colitis: a multicenter study.  
*Clin Gastroenterol Hepatol.* 2021 Jan 22:S1542-3565(21)00078-1. doi: 10.1016/j.cgh.2021.01.028. Online ahead of print. (IF 2020: 11,382)
646. Peppas S, Pansieri C, Piovani D, **Danese S**, Peyrin-Biroulet L, Tsantes AG, Brunetta E, Tsantes AE, Bonovas S.

The Brain-Gut Axis: Psychological Functioning and Inflammatory Bowel Diseases.

*J Clin Med.* 2021 Jan 20;10(3):E377. doi: 10.3390/jcm10030377. (IF 2020: 4,241)

647. Fiorino G, Estevinho MM, Lopes DJM, Chersi F, Allocca M, Souto MT, **Danese S**, Magro F  
Inflammatory Bowel Disease in Migrant Populations: Should we look Even Further Back?  
*Curr Drug Targets.* 2021 Feb 3. doi: 10.2174/1389450122666210203193817. Online ahead of print. (IF 2020: 3,465)
648. D'Amico F, Peyrin-Biroulet L, **Danese S**.  
Reply.  
*Gastroenterology.* 2021 May;160(6):2223-2224. doi: 10.1053/j.gastro.2021.02.001. Epub 2021 Feb 4. (IF 2020: 22,682)
649. Caron B, D'Amico F, **Danese S**, Peyrin-Biroulet L.  
Endpoints for perianal Crohn's disease trials: past, present, and future.  
*J Crohns Colitis.* 2021 Feb 7;jjab026. doi: 10.1093/ecco-jcc/jjab026. Online ahead of print. (IF 2020: 9,071)
650. Kim H, Alten R, Cummings F, **Danese S**, D'Haens G, Emery P, Ghosh S, Gilletta de Saint Joseph C, Lee J, Lindsay JO, Nikiphorou E, Parker B, Schreiber S, Simoens S, Westhovens R, Jeong JH, Peyrin-Biroulet L.  
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters.  
*MAbs.* 2021 Jan-Dec;13(1):1868078. doi: 10.1080/19420862.2020.1868078. (IF 2020: 5,857)
651. Guillo L, D'Amico F, Achit H, Ayav C, Guillemin F, **Danese S**, Frimat L, Peyrin-Biroulet L.  
Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know.  
*Dig Liver Dis.* 2021 Jun;53(6):691-696. doi: 10.1016/j.dld.2021.01.015. Epub 2021 Feb 6. (IF 2020: 4,088)
652. William S, Geert D, Doug W, Stephen H, Igor J, Subrata G, AnnKatrin P, Steven H, Hwan LJ, Lorna C, Keith U, **Danese S**, Brian F.  
P025 Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Induction in the Phase 3 True North Study.

*Am J Gastroenterol.* 2020 Dec 1;115(Suppl 1):S6-S7. doi: 10.14309/01.ajg.0000722896.32651.d6. (IF 2020: 10,864)

653. **Danese S**, Brian F, Stephen H, Igor J, Subrata G, AnnKatrin P, Steven H, Hwan LJ, Lorna C, Denesh C, William S, Geert D.

P030 Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Maintenance in the Phase 3 True North Study.

*Am J Gastroenterol.* 2020 Dec 1;115(Suppl 1):S8. doi: 10.14309/01.ajg.0000722916.98351.89. (IF 2020: 10,864)

654. Reinisch W, Sandborn WJ, **Danese S**, Hébuterne X, Kłopocka M, Tarabar D, Vaňásek T, Greguš M, Hellstern PA, Kim JS, Sparrow MP, Gorelick KJ, Hoy M, Goetsch M, Bliss C, Gupta C, Cataldi F, Vermeire S.

Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II.

*J Crohns Colitis.* 2021 Jun 22;15(6):938-949. doi: 10.1093/ecco-jcc/jjab023. (IF 2020: 9,071)

655. Lasa JS, Olivera PA, Bonovas S, **Danese S**, Peyrin-Biroulet L.

Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis.

*Drug Saf.* 2021 Jun;44(6):645-660. doi: 10.1007/s40264-021-01057-z. Epub 2021 Mar 5. (IF 2020: 5,606)

656. Livanos AE, Jha D, Cossarini F, Gonzalez-Reiche AS, Tokuyama M, Aydillo T, Parigi TL, Ladinsky MS, Ramos I, Dunleavy K, Lee B, Dixon RE, Chen ST, Martinez-Delgado G, Nagula S, Bruce EA, Ko HM, Glicksberg BS, Nadkarni G, Pujadas E, Reidy J, Naymagon S, Grinspan A, Ahmad J, Tankelevich M, Bram Y, Gordon R, Sharma K, Houldsworth J, Britton GJ, Chen-Liaw A, Spindler MP, Plitt T, Wang P, Cerutti A, Faith JJ, Colombel JF, Kenigsberg E, Argmann C, Merad M, Gnjjatic S, Harpaz N, **Danese S**, Cordon-Cardo C, Rahman A, Schwartz RE, Kumta NA, Aghemo A, Bjorkman PJ, Petralia F, van Bakel H, Garcia-Sastre A, Mehandru S.

Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms.

*Gastroenterology.* 2021 Jun;160(7):2435-2450.e34. doi: 10.1053/j.gastro.2021.02.056. Epub 2021 Mar 4. (IF 2020: 22,682)

657. Piovani D, Pansieri C, Kotha SRR, Piazza AC, Comberg CL, Peyrin-Biroulet L, **Danese S**, Bonovas S.  
Ethnic Differences in the Smoking-Related Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.  
*J Crohns Colitis*. 2021 Mar 15;jjab047. doi: 10.1093/ecco-jcc/jjab047. Online ahead of print. (IF 2020: 9,071)
658. Lang-Schwarz C, Angeloni M, Agaimy A, Atreya R, Becker C, Dregelies T, **Danese S**, Fléjou JF, Gaßler N, Grabsch HI, Hartmann A, Kamarádová K, Kühl AA, Lauwers GY, Lugli A, Nagtegaal I, Neurath MF, Oberhuber G, Peyrin-Biroulet L, Rath T, Riddell R, Rubio CA, Sheahan K, Siegmund B, Tilg H, Villanacci V, Westerhoff M, Ferrazzi F, Vieth M.  
Validation of the "Inflammatory Bowel Disease - Distribution, Chronicity, Activity (IBD-DCA) Score" for Ulcerative Colitis and Crohn's disease.  
*J Crohns Colitis*. 2021 Mar 27;jjab055. doi: 10.1093/ecco-jcc/jjab055. Online ahead of print. (IF 2020: 9,071)
659. Solitano V, Vuitton L, Peyrin-Biroulet L, **Danese S**.  
The Evolution of Biologics Administration From Intravenous to Subcutaneous: Treatments for Inflammatory Bowel Disease Go Home.  
*Gastroenterology*. 2021 Jun;160(7):2244-2247. doi: 10.1053/j.gastro.2021.03.038. Epub 2021 Mar 25. (IF 2020: 22,682)
660. Caron B, Sandborn WJ, Schreiber S, Panaccione R, **Danese S**, Peyrin-Biroulet L.  
Drug development for ulcerative proctitis: current concepts.  
*Gut*. 2021 Jul;70(7):1203-1209. doi: 10.1136/gutjnl-2021-324108. Epub 2021 Mar 31. (IF 2020: 23,059)
661. D'Amico F, Guillo L, Baumann C, **Danese S**, Peyrin-Biroulet L.  
Histological disease activity measured by the Nancy index is associated with long-term outcomes in patients with ulcerative colitis.  
*J Crohns Colitis*. 2021 Apr 5;jjab063. doi: 10.1093/ecco-jcc/jjab063. Online ahead of print. (IF 2020: 9,071)
662. Privitera G, Pugliese D, Onali S, Petito V, Scaldaferri F, Gasbarrini A, **Danese S**, Armuzzi A.  
Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy.

*Autoimmun Rev.* 2021 Jun;20(6):102832. doi: 10.1016/j.autrev.2021.102832. Epub 2021 Apr 15. (IF 2020: 9,754)

663. Allocca M, Craviotto V, Bonovas S, Furfaro F, Zilli A, Peyrin-Biroulet L, Fiorino G, **Danese S**.  
Predictive Value of Bowel Ultrasound in Crohn's Disease: A 12-Month Prospective Study.  
*Clin Gastroenterol Hepatol.* 2021 Apr 22:S1542-3565(21)00463-8. doi: 10.1016/j.cgh.2021.04.029. Online ahead of print. (IF 2020: 11,382)
664. Solitano V, D'Amico F, Allocca M, Fiorino G, Zilli A, Loy L, Gilardi D, Radice S, Correale C, **Danese S**, Peyrin-Biroulet L, Furfaro F.  
Rediscovering histology: what is new in endoscopy for inflammatory bowel disease?  
*Therap Adv Gastroenterol.* 2021 Apr 16;14:17562848211005692. doi: 10.1177/17562848211005692. eCollection 2021. (IF 2020: 4,409)
665. D'Amico F, Rubin DT, Kotze PG, Magro F, Siegmund B, Kobayashi T, Olivera PA, Bossuyt P, Pouillon L, Louis E, Domènech E, Ghosh S, **Danese S**, Peyrin-Biroulet L.  
International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases.  
*United European Gastroenterol J.* 2021 May;9(4):451-460. doi: 10.1002/ueg2.12069. Epub 2021 May 7. (IF 2020: 4,623)
666. D'Amico F, Solitano V, Aletaha D, Hart A, Magro F, Selmi C, Ng SC, Al Awadhi S, Choy E, Schulze-Koops H, Bossuyt P, Olivera PA, Kotze PG, Ghosh S, Peyrin-Biroulet L, **Danese S**.  
Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus.  
*Autoimmun Rev.* 2021 Jul;20(7):102849. doi: 10.1016/j.autrev.2021.102849. Epub 2021 May 8. (IF 2020: 9,754)
667. **Danese S**, Parigi TL, Peyrin-Biroulet L, Ghosh S.  
Defining difficult-to-treat inflammatory bowel disease: why and how.  
*Lancet Gastroenterol Hepatol.* 2021 Jul;6(7):520-522. doi: 10.1016/S2468-1253(21)00141-2. Epub 2021 May 19. (IF 2020: 18,486)
668. Allocca M, **Danese S**.  
Reply.  
*Clin Gastroenterol Hepatol.* 2021 May 25:S1542-3565(21)00574-7. doi: 10.1016/j.cgh.2021.05.036. Online ahead of print. (IF 2020: 11,382)

669. **Danese S**, Peyrin-Biroulet L.  
Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise.  
*Inflamm Bowel Dis*. 2021 Jun 5:izab135. doi: 10.1093/ibd/izab135. Online ahead of print. (IF 202: 5,325)
670. Geyl S, Guillo L, Laurent V, D'Amico F, **Danese S**, Peyrin-Biroulet L.  
Transmural healing as a therapeutic goal in Crohn's disease: a systematic review.  
*Lancet Gastroenterol Hepatol*. 2021 Jun 3:S2468-1253(21)00096-0. doi: 10.1016/S2468-1253(21)00096-0. Online ahead of print. (IF 2020: 18,486)
671. Feagan BG, **Danese S**, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempinski R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L.  
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.  
*Lancet*. 2021 Jun 19;397(10292):2372-2384. doi: 10.1016/S0140-6736(21)00666-8. Epub 2021 Jun 3. (IF 2020: 79,321)
672. Ghosh S, Sanchez Gonzalez Y, Zhou W, Clark R, Xie W, Louis E, Loftus EV Jr, Panes J, **Danese S**.  
Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis.  
*J Crohns Colitis*. 2021 Jun 9;jjab099. doi: 10.1093/ecco-jcc/jjab099. Online ahead of print. (IF 2020: 9,071)
673. Solitano V, Alfarone L, D'Amico F, Peyrin-Biroulet L, **Danese S**.  
IBD goes home: from telemedicine to self-administered advanced therapies.  
*Expert Opin Biol Ther*. 2021 Jun 11. doi: 10.1080/14712598.2021.1942833. Online ahead of print. (IF 2020: 4,388)
674. **Danese S**, Klopocka M, Scherl EJ, Romatowski J, Allegretti JR, Peeva E, Vincent MS, Schoenbeck U, Ye Z, Hassan-Zahraee M, Rath N, Li G, Neelakantan S, Banfield C, Lepsy C, Chandra DE, Hung KE.



Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study [102/120 characters including spaces].

*Clin Gastroenterol Hepatol.* 2021 Jun 11:S1542-3565(21)00614-5. doi: 10.1016/j.cgh.2021.06.011. Online ahead of print. (IF 2020: 11,382)

675. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, **Danese S**, Rogers R, Bornstein JD, Chen J, Schreiber S, Sands BE, Lirio RA.

Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From VARSITY.

*Gastroenterology.* 2021 Jun 15:S0016-5085(21)03126-7. doi: 10.1053/j.gastro.2021.06.015. Online ahead of print. (IF 2020: 22,682)

676. Grandmougin A, D'Amico F, Remen T, **Danese S**, Bonneton M, Galloy MA, Peyrin-Biroulet L, Laurent V.

Role of Cross-Sectional Imaging in Pediatric Inflammatory Bowel Disease.

*Dig Dis Sci.* 2021 Jun 22. doi: 10.1007/s10620-021-07016-z. Online ahead of print. (IF 2020: 3,199)

677. Fiorino G, **Danese S**.

The new frontier: Certifying quality standards in the inflammatory bowel disease care.

*United European Gastroenterol J.* 2021 Jul 10;9(7):745-7. doi: 10.1002/ueg2.12122. Online ahead of print. (IF 2020: 4,623)

678. Spinelli A, Carvello M, Adamina M, Panis Y, Warusavitarne J, Tulchinsky H, Bemelman WA, Kotze PG, D'Hoore A, Lastikova L, **Danese S**, Peyrin-Biroulet L, Avedano L, Pagnini F.

Patients' perceptions of surgery for inflammatory bowel disease.

*Colorectal Dis.* 2021 Jul 16. doi: 10.1111/codi.15813. Online ahead of print. (IF 2020: 3,788)

679. Carvello M, Bellato V, Maroli A, Hart A, **Danese S**, Warusavitarne J, Spinelli A.

A multidisciplinary approach to rectal cancer treatment in ulcerative colitis results in high rate of restorative minimally invasive surgery.

*J Crohns Colitis.* 2021 Aug 4;jjab139. doi: 10.1093/ecco-jcc/jjab139. Online ahead of print. (IF 2020: 9,071)

680. Furfaro F, Dal Buono A, Allocca M, D'Amico F, Zilli A, Gabbiadini R, **Danese S**.  
Bowel Ultrasound in Inflammatory Bowel Disease: How Far in the Grayscale?

*Life (Basel)*. 2021 Jul 4;11(7):649. doi: 10.3390/life11070649. (IF 2020: 3,817)

681. Craviotto V, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L, Fiorino G, **Danese S**, Allocca M.  
Viral infections in inflammatory bowel disease: Tips and tricks for correct management.  
*World J Gastroenterol*. 2021 Jul 21;27(27):4276-4297. doi: 10.3748/wjg.v27.i27.4276. (IF 2020: 5,742)
682. Fiorino G, Allocca M, **Danese S**.  
Adalimumab biosimilar in inflammatory bowel disease.  
*Lancet Gastroenterol Hepatol*. 2021 Oct;6(10):775-776. doi: 10.1016/S2468-1253(21)00266-1. Epub 2021 Aug 11. (IF 2020: 18,486)
683. Caron B, D'Amico F, **Danese S**, Peyrin-Biroulet L.  
Cluster Randomized Trials: Lessons for Inflammatory Bowel Disease Trials.  
*J Crohns Colitis*. 2021 Aug 14;jjab149. doi: 10.1093/ecco-jcc/jjab149. Online ahead of print. (IF 2020: 9,071)
684. Vermeire S, D'Haens G, Baert F, **Danese S**, Kobayashi T, Loftus EV Jr, Bhatia S, Agboton C, Rosario M, Chen C, Zhang W, Kisfalvi K, Sandborn WJ.  
Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial.  
*J Crohns Colitis*. 2021 Aug 17;jjab133. doi: 10.1093/ecco-jcc/jjab133. Online ahead of print. (IF 2020: 9,071)
685. Hassan-Zahraee M, Ye Z, Xi L, Baniecki ML, Li X, Hyde CL, Zhang J, Raha N, Karlsson F, Quan J, Ziemek D, Neelakantan S, Lepsy C, Allegretti JR, Romatowski J, Scherl EJ, Klopocka M, **Danese S**, Chandra DE, Schoenbeck U, Vincent MS, Longman R, Hung KE.  
Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis.  
*Inflamm Bowel Dis*. 2021 Aug 24;izab193. doi: 10.1093/ibd/izab193. Online ahead of print. (IF 2020: 5,325)
686. Solitano V, Parigi TL, Ragaini E, **Danese S**.  
Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents.

*Expert Opin Investig Drugs*. 2021 Sep 6:1-10. doi: 10.1080/13543784.2021.1974396.  
Online ahead of print. (IF 2020: 6,206)

687. Olivera PA, Zuily S, Kotze PG, Regnault V, Al Awadhi S, Bossuyt P, Gearry RB, Ghosh S, Kobayashi T, Lacolley P, Louis E, Magro F, Ng SC, Papa A, Raine T, Teixeira FV, Rubin DT, **Danese S**, Peyrin-Biroulet L.

International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease.

*Nat Rev Gastroenterol Hepatol*. 2021 Aug 27:1-17. doi: 10.1038/s41575-021-00492-8.  
Online ahead of print. (IF 2020: 46,802)

688. Sandborn W, Mattheakis LC, Modi NB, Pugatch D, Bressler B, Lee S, Bhandari R, Kanwar B, Shames R, D'Haens G, Schreiber S, **Danese S**, Feagan B, Pai RK, Liu DY, Gupta S.

PTG-100, an Oral  $\alpha 4\beta 7$  Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis.

*Gastroenterology*. 2021 Aug 30:S0016-5085(21)03463-6. doi:  
10.1053/j.gastro.2021.08.045. Online ahead of print. (IF 2020: 22,682)

689. Norsa L, Bonaffini PA, Caldato M, Bonifacio C, Sonzogni A, Indriolo A, Valle C, Furfaro F, Bonanomi A, Franco PN, Gori M, Smania V, Scaramella L, Forzenigo L, Vecchi M, Solbiati M, Costantino G, **Danese S**, D'Antiga L, Sironi S, Elli L.

Intestinal ischemic manifestations of SARS-CoV-2: Results from the ABDOCOVID multicentre study.

*World J Gastroenterol*. 2021 Aug 28;27(32):5448-5459. doi: 10.3748/wjg.v27.i32.5448. (IF 2020: 5,742)

690. Tursi A, Nenna R, **Danese S**.

Therapeutic Response to Adalimumab in a Case of Steroid-Dependent Segmental Colitis Associated With Diverticulosis.

*Am J Gastroenterol*. 2021 Aug 1;116(8):1760-1761. doi: 10.14309/ajg.0000000000001226.  
(IF 2020: 10,864)

691. Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, **Danese S**; True North Study Group.

Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.

*N Engl J Med.* 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617. (IF 2020: 91,245)

692. Schwartz DA, Peyrin-Biroulet L, Lasch K, Adsul S, **Danese S**.  
Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study.  
*Clin Gastroenterol Hepatol.* 2021 Sep 28:S1542-3565(21)01042-9. doi: 10.1016/j.cgh.2021.09.028. Online ahead of print. (IF 2020: 11,382)
693. Caron B, Netter P, **Danese S**, Peyrin-Biroulet L.  
Bispecific antibodies for the treatment in inflammatory bowel disease: an avenue worth exploring?  
*Expert Opin Biol Ther.* 2021 Oct 6. doi: 10.1080/14712598.2022.1985999. Online ahead of print. (IF 2020: 4,388)
694. Rubin DT, Modesto I, Vermeire S, **Danese S**, Ng SC, Kwok KK, Koram N, Jones TV.  
Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis.  
*Aliment Pharmacol Ther.* 2022 Feb;55(3):302-310. doi: 10.1111/apt.16619. Epub 2021 Oct 9 (IF 2020: 8,171)
695. Garlatti V, Lovisa S, **Danese S**, Vetrano S  
The Multiple Faces of Integrin-ECM Interactions in Inflammatory Bowel Disease.  
*Int J Mol Sci.* 2021 Sep 28;22(19):10439. doi: 10.3390/ijms221910439. (IF 2020: 5,924)
696. Parigi TL, Peyrin-Biroulet L, **Danese S**.  
Endoscopic Surveillance in Inflammatory Bowel Disease: The VIRTUE Is in High Definition.  
*Gastroenterology.* 2021 Oct 21:S0016-5085(21)03663-5. doi: 10.1053/j.gastro.2021.10.025. Online ahead of print. (IF 2020: 22,682)
697. Tursi A, Brandimarte G, Di Mario F, Elisei W, Picchio M, Allegretta L, Annunziata ML, Bafutto M, Bassotti G, Bianco MA, Colucci R, Conigliaro R, Dumitrascu D, Escalante R, Ferrini L, Forti G, Franceschi M, Graziani MG, Lammert F, Latella G, Maconi G, Nardone G, Camara de Castro Oliveira L, Chaves Oliveira E, Papa A, Papagrigroriadis S, Pietrzak A, Pontone S, Poskus T, Pranzo G, Reichert MC, Rodinò S, Regula J, Scaccianoce

- G, Scaldaferrì F, Vassallo R, Zampalèta C, Zullo A, Piovani D, Bonovas S, **Danese S**; DICA International Group  
Prognostic performance of the 'DICA' endoscopic classification and the 'CODA' score in predicting clinical outcomes of diverticular disease: an international, multicentre, prospective cohort study.  
*Gut*. 2021 Oct 26;gutjnl-2021-325574. doi: 10.1136/gutjnl-2021-325574. Online ahead of print. (IF 2020: 23,059)
698. Mysler E, Azevedo VF, Danese S, Alvarez D, Iikuni N, Ingram B, Mueller M, Peyrin-Biroulet L.  
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?  
*Drugs*. 2021 Nov;81(16):1859-1879. doi: 10.1007/s40265-021-01610-1. Epub 2021 Oct 27. (IF 2020: 9,546)
699. Mosli M, Alawadhi S, Hasan F, Abou Rached A, Sanai F, **Danese S**.  
Incidence, Prevalence, and Clinical Epidemiology of Inflammatory Bowel Disease in the Arab World: A Systematic Review and Meta-Analysis.  
*Inflamm Intest Dis*. 2021 Sep 7;6(3):123-131. doi: 10.1159/000518003. eCollection 2021 Sep.
700. Marasco G, Cremon C, Barbaro MR, Salvi D, Cacciari G, Kagramanova A, Bordin D, Drug V, Miftode E, Fusaroli P, Mohamed SY, Ricci C, Bellini M, Rahman MM, Melcarne L, Santos J, Lobo B, Bor S, Yapali S, Akyol D, Sapmaz FP, Urun YY, Eskazan T, Celebi A, Kacmaz H, Ebik B, Binicier HC, Bugdayci MS, Yağcı MB, Pullukcu H, Kaya BY, Tureyen A, Hatemi İ, Koc ES, Sirin G, Caliskan AR, Bengi G, Alıs EE, Lukic S, Trajkovska M, Hod K, Dumitrascu D, Pietrangelo A, Corradini E, Simren M, Sjolund J, Tornkvist N, Ghoshal UC, Kolokolnikova O, Colecchia A, Serra J, Maconi G, De Giorgio R, **Danese S**, Portincasa P, Di Stefano M, Maggio M, Philippou E, Lee YY, Venturi A, Borghi C, Zoli M, Gionchetti P, Viale P, Stanghellini V, Barbara G; GI-COVID19 Study Group.  
Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study.  
*Am J Gastroenterol*. 2022 Jan 1;117(1):147-157. doi: 10.14309/ajg.0000000000001541 (IF 2020: 10,864)
701. D'Haens G, **Danese S**, Davies M, Watanabe M, Hibi T.  
A Phase II, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Efficacy of Amiselimod in Patients with Moderate to Severe Active Crohn's Disease.

- J Crohns Colitis*. 2021 Nov 10;jjab201. doi: 10.1093/ecco-jcc/jjab201. Online ahead of print. (IF 2020: 9,071)
702. Allocca M, Craviotto V, Dell'Avalle C, Furfaro F, Zilli A, D'Amico F, Bonovas S, Peyrin-Biroulet L, Fiorino G, **Danese S**.  
Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn's disease.  
*Aliment Pharmacol Ther*. 2021 Nov 15. doi: 10.1111/apt.16700. Online ahead of print. (IF 2020: 8,171)
703. D'Amico F, Magro F, Peyrin-Biroulet L, **Danese S**.  
Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis.  
*J Crohns Colitis*. 2021 Nov 16;jjab206. doi: 10.1093/ecco-jcc/jjab206. Online ahead of print. (IF 2020: 9,071)
704. **Danese S**, Colombel JF, Lukas M, Gisbert JP, D'Haens G, Hayee B, Panaccione R, Kim HS, Reinisch W, Tyrrell H, Oh YS, Tole S, Chai A, Chamberlain-James K, Tang MT, Schreiber S; GARDENIA Study Group.  
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.  
*Lancet Gastroenterol Hepatol*. 2022 Feb;7(2):118-127. doi: 10.1016/S2468-1253(21)00294-6. Epub 2021 Nov 17. (IF 2020: 18,486)
705. Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV Jr, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ; HICKORY Study Group.  
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.  
*Lancet Gastroenterol Hepatol*. 2022 Feb;7(2):128-140. doi: 10.1016/S2468-1253(21)00298-3. Epub 2021 Nov 17. (IF 2020: 18,486)
706. Avila F, Caron B, Hossu G, Ambarki K, Kannengiesser S, Odille F, Felblinger J, **Danese S**, Choukour M, Laurent V, Peyrin-Biroulet L.  
Magnetic Resonance Elastography for Assessing Fibrosis in Patients with Crohn's Disease: A Pilot Study.  
*Dig Dis Sci*. 2021 Nov 21. doi: 10.1007/s10620-021-07311-9. Online ahead of print. (IF 2020: 3,199)

707. Graffigna G, Bosio C, Pagnini F, Volpato E, Previtali E, Leone S, D'Amico F, Armuzzi A, **Danese S**.  
Promoting psycho-social wellbeing for engaging inflammatory bowel disease patients in their care: an Italian consensus statement.  
*BMC Psychol.* 2021 Nov 28;9(1):186. doi: 10.1186/s40359-021-00692-6. (IF 2020: 2,54)
708. Dal Buono A, Carvello M, Sachar DB, Spinelli A, **Danese S**, Roda G.  
Diversion proctocolitis and the problem of the forgotten rectum in inflammatory bowel diseases: A systematic review.  
*United European Gastroenterol J.* 2021 Dec;9(10):1157-1167. doi: 10.1002/ueg2.12175. Epub 2021 Nov 29. (IF 2020: 4,623)
709. Caron B, Sandborn WJ, Panaccione R, Schreiber S, Hart A, Solitano V, **Danese S**, Peyrin-Biroulet L.  
Efficacy of pharmacological agents for ulcerative proctitis: a systematic literature review.  
*J Crohns Colitis.* 2021 Nov 30;jjab218. doi: 10.1093/ecco-jcc/jjab218. Online ahead of print. (IF 2020: 9,071)
710. Sandborn WJ, Lawendy N, **Danese S**, Su C, Loftus EV Jr, Hart A, Dotan I, Damião AOMC, Judd DT, Guo X, Modesto I, Wang W, Panés J.  
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.  
*Aliment Pharmacol Ther.* 2021 Dec 1. doi: 10.1111/apt.16712. Online ahead of print. (IF 2020: 8,171)
711. Lasa JS, Olivera PA, **Danese S**, Peyrin-Biroulet L.  
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.  
*Lancet Gastroenterol Hepatol.* 2022 Feb;7(2):161-170. doi: 10.1016/S2468-1253(21)00377-0. Epub 2021 Nov 29. (IF 2020: 18,486)
712. D'Alessio S, Ungaro F, Noviello D, Lovisa S, Peyrin-Biroulet L, **Danese S**.  
Revisiting fibrosis in inflammatory bowel disease: the gut thickens.  
*Nat Rev Gastroenterol Hepatol.* 2021 Dec 7. doi: 10.1038/s41575-021-00543-0. Online ahead of print. (IF 2020: 46,802)
713. Nones RB, Fleshner PR, Queiroz NSF, Cheifetz AS, Spinelli A, **Danese S**, Peyrin-Biroulet L, Papamichael K, Kotze PG.

Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient.

*J Clin Med.* 2021 Nov 29;10(23):5642. doi: 10.3390/jcm10235642. (IF 2020: 4,242)

714. Puzzono M, Mannucci A, Grannò S, Zuppardo RA, Galli A, **Danese S**, Cavestro GM. The Role of Diet and Lifestyle in Early-Onset Colorectal Cancer: A Systematic Review. *Cancers (Basel)*. 2021 Nov 25;13(23):5933. doi: 10.3390/cancers13235933. (IF 2020: 6,639)
715. Magro F, Magalhaes D, Patita M, Arroja B, Lago P, Rosa I, Tavares de Sousa H, Ministro P, Mocanu I, Vieira A, Castela J, Moleiro J, Roseira J, Cancela E, Sousa P, Portela F, Correia L, Santiago M, Dias S, Alves C, Afonso J, **Danese S**, Peyrin-Biroulet L, Dias CC; GEDII. Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years. *Clin Gastroenterol Hepatol.* 2021 Dec 9:S1542-3565(21)01298-2. doi: 10.1016/j.cgh.2021.12.004. Online ahead of print. (IF 2020: 11,382)
716. Magro F, Alves C, Santiago M, Ministro P, Lago P, Correia L, Gonçalves R, Carvalho D, Portela F, Dias CC, Dignass A, **Danese S**, Peyrin-Biroulet L, Estevinho MM, Moreira P; on behalf GEDII (Portuguese IBD Group). Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta-analysis. *United European Gastroenterol J.* 2021 Dec 14. doi: 10.1002/ueg2.12183. Online ahead of print. (IF 2020: 4,623)
717. Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, **Danese S**, Ghosh S. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. *Therap Adv Gastroenterol.* 2021 Dec 9;14:17562848211059954. doi: 10.1177/17562848211059954. eCollection 2021. (IF 2020: 4,409)
718. Houshyar Y, Massimino L, Lamparelli LA, **Danese S**, Ungaro F. Going Beyond Bacteria: Uncovering the Role of Archaeome and Mycobiome in Inflammatory Bowel Disease. *Front Physiol.* 2021 Dec 6;12:783295. doi: 10.3389/fphys.2021.783295. eCollection 2021. (IF 2020: 4,566)
719. Sandborn WJ, Armuzzi A, Liguori G, Irving PM, Sharara AI, Mundayat R, Lawendy N, Woolcott JC, **Danese S**. Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis.



- Inflamm Bowel Dis.* 2021 Dec 27;izab278. doi: 10.1093/ibd/izab278. Online ahead of print. (IF 2020: 5,325)
720. Parigi TL, Solitano V, Peyrin-Biroulet L, **Danese S**.  
Do JAK inhibitors have a realistic future in treating Crohn's disease?  
*Expert Rev Clin Immunol.* 2021 Dec 31:1-3. doi: 10.1080/1744666X.2022.2020101. Online ahead of print. (IF 2020: 4,473)
721. Schreiber S, Ben-Horin S, Alten R, Westhovens R, Peyrin-Biroulet L, **Danese S**, Hibi T, Takeuchi K, Magro F, An Y, Kim DH, Yoon S, Reinisch W.  
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era.  
*Adv Ther.* 2022 Jan 6:1-23. doi: 10.1007/s12325-021-01990-6. Online ahead of print. (IF 2020: 3,847)
722. Raine T, **Danese S**.  
Breaking through the therapeutic ceiling: what will it take?  
*Gastroenterology.* 2021 Dec 16:S0016-5085(21)04080-4. doi: 10.1053/j.gastro.2021.09.078. Online ahead of print. (IF 2020: 22,682)
723. Colombel JF, D'Haens G, Irving P, Petersen A, Chitkara D, Marta C, Chen T, Charles L, **Danese S**, Ghosh S.  
P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial.  
*Am J Gastroenterol.* 2021 Dec 1;116(Suppl 1):S9. doi: 10.14309/01.ajg.0000798748.09138.3f. (IF 2020: 10,864)
724. Rubbino F, Garlatti V, Garzarelli V, Massimino L, Spanò S, Iadarola P, Cagnone M, Giera M, Heijink M, Guglielmetti S, Arena V, Malesci A, Laghi L, **Danese S**, Vetrano S.  
GPR120 prevents colorectal adenocarcinoma progression by sustaining the mucosal barrier integrity.  
*Sci Rep.* 2022 Jan 10;12(1):381. doi: 10.1038/s41598-021-03787-7. (IF 2020: 4,380)
725. **Danese S**, Levesque BG, Feagan BG, Jucov A, Bhandari BR, Pai RK, Taylor Meadows K, Kirby BJ, Bruey JM, Olson A, Osterhout R, Van Biene C, Ford J, Aranda R, Raghupathi K, Sandborn WJ.  
Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1 $\alpha$  stabiliser, for treatment of ulcerative colitis.

*Aliment Pharmacol Ther.* 2022 Jan 10. doi: 10.1111/apt.16753. Online ahead of print. (IF 2020: 8,171)

726. Sandborn WJ, **Danese S.**

Ozanimod for Ulcerative Colitis. Reply.

*N Engl J Med.* 2022 Jan 13;386(2):194-195. doi: 10.1056/NEJMc2117224. (IF 2020: 91,253)

727. Papamichael K, Afif W, Drobne D, Dubinsky MC, Ferrante M, Irving PM, Kamperidis N, Kobayashi T, Kotze PG, Lambert J, Noor NM, Roblin X, Roda G, Vande Casteele N, Yarur AJ, Arebi N, **Danese S**, Paul S, Sandborn WJ, Vermeire S, Cheifetz AS, Peyrin-Biroulet L; International Consortium for Therapeutic Drug Monitoring.

Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.

*Lancet Gastroenterol Hepatol.* 2022 Feb;7(2):171-185. doi: 10.1016/S2468-1253(21)00223-5. (IF 2020: 18,486)

728. Massimino L, Spanò S, Lamparelli LA, Fuggetta D, Peyrin-Biroulet L, Sileri P, **Danese S**, D'Alessio S, Ungaro F.

Tofacitinib Inhibits Leukocyte Trafficking Across the Intestinal Endothelial Barrier in a Specific Cohort of Ulcerative Colitis Patients.

*Inflamm Bowel Dis.* 2022 Jan 15:izab349. doi: 10.1093/ibd/izab349. Online ahead of print. (IF 2020: 5,325)

729. Allocca M, **Danese S.**

Editorial: an accurate, reliable and responsive ultrasound activity score for Crohn's disease?

Sounds good to US. Authors' reply.

*Aliment Pharmacol Ther.* 2022 Feb;55(3):362-363. doi: 10.1111/apt.16754. (IF 2020: 8,171)

Milano, 19/01/2022

